

EAU Guidelines on Urolithiasis

C. Türk (Chair), A. Neisius, A. Petrik, C. Seitz,
A. Skolarikos, K. Thomas
Guidelines Associates: J.F. Donaldson, T. Drake,
N. Grivas, Y. Ruhayel

TABLE OF CONTENTS

PAGE

1.	INTRODUCTION	5
1.1	Aims and scope	5
1.2	Panel composition	5
1.3	Available publications	5
1.4	Publication history and summary of changes	5
1.4.1	Publication history	5
1.4.2	Summary of changes	5
2.	METHODS	7
2.1	Data identification	7
2.2	Review	8
2.3	Future goals	8
3.	GUIDELINES	8
3.1	Prevalence, aetiology, risk of recurrence	8
3.1.1	Introduction	8
3.1.2	Stone composition	8
3.1.3	Risk groups for stone formation	9
3.2	Classification of stones	10
3.2.1	Stone size	10
3.2.2	Stone location	10
3.2.3	X-ray characteristics	10
3.3	Diagnostic evaluation	10
3.3.1	Diagnostic imaging	10
3.3.1.1	Evaluation of patients with acute flank pain/suspected ureteral stones	11
3.3.1.2	Radiological evaluation of patients with renal stones	11
3.3.1.3	Summary of evidence and guidelines for diagnostic imaging	11
3.3.2	Diagnostics - metabolism-related	11
3.3.2.1	Basic laboratory analysis - non-emergency urolithiasis patients	12
3.3.2.2	Analysis of stone composition	12
3.3.2.3	Guidelines for laboratory examinations and stone analysis	12
3.3.3	Diagnosis in special groups and conditions	12
3.3.3.1	Diagnostic imaging during pregnancy	12
3.3.3.1.1	Summary of evidence and guidelines for diagnostic imaging during pregnancy	13
3.3.3.2	Diagnostic imaging in children	13
3.3.3.2.1	Summary of evidence and guidelines for diagnostic imaging in children	14
3.4	Disease Management	14
3.4.1	Renal colic	14
3.4.1.1	Summary of evidence and guidelines for the management of renal colic	15
3.4.2	Management of sepsis and/or anuria in obstructed kidney	15
3.4.2.1	Summary of evidence and guidelines for the management of sepsis and anuria	15
3.4.3	Medical expulsive therapy (MET)	16
3.4.3.1	Summary of evidence and guidelines for MET	16
3.4.4	Chemolysis	16
3.4.4.1	Summary of evidence and guidelines for chemolysis	17
3.4.5	Extracorporeal shock wave lithotripsy (SWL)	17
3.4.5.1	Summary of evidence and guidelines for SWL	19
3.4.6	Ureterorenoscopy (URS) (retrograde and antegrade, RIRS)	19
3.4.7	Percutaneous nephrolithotomy (PNL)	21
3.4.7.1	Summary of evidence and guidelines for endourology techniques for renal stone removal	22
3.4.8	General recommendations and precautions for stone removal	23
3.4.8.1	Antibiotic therapy	23
3.4.8.2	Antithrombotic therapy and stone treatment	23
3.4.8.2.1	Summary of evidence and guidelines for antithrombotic therapy and stone treatment	24

3.4.8.3	Obesity	25
3.4.8.4	Stone composition	25
3.4.8.5	Contraindications of procedures	25
3.4.9	Specific stone management of ureteral stones	25
3.4.9.1	Conservative treatment/observation	25
3.4.9.2	Pharmacological treatment, Medical expulsive therapy	26
3.4.9.3	Indications for active removal of ureteral stones	26
3.4.9.4	Selection of procedure for active removal of ureteral stones	26
3.4.9.4.1	Summary of evidence and guidelines for selection of procedure for active removal of ureteral stones	26
3.4.10	Specific stone management of renal stones	27
3.4.10.1	Conservative treatment (Observation)	27
3.4.10.2	Pharmacological treatment of renal stones	27
3.4.10.3	Indications for active stone removal of renal stones	28
3.4.10.4	Selection of procedure for active removal of renal stones	28
3.4.10.4.1	Stones in renal pelvis or upper/middle calices	28
3.4.10.4.2	Stones in the lower renal pole	28
3.4.10.5	Summary of evidence and guidelines for the management of renal stones	29
3.4.11	Laparoscopy and open surgery	30
3.4.11.1	Summary of evidence and guidelines for laparoscopy and open surgery	30
3.4.12	Steinstrasse	31
3.4.12.1	Summary of evidence and guidelines for steinstrasse	31
3.4.13	Management of patients with residual stones	31
3.4.13.1	Summary of evidence and guideline for management of patients with residual stones	31
3.4.14	Management of specific patient groups	32
3.4.14.1	Management of urinary stones and related problems during pregnancy	32
3.4.14.1.1	Summary of evidence and guidelines for the management of urinary stones and related problems during pregnancy	32
3.4.14.2	Management of stones in patients with urinary diversion	32
3.4.14.2.1	Summary of evidence and guidelines for the management of stones in patients with urinary diversion	33
3.4.14.3	Management of stones in patients with neurogenic bladder	33
3.4.14.3.1	Summary of evidence and guidelines for the management of stones in patients with neurogenic bladder	33
3.4.14.4	Management of stones in patients with transplanted kidneys	34
3.4.14.4.1	Summary of evidence and guidelines for the management of stones in patients with transplanted kidneys.	34
3.4.14.5	Special problems in stone removal	34
3.4.15	Management of stones in children	35
3.4.15.1	Medical expulsive therapy in children	35
3.4.15.2	Extracorporeal shock wave lithotripsy	35
3.4.15.3	Endourological procedures	36
3.4.15.4	Open or laparoscopic surgery	36
3.4.15.5	Special considerations on recurrence prevention	36
3.4.15.6	Summary of evidence and guidelines for the management of stones in children	37
4.	FOLLOW UP: METABOLIC EVALUATION AND RECURRENCE PREVENTION	37
4.1	General metabolic considerations for patient work-up	37
4.1.1	Evaluation of patient risk	37
4.1.2	Urine sampling	38
4.1.3	Timing of specific metabolic work-up	38
4.1.4	Reference ranges of laboratory values	39
4.1.5	Risk indices and additional diagnostic tools	39
4.2	General considerations for recurrence prevention	40
4.2.1	Fluid intake	41
4.2.2	Diet	41

4.2.3	Lifestyle	42
4.2.4	Summary of evidence and guidelines for recurrence prevention	42
4.3	Stone-specific metabolic evaluation and pharmacological recurrence prevention	42
4.3.1	Introduction	42
4.4	Calcium oxalate stones	44
4.4.1	Diagnosis	44
4.4.2	Interpretation of results and aetiology	44
4.4.3	Specific treatment	45
4.4.4	Summary of evidence and guidelines for pharmacological treatments for patients with specific abnormalities in urine composition (based on 24-hour urine samples)	45
4.5	Calcium phosphate stones	46
4.5.1	Diagnosis	46
4.5.2	Interpretation of results and aetiology	46
4.5.3	Pharmacological therapy	47
4.5.4	Summary of evidence and guidelines for the management of calcium phosphate stones	47
4.6	Disorders and diseases related to calcium stones	48
4.6.1	Hyperparathyroidism	48
4.6.2	Granulomatous diseases	48
4.6.3	Primary hyperoxaluria	48
4.6.3.1	Summary of evidence and guidelines for the management of primary hyperoxaluria	48
4.6.4	Enteric hyperoxaluria	48
4.6.4.1	Summary of evidence and guidelines for the management of enteric hyperoxaluria	49
4.6.5	Renal tubular acidosis	49
4.6.5.1	Summary of evidence and guidelines for the management of tubular acidosis	50
4.6.6	Nephrocalcinosis	50
4.6.6.1	Diagnosis	51
4.7	Uric acid and ammonium urate stones	51
4.7.1	Diagnosis	51
4.7.2	Interpretation of results	51
4.7.3	Specific treatment	51
4.7.4	Summary of evidence and guideline for the management of uric acid- and ammonium urate stones	52
4.8	Struvite and infection stones	52
4.8.1	Diagnosis	53
4.8.2	Specific treatment	53
4.8.3	Summary of evidence and guidelines for the management of infection stones	53
4.9	Cystine stones	55
4.9.1	Diagnosis	55
4.9.2	Specific treatment	55
4.9.2.1	Pharmacological treatment of cystine stones	55
4.9.3	Summary of evidence and guidelines for the management of cystine stones	56
4.10	2,8-Dihydroxyadenine stones and xanthine stones	57
4.10.1	2,8-Dihydroxyadenine stones	57
4.10.2	Xanthine stones	57
4.10.3	Fluid intake and diet	57
4.11	Drug stones	57
4.12	Matrix Stones	57
4.13	Unknown stone composition	57
4.13.1	Guidelines for investigations for the assessment of patients with stones of unknown composition	58
5.	REFERENCES	58
6.	CONFLICT OF INTEREST	88
7.	CITATION INFORMATION	88

1. INTRODUCTION

1.1 Aims and scope

The European Association of Urology (EAU) Urolithiasis Guidelines Panel has prepared these guidelines to help urologists assess evidence-based management of stones/calculi in the urinary tract and incorporate recommendations into clinical practice. Management of bladder stones is not addressed in these guidelines.

This document covers most aspects of the disease, which is still a cause of significant morbidity despite technological and scientific advances. The Panel is aware of the geographical variations in healthcare provision.

It must be emphasised that clinical guidelines present the best evidence available to the experts but following guideline recommendations will not necessarily result in the best outcome. Guidelines can never replace clinical expertise when making treatment decisions for individual patients, but rather help to focus decisions - also taking personal values and preferences/individual circumstances of patients into account.

Guidelines are not mandates and do not purport to be a legal standard of care.

1.2 Panel composition

The EAU Urolithiasis Guidelines Panel consists of an international group of clinicians with particular expertise in this area. All experts involved in the production of this document have submitted potential conflict of interest statements which can be viewed on the EAU website Uroweb: <http://uroweb.org/guideline/urolithiasis/>.

1.3 Available publications

A quick reference document (Pocket guidelines) is available, both in print and as an app for iOS and Android devices. These are abridged versions which may require consultation together with the full text versions. Also a number of scientific publications are available [1-3]. All documents can be accessed through the EAU website: <http://uroweb.org/guideline/urolithiasis/>.

1.4 Publication history and summary of changes

1.4.1 Publication history

The EAU Urolithiasis Guidelines were first published in 2000. This 2018 document presents a limited update of the 2017 publication of the EAU Urolithiasis Guidelines.

1.4.2 Summary of changes

The literature for the entire document has been assessed and updated, whenever relevant (see Methods section below).

New sections and recommendations have been included in the 2018 publication in sections:

3.4.1.1 Summary of evidence and guidelines for the management of renal colic

Summary of evidence	LE
Non-steroidal anti-inflammatory drugs are very effective in treating renal colic and are superior to opioids.	1b

Recommendation	Strength rating
Non-steroidal anti-inflammatory drugs are very effective in treating renal colic and are superior to opioids.	Strong

3.4.4.1 Summary of evidence and guidelines for chemolysis

Summary of evidence	LE
Irrigation chemolysis has been in limited clinical use to dissolve struvite stones.	3
Uric acid stones can be dissolved based on oral alkalinisation of the urine above 7.0.	3
For obstructing uric acid stones, a combination of oral chemolysis with Tamsulosin is more effective than each substance alone, in particular in stones > 8 mm.	1b

Recommendation (oral chemolysis of uric acid stones)	Strength rating
Combine oral chemolysis with Tamsulosin in case of (larger) ureteral stones (if active intervention is not indicated).	Weak

3.4.6.1 Summary of evidence and guidelines for retrograde URS, RIRS and antegrade ureteroscopy

Summary of evidence	LE
Medical expulsion therapy following Ho:YAG laser lithotripsy accelerates the spontaneous passage of fragments and reduces episodes of colic.	1b
The most effective lithotripsy system for flexible ureteroscopy is the Ho:YAG laser.	2a
Pneumatic and US systems can be used with high disintegration efficacy in rigid URS.	2a
Medical expulsion therapy following Ho:YAG laser lithotripsy increases SFRs and reduces colic episodes.	1b
Percutaneous antegrade removal of proximal ureter stones or laparoscopic ureterolithotomy are feasible alternatives to retrograde ureteroscopy in selected cases.	1a

Recommendation	Strength rating
Offer MET for patients suffering from stent-related symptoms and after Ho:Yag laser lithotripsy for the passage of fragments.	Strong

3.4.9.4.1 Summary of evidence and guidelines for selection of procedure for active removal of ureteral stones

Summary of evidence	LE
Observation is feasible in informed patients who develop no complications (infection, refractory pain, deterioration of renal function).	1a
Compared with SWL, URS was associated with significantly greater SFRs up to four weeks, but the difference was not significant at three months in the included studies.	1a
Ureterorenoscopy was associated with fewer re-treatments and need for secondary procedures, but with a higher need for adjunctive procedures, greater complication rates and longer hospital stay.	1a

Recommendations	Strength rating
Offer α -blockers as MET as one of the treatment options for (distal)ureteral stones ≥ 5 mm.	Strong
In cases of severe obesity use ureterorenoscopy as first-line therapy for ureteral (and renal) stones.	Strong

3.4.13.1 Summary of evidence and guideline for management of patients with residual stones

Summary of evidence	LE
To detect residual fragments after SWL, URS or PNL, deferred imaging is more appropriate than immediate imaging post intervention.	3

Recommendations	Strength rating
Perform imaging after SWL, URS or PNL to determine presence of residual fragments.	Strong

3.4.15.6 Summary of evidence and guidelines for the management of stones in children

Summary of evidence	LE
Ureterorenoscopy has become the treatment of choice for larger distal ureteral stones in children.	1a

Recommendations	Strength rating
Offer children with ureteral stones shockwave lithotripsy as first-line option but consider ureterorenoscopy if SWL is not possible and larger distal ureteral stones.	Strong
Offer children with renal pelvic or calyceal stones with a diameter > 20 mm ($\sim 300\text{ mm}^2$) percutaneous nephrolithotomy.	Strong

4.7.4 Summary of evidence and guideline for the management of uric acid- and ammonium urate stones

Summary of evidence	LE
Potassium citrate can be beneficial to alkalinise the urine in urate stone formers.	3
Allopurinol can be beneficial in hyperuricosuric urate stone formers.	1b

Recommendations	Strength rating
Prescribe potassium citrate to alkalinise the urine in urate stone formers.	Strong
Prescribe allopurinol in hyperuricosuric urate stone formers.	Strong

2. METHODS

2.1 Data identification

For the 2018 Urolithiasis Guidelines, new and relevant evidence has been identified, collated and appraised through a structured assessment of the literature.

A broad and comprehensive scoping exercise covering all areas of the guideline was performed. The search was limited to studies representing high levels of evidence only (i.e. systematic reviews with meta-analysis (MA), randomised controlled trials (RCTs), and prospective non-randomised comparative studies) published in the English language. The search was restricted to articles published between October 12th 2016 and July 9th 2017. Databases covered by the search included Medline, EMBASE and the Cochrane Libraries. A total of 694 unique records were identified, and screened for relevance. The search strategy is published online: <http://uroweb.org/guideline/urolithiasis/?type=appendices-publications>.

A total of 55 new papers were added to the Urolithiasis 2018 Guidelines publication.

For the 2018 edition of the EAU Guidelines the Guidelines Office have transitioned to a modified GRADE methodology across all 20 guidelines [4, 5]. For each recommendation within the guidelines there is an accompanying online strength rating form which addresses a number of key elements namely:

1. the overall quality of the evidence which exists for the recommendation, references used in this text are graded according to a classification system modified from the Oxford Centre for Evidence-Based Medicine Levels of Evidence [6];
2. the magnitude of the effect (individual or combined effects);
3. the certainty of the results (precision, consistency, heterogeneity and other statistical or study related factors);
4. the balance between desirable and undesirable outcomes;
5. the impact of patient values and preferences on the intervention;
6. the certainty of those patient values and preferences.

These key elements are the basis which panels use to define the strength rating of each recommendation. The strength of each recommendation is represented by the words 'strong' or 'weak' [4, 5]. The strength of each recommendation is determined by the balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including certainty of estimates), and nature and variability of patient values and preferences. The strength rating forms will be available online.

Additional information can be found in the general Methodology section of this print, and online at the EAU website; <http://www.uroweb.org/guideline/>.

A list of associations endorsing the EAU Guidelines can also be viewed online at the above address.

2.2 Review

The 2015 Urolithiasis Guidelines were subjected to peer review prior to publication.

2.3 Future goals

For their 2019 text update the Urolithiasis Guidelines Panel aim to include a new section on Bladder Stones. A systematic review on the topic of 'What is the best treatment for bladder stones in adults?' is forseen. The Paediatric urolithiasis section will be completely revised.

3. GUIDELINES

3.1 Prevalence, aetiology, risk of recurrence

3.1.1 Introduction

Stone incidence depends on geographical, climatic, ethnic, dietary and genetic factors. The recurrence risk is basically determined by the disease or disorder causing the stone formation. Accordingly, the prevalence rates for urinary stones vary from 1% to 20% [7]. In countries with a high standard of life such as Sweden, Canada or the USA, renal stone prevalence is notably high (> 10%). For some areas an increase of more than 37% over the last 20 years has been reported [8-10].

Stones can be classified into those caused by: infection, or non-infectious causes (infection- and non-infection stones); genetic defects [11]; or adverse drug effects (drug stones) (Table 3.1.1).

Table 3.1.1: Stones classified by aetiology*

Non-infection stones
Calcium oxalate
Calcium phosphate
Uric acid
Infection stones
Magnesium ammonium phosphate
Carbonate apatite
Ammonium urate
Genetic causes
Cystine
Xanthine
2,8-Dihydroxyadenine
Drug stones

*See Section 4.4.2

3.1.2 Stone composition

Stone composition is the basis for further diagnostic and management decisions. Stones are often formed from a mixture of substances. Table 3.1.2 lists the most clinically relevant substances and their mineral components.

Table 3.1.2: Stone composition

Chemical name	Mineral name	Chemical formula
Calcium oxalate monohydrate	Whewellite	$\text{CaC}_2\text{O}_4 \cdot \text{H}_2\text{O}$
Calcium oxalate dihydrate	Wheddelite	$\text{CaC}_2\text{O}_4 \cdot 2\text{H}_2\text{O}$
Basic calcium phosphate	Apatite	$\text{Ca}_{10}(\text{PO}_4)_6 \cdot (\text{OH})_2$
Calcium hydroxyl phosphate	Carbonite apatite	$\text{Ca}_5(\text{PO}_3)_3(\text{OH})$
b-tricalcium phosphate	Whitlockite	$\text{Ca}_3(\text{PO}_4)_2$
Carbonate apatite phosphate	Dahllite	$\text{Ca}_5(\text{PO}_4)_3\text{OH}$
Calcium hydrogen phosphate	Brushite	$\text{CaHPO}_4 \cdot 2\text{H}_2\text{O}$
Calcium carbonate	Aragonite	CaCO_3

Octacalcium phosphate		$\text{Ca}_8\text{H}_2(\text{PO}_4)_6 \cdot 5\text{H}_2\text{O}$
Uric acid	Uricite	$\text{C}_5\text{H}_4\text{N}_4\text{O}_3$
Uric acid dehydrate	Uricite	$\text{C}_5\text{H}_4\text{O}_3 \cdot 2\text{H}_2\text{O}$
Ammonium urate		$\text{NH}_4\text{C}_5\text{H}_3\text{N}_4\text{O}_3$
Sodium acid urate monohydrate		$\text{NaC}_5\text{H}_3\text{N}_4\text{O}_3 \cdot \text{H}_2\text{O}$
Magnesium ammonium phosphate	Struvite	$\text{MgNH}_4\text{PO}_4 \cdot 6\text{H}_2\text{O}$
Magnesium acid phosphate trihydrate	Newberyite	$\text{MgHPO}_4 \cdot 3\text{H}_2\text{O}$
Magnesium ammonium phosphate monohydrate	Dittmarite	$\text{MgNH}_4(\text{PO}_4) \cdot \text{H}_2\text{O}$
Cystine		$[\text{SCH}_2\text{CH}(\text{NH}_2)\text{COOH}]_2$
Xanthine		
2,8-Dihydroxyadenine		
Proteins		
Cholesterol		
Calcite		
Potassium urate		
Trimagnesium phosphate		
Melamine		
Matrix		
Drug stones	<ul style="list-style-type: none"> • Active compounds crystallising in urine • Substances impairing urine composition (Section 4.11) 	
Foreign body calculi		

3.1.3 Risk groups for stone formation

The risk status of stone formers is of particular interest because it defines the probability of recurrence or regrowth, and is imperative for pharmacological treatment.

About 50% of recurrent stone formers have just one lifetime recurrence [9, 12]. Highly recurrent disease is observed in slightly more than 10% of patients. Stone type and disease severity determine low- or high risk of recurrence (Table 3.1.3) [13, 14].

Table 3.1.3: High-risk stone formers [13-24]

General factors
Early onset of urolithiasis (especially children and teenagers)
Familial stone formation
Brushite-containing stones ($\text{CaHPO}_4 \cdot 2\text{H}_2\text{O}$)
Uric acid and urate-containing stones
Infection stones
Solitary kidney (the kidney itself does not particularly increase the risk of stone formation, but prevention of stone recurrence is of more importance)
Diseases associated with stone formation
Hyperparathyroidism
Metabolic syndrome
Nephrocalcinosis
Polycystic kidney disease (PKD)
Gastrointestinal diseases (i.e., jejunio-ileal bypass, intestinal resection, Crohn's disease, malabsorptive conditions, enteric hyperoxaluria after urinary diversion) and bariatric surgery [19]
Sarcoidosis
Spinal cord injury, neurogenic bladder
Genetically determined stone formation
Cystinuria (type A, B and AB)
Primary hyperoxaluria (PH)
Renal tubular acidosis (RTA) type I

2,8-Dihydroxyadeninuria
Xanthinuria
Lesch-Nyhan syndrome
Cystic fibrosis
Drug-induced stone formation (see Table 4.11)
Anatomical abnormalities associated with stone formation
Medullary sponge kidney (tubular ectasia)
Ureteropelvic junction (UPJ) obstruction
Calyceal diverticulum, calyceal cyst
Ureteral stricture
Vesico-uretero-renal reflux
Horseshoe kidney
Ureterocele
Environmental factors
Chronic lead exposure

3.2 Classification of stones

Urinary stones can be classified according to size, location, X-ray characteristics, aetiology of formation, composition, and risk of recurrence [9, 25-27].

3.2.1 Stone size

Stone size is usually given in one or two dimensions, and stratified into those measuring up to 5, 5-10, 10-20, and > 20 mm in largest diameter.

3.2.2 Stone location

Stones can be classified according to anatomical position: upper, middle or lower calyx; renal pelvis; upper, middle or distal ureter; and urinary bladder. Treatment of bladder stones is not discussed in these guidelines.

3.2.3 X-ray characteristics

Stones can be classified according to plain X-ray appearance [kidney-ureter-bladder (KUB) radiography] (Table 3.2.1), which varies according to mineral composition [27]. Non-contrast-enhanced computed tomography (NCCT) can be used to classify stones according to density, inner structure and composition, which can affect treatment decisions (Section 3.3) [26, 27].

Table 3.2.1: X-ray characteristics

Radiopaque	Poor radiopacity	Radiolucent
Calcium oxalate dehydrate	Magnesium ammonium phosphate	Uric acid
Calcium oxalate monohydrate	Apatite	Ammonium urate
Calcium phosphates	Cystine	Xanthine
		2,8-Dihydroxyadenine
		Drug-stones (Section 4.11)

Stratification of stones according to aetiology, composition and risk of recurrence is addressed in Section 3.1.

3.3 Diagnostic evaluation

3.3.1 Diagnostic imaging

The most appropriate imaging modality will be determined by the clinical situation, which will differ depending on if a ureteral or a renal stone is suspected.

Standard evaluation includes a detailed medical history and physical examination. Patients with ureteral stones usually present with loin pain, vomiting, and sometimes fever, but may also be asymptomatic [28]. Immediate evaluation is indicated in patients with solitary kidney, fever or when there is doubt regarding a diagnosis of renal colic. Ultrasound (US) should be used as the primary diagnostic imaging tool, although pain relief, or any other emergency measures, should not be delayed by imaging assessments. Ultrasound is safe (no risk of radiation), reproducible and inexpensive. It can identify stones located in the calices, pelvis, and pyeloureteric and vesicoureteric junctions (US with filled bladder), as well as in patients with upper urinary tract (UUT) dilatation. Ultrasound has a sensitivity of 45% and specificity of 94% for ureteral stones and a sensitivity of 45% and specificity of 88% for renal stones [29, 30].

The sensitivity and specificity of KUB is 44-77% [31]. Kidney-ureter-bladder radiography should not be performed if NCCT is considered [32]. However, KUB is helpful in differentiating between radiolucent and radiopaque stones and should be used for comparison during follow-up.

3.3.1.1 Evaluation of patients with acute flank pain/suspected ureteral stones

Non-contrast-enhanced computed tomography (CT) has become the standard for diagnosing acute flank pain, and has replaced intravenous urography (IVU). Non-contrast-enhanced CT can determine stone diameter and density. When stones are absent, the cause of abdominal pain should be identified. In evaluating patients with suspected acute urolithiasis, NCCT is significantly more accurate than IVU [33].

Non-contrast-enhanced computed tomography can detect uric acid and xanthine stones, which are radiolucent on plain films, but not indinavir stones [34]. Non-contrast-enhanced CT can determine stone density, inner structure of the stone, skin-to-stone distance and surrounding anatomy; all of which affect selection of treatment modality [27, 35-37]. The advantage of non-contrast imaging must be balanced against loss of information on renal function and urinary collecting system anatomy, as well as higher radiation dose [38-41].

Radiation risk can be reduced by low-dose CT, which may, however, be difficult to introduce in standard clinical practice [42-44]. In patients with a body mass index (BMI) < 30, low-dose CT has been shown to have a sensitivity of 86% for detecting ureteral stones < 3 mm and 100% for calculi > 3 mm [45]. A MA of prospective studies [44] has shown that low-dose CT diagnosed urolithiasis with a pooled sensitivity of 93.1% (95% CI: 91.5-94.4), and a specificity of 96.6% (95% CI: 95.1-97.7%). Dual-energy CT can differentiate uric acid containing stones from calcium-containing stones [46].

3.3.1.2 Radiological evaluation of patients with renal stones

Intravenous urography can provide information about renal function, the anatomy of the collecting system and the level of an obstruction. Non-contrast-enhanced CT allows for rapid 3D data acquisition including information on stone size and density, skin-to-stone distance and surrounding anatomy, but at the cost of increased radiation exposure. Low-dose and ultra-low-dose protocols seem to yield comparable results as standard-dose protocols with the exception of detection of very small stones or stones in obese patients [44, 45, 47].

A small randomised study showed that in supine percutaneous antegrade ureterorenoscopy (PNL), pre-operative planning using CT, compared to IVU, resulted in easier access and shorter operating times [48].

In case stone removal is planned and the renal collecting system needs to be assessed, a contrast study should be performed [49].

3.3.1.3 Summary of evidence and guidelines for diagnostic imaging

Summary of evidence	LE
Non-contrast-enhanced CT is used to confirm stone diagnosis in patients with acute flank pain, as it is superior to IVU.	1a
Enhanced CT enables 3D reconstruction of the collecting system, as well as measurement of stone density and skin-to-stone distance.	2a

Recommendations	Strength rating
With fever or solitary kidney, and when diagnosis is doubtful, immediate imaging is indicated.	Strong
Following initial ultrasound assessment, use non-contrast-enhanced computed tomography to confirm stone diagnosis in patients with acute flank pain.	Strong
Perform a contrast study if stone removal is planned and the anatomy of the renal collecting system needs to be assessed.	Strong

3.3.2 Diagnostics - metabolism-related

Each emergency patient with urolithiasis needs a succinct biochemical work-up of urine and blood besides imaging. At this point, no distinction is made between high- and low-risk patients for stone formation.

3.3.2.1 Basic laboratory analysis - non-emergency urolithiasis patients

Biochemical work-up is similar for all stone patients. However, if no intervention is planned, examination of sodium, potassium, C-reactive protein (CRP), and blood coagulation time can be omitted.

Only patients at high risk for stone recurrence should undergo a more specific analytical programme [14]. Stone-specific metabolic evaluation is described in Chapter 4.

The easiest method for diagnosing stones is by analysis of a passed stone using a validated method as listed below (see 3.2.2.3). Once the mineral composition is known, a potential metabolic disorder can be identified.

3.3.2.2 Analysis of stone composition

Stone analysis should be performed in all first-time stone formers.

In clinical practice, repeat stone analysis is needed in the case of:

- recurrence under pharmacological prevention;
- early recurrence after interventional therapy with complete stone clearance;
- late recurrence after a prolonged stone-free period [50-52].

Patients should be instructed to filter their urine to retrieve a concrement for analysis. Stone passage and restoration of normal renal function should be confirmed.

The preferred analytical procedures are infrared spectroscopy (IRS) or X-ray diffraction (XRD) [53-55]. Equivalent results can be obtained by polarisation microscopy. Chemical analysis (wet chemistry) is generally deemed to be obsolete [53, 56].

3.3.2.3 Guidelines for laboratory examinations and stone analysis

Recommendations	Strength rating
Recommendations: basic laboratory analysis - emergency urolithiasis patients [14, 15, 50, 57]	
Urine	
Dipstick test of spot urine sample: <ul style="list-style-type: none"> • red cells; • white cells; • nitrite; • approximate urine pH; • Urine microscopy and/or culture. 	Strong
Blood	
Serum blood sample: <ul style="list-style-type: none"> • creatinine; • uric acid; • (ionised) calcium; • sodium; • potassium; • Blood cell count; • C-reactive protein. 	Strong
Perform a coagulation test (partial thromboplastin time and international normalised ratio) if intervention is likely or planned.	Strong
Perform stone analysis in first-time formers using a valid procedure (X-ray diffraction or infrared spectroscopy).	Strong
Repeat stone analysis in patients: <ul style="list-style-type: none"> • presenting with recurrent stones despite drug therapy; • with early recurrence after complete stone clearance; • with late recurrence after a long stone-free period because stone composition may change. 	Strong

3.3.3 Diagnosis in special groups and conditions

3.3.3.1 Diagnostic imaging during pregnancy

In pregnant women radiation exposure may cause non-stochastic (teratogenesis) or stochastic (carcinogenesis, mutagenesis) effects. Teratogenic effects are cumulative with increasing dose, and require a threshold dose (< 50 mGy are considered as safe) and depend on the gestation age (minimum risk prior to 8th week and after

the 23rd week). Carcinogenesis (dose even < 10 mGy present a risk) and mutagenesis (500-1000 mGy doses are required, far in excess of the doses in common radiographic studies) get worse with increasing dose but they do not require a dose threshold and are not dependent on the gestational age [58].

There is no imaging modality that should be routinely repeated in pregnant women.

Scientific societies and organisations agree on the safety of the diagnostic evaluation when ultrasound [59], X-ray imaging [60, 61], and MRI [62, 63] are used as and when indicated [64-70].

A radiographic procedure should not be withheld from a pregnant woman if the procedure is clearly indicated and doing so will affect her medical care.

It is generally recommended that an investigation resulting in an absorbed dose to the foetus of greater than 0.5 mGy requires justification.

Ultrasound (when necessary using change in renal resistive index and transvaginal/transabdominal US with a full bladder) has become the primary radiological diagnostic tool when evaluating pregnant patients suspected of renal colic. However, normal physiological changes in pregnancy can mimic ureteral obstruction [66-68].

Magnetic resonance imaging can be used, as a second-line procedure, to define the level of urinary tract obstruction, and to visualise stones as a filling defect [65, 70]. As 3 Tesla (T) MRI has not been evaluated in pregnancy, the use of 1.5T is currently recommended. The use of gadolinium is not routinely recommended in pregnancy to avoid toxic effects to the embryo.

For the detection of urolithiasis during pregnancy, low-dose CT is associated with a higher positive predictive value (95.8%) compared to MRI (80%) and US (77%). Its high accuracy is combined with the least negative interventions such as ureteroscopy [71]. Although low-dose CT protocols reduce the radiation exposure, they are currently recommended for judicious use in pregnant women as a last-line option [66].

3.3.3.1.1 Summary of evidence and guidelines for diagnostic imaging during pregnancy

Summary of evidence	LE
Only low-level data exist for imaging in pregnant women supporting US and MRI.	3

Recommendations	Strength rating
Use ultrasound as the preferred method of imaging in pregnant women.	Strong
In pregnant women, use magnetic resonance imaging as a second-line imaging modality.	Strong
In pregnant women, offer low-dose computed tomography as a last-line option.	Strong

3.3.3.2 Diagnostic imaging in children

Children with urinary stones have a high risk of recurrence; therefore, standard diagnostic procedures for high-risk patients apply, including a valid stone analysis (Section 3.1.3 and Chapter 4). The most common non-metabolic disorders facilitating stone formation are vesicoureteral reflux (VUR), UPJ obstruction, neurogenic bladder, and other voiding difficulties [72].

When selecting diagnostic procedures to identify urolithiasis in children, it should be remembered that these patients might be uncooperative, require anaesthesia, and may be sensitive to ionising radiation [73-75]. Again, the principle of ALARA (As Low As Reasonably Achievable) should be observed.

Ultrasound

Ultrasound is the primary imaging technique [73] in children. Its advantages are absence of radiation and no need for anaesthesia. Imaging should include both the fluid-filled bladder with adjoining portion of the ureters, as well as the upper ureter [76-80]. Colour Doppler US shows differences in the ureteral jet [77] and resistive index of the arciform arteries of both kidneys, which are indicative of the grade of obstruction [78]. Nevertheless, US fails to identify stones in > 40% of children [79-82] and provides limited information on renal function.

Plain films (KUB radiography)

Kidney-ureter-bladder radiography can help to identify stones and their radiopacity, and facilitate follow-up.

Intravenous urography (IVU)

The radiation dose for IVU is comparable to that for voiding cystourethrography (0.33 mSv) [83]. However, the need for contrast medium injection is a major drawback.

Helical computed tomography (CT)

Recent low-dose CT protocols have been shown to significantly reduce radiation exposure [41, 84]. In children, only 5% of stones escape detection by NCCT [77, 84, 85]. Sedation or anaesthesia is rarely needed with modern high-speed CT equipment.

Magnetic resonance urography (MRU)

Magnetic resonance urography cannot be used to detect urinary stones. However, it might provide detailed anatomical information about the urinary collecting system, the location of an obstruction or stenosis in the ureter, and renal parenchymal morphology [86].

3.3.3.2.1 Summary of evidence and guidelines for diagnostic imaging in children

Summary of evidence	LE
Ultrasound is the first-line imaging modality in children when a stone is suspected; it should include the kidney, fluid-filled bladder and the ureter next to the kidney and the (filled) bladder.	2b
A kidney-ureter-bladder radiography (or low-dose NCCT) is an alternative investigation if US will not provide the required information.	2b

Recommendations	Strength rating
In all children, complete a metabolic evaluation based on stone analysis.	Strong
Collect stone material for analysis to classify the stone type.	Strong
Perform ultrasound as first-line imaging modality in children when a stone is suspected; it should include the kidney, fluid-filled bladder and the ureter.	Strong
Perform a kidney-ureter-bladder radiography (or low-dose non-contrast-enhanced computed tomography) if ultrasound will not provide the required information.	Strong

3.4 Disease Management

3.4.1 Renal colic

Pain relief

Non-steroidal anti-inflammatory drugs (NSAIDs) (including metamizolopyrone), and paracetamol are effective in patients with acute stone colic [87-89], and have better analgesic efficacy than opioids. The addition of antispasmodics to NSAIDs does not result in better pain control. Data on other types of non-opioid, non-NSAID medication is scarce [90]. Patients receiving NSAIDs are less likely to require further analgesia in the short term. It should be taken into consideration that the use of diclofenac and ibuprofen increased major coronary events. Diclofenac is contraindicated in patients with congestive heart failure (New York Heart Association class II-IV), ischaemic heart disease and peripheral arterial- and cerebrovascular disease. Patients with significant risk factors for cardiovascular events should be treated with diclofenac only after careful consideration. As risks increase with dose and duration, the lowest effective dose should be used for the shortest duration [91, 92].

Opioids, particularly pethidine, are associated with a high rate of vomiting compared to NSAIDs, and carry a greater likelihood of further analgesia being needed [89, 93] (see below). If an opioid is used, it is recommended that it is not pethidine.

Prevention of recurrent renal colic

Facilitation of passage of ureteral stones is discussed in Section 3.4.3.

For patients with ureteral stones that are expected to pass spontaneously, NSAID tablets or suppositories (e.g., diclofenac sodium, 100-150 mg/day, 3-10 days) may help reduce inflammation and the risk of recurrent pain [94, 95]. Although diclofenac can affect renal function in patients with already reduced function, it has no functional effect in patients with normal renal function [96].

The most recent SR and MA by Hollingsworth *et al.* [97] addressed pain reduction as a secondary outcome and concluded that medical expulsive therapy (MET) seems efficacious in reducing pain episodes of patients with ureteral stones.

If analgesia cannot be achieved medically, drainage, using stenting, percutaneous nephrostomy or stone removal, is indicated [98].

3.4.1.1 Summary of evidence and guidelines for the management of renal colic

Summary of evidence	LE
Non-steroidal anti-inflammatory drugs are very effective in treating renal colic and are superior to opioids.	1b
For symptomatic ureteral stones, stone removal as first-line treatment is a feasible option in selected patients.	1b

Recommendations	Strength rating
Offer a non-steroidal anti-inflammatory as the first drug of choice. e.g. metamizol (dipyrone); alternatively paracetamol or, depending on cardio-vascular risk factors, diclofenac*, indomethacin or ibuprofen**.	Strong
Offer hydromorphone, pentazocine or tramadol as a second choice.	Weak
Offer renal decompression or ureteroscopic stone removal in case of analgesic refractory colic pain.	Strong

*Affects glomerular filtration rate (GFR) in patients with reduced renal function.

**Recommended to counteract recurrent pain after ureteral colic.

3.4.2 Management of sepsis and/or anuria in obstructed kidney

The obstructed kidney with all signs of urinary tract infection (UTI) and/or anuria is a urological emergency. Urgent decompression is often necessary to prevent further complications in infected hydronephrosis secondary to stone-induced, unilateral or bilateral, renal obstruction.

Decompression

Currently, there are two options for urgent decompression of obstructed collecting systems:

- placement of an indwelling ureteral stent;
- percutaneous placement of a nephrostomy tube.

There is little evidence to support the superiority of percutaneous nephrostomy over retrograde stenting for primary treatment of infected hydronephrosis. There is no good quality evidence to suggest that ureteral stenting has more complications than percutaneous nephrostomy [99, 100].

Only one RCT [101] compared different modalities of decompression of acute infected hydronephrosis. The complications of percutaneous nephrostomy insertion have been reported consistently, but those of ureteral stent insertion are less well described [99]. Definitive stone removal should be delayed until the infection is cleared following a complete course of antimicrobial therapy. A small RCT showed the feasibility of immediate ureteroscopic stone removal combined with appropriate antibiotic regimen; however, at the cost of longer hospital stay and higher analgesic requirements [102].

Further measures

Following urgent decompression of the obstructed and infected urinary collecting system, both urine- and blood samples should be sent for culture-antibiogram sensitivity testing, and antibiotics should be initiated immediately thereafter or continued, if initiated prior to testing. The regimen should be re-evaluated in the light of the culture-antibiogram test. Although clinically well accepted, the impact of a second antibiogram test on treatment outcome has not yet been evaluated. Intensive care might become necessary [103].

3.4.2.1 Summary of evidence and guidelines for the management of sepsis and anuria

Summary of evidence	LE
For decompression of the renal collecting system, ureteral stents and percutaneous nephrostomy catheters are equally effective.	1b

Recommendations	Strength rating
Urgently decompress the collecting system in case of sepsis with obstructing stones, using percutaneous drainage or ureteral stenting.	Strong
Delay definitive treatment of the stone until sepsis is resolved.	Strong
Collect (again) urine for antibiogram test following decompression.	Strong
Start antibiotics immediately (+ intensive care if necessary).	Strong
Re-evaluate antibiotic regimen following antibiogram findings.	Strong

3.4.3 Medical expulsive therapy (MET)

Medical expulsive therapy should only be used in informed patients if active stone removal is not indicated. Treatment should be discontinued if complications develop (infection, refractory pain, deterioration of renal function). Several drug classes are used for MET [104-107]. When using α -blockers for MET, possible side effects include retrograde ejaculation and hypotension [95].

Patients treated with α -blockers, Ca-channel inhibitors (nifedipine) and phosphodiesterase type 5 (PDE5) inhibitors (Tadalafil) are more likely to pass stones with fewer colic episodes than those not receiving such therapy [95, 108, 109]. Based on studies with a limited number of patients [107, 109-111], no recommendation for the use of PDE-5 Inhibitors or corticosteroids in combination with α -blockers in MET can be made.

Tamsulosin showed an overall superiority to nifedipine for distal ureteral calculi [112]. A class effect of α -blockers has been demonstrated in MAs [111, 113]. However, there is contradictory evidence between these studies and several well-designed, multicentre, placebo-controlled, double-blinded randomised studies showing limited, or no, benefit using α -blockers, besides some advantage for distal ureteral stones > 5 mm) [114-116]. A published MA, including 55 trials with a data search cut-off of July 1st 2015, also including the publications addressed above, assessed stone passage as primary outcome [97]. Based on the well-designed sensitivity analyses of this MA, α -blockers promote spontaneous stone expulsion of large stones located in any part of the ureter.

The primary outcome of most trials assessing MET was stone passage, or follow up, up to four weeks. No data are currently available to support other time-intervals.

The Panel concludes that MET seems efficacious in the treatment of patients with ureteral stones who are amenable to conservative management. The greatest benefit might be among those with \geq 5 mm distal stones [117].

3.4.3.1 Summary of evidence and guidelines for MET

Summary of evidence	LE
MET seems to be efficacious treating patients with ureteral stones who are amenable to conservative management. The greatest benefit might be among those with > 5 mm (distal) stones.	1a
Insufficient data exist to support the use of PDE-5 Inhibitors or corticosteroids in combination with α -blockers as an accelerating adjunct.	2a
α -blockers increase stone expulsion rates in distal ureteral stones \geq 5mm.	1a
A class effect of α -blockers is demonstrated.	1a

Recommendation	Strength rating
Offer α -blockers as medical expulsive therapy as one of the treatment options for (distal) ureteral stones \geq 5 mm.	Strong

Medical expulsive therapy in special situations is addressed in the particular chapters.

3.4.4 Chemolysis

Percutaneous irrigation chemolysis

Percutaneous chemolysis is rarely used nowadays, for practical reasons. Percutaneous irrigation chemolysis may be an option for infection- and theoretically also for uric acid stones. For dissolution of struvite stones, Suby's G solution (10% hemiacidrin; pH 3.5-4) can be used. The method has been described in case series along with literature reviews [118-120].

Oral chemolysis

Stones composed of uric acid, but not sodium or ammonium urate stones, can be dissolved by oral chemolysis. Prior stone analysis may provide information on stone composition. Urinary pH measurement and X-ray characteristics can provide information on the type of stone.

Oral chemolitholysis is based on alkalinisation of urine by application of alkaline citrate or sodium bicarbonate. The pH should be adjusted to 7.0-7.2. Chemolysis is more effective at a higher pH, which might, however, promote calcium phosphate stone formation. Patients will need to adjust the dosage of alkalinising medication by self-monitoring the pH of their urine. No RCTs are available for this therapy, which has been in use for decades. Rodman, *et al* [121] reviewed the principles and provided guidance to its clinical use, which was supported by Becker, *et al* in 2007 [122]. Monitoring of radiolucent stones during therapy is the domain of US; however, repeat-NCCT might be necessary [121, 122].

In the case of uric acid obstruction of the collecting system, oral chemolysis in combination with urinary drainage is indicated [123]. A combination of alkalinisation with tamsulosin can increase the frequency of spontaneous passage of distal ureteral uric acid stones as shown in one RCT for stones > 5 mm [123].

3.4.4.1 Summary of evidence and guidelines for chemolysis

Summary of evidence	LE
Irrigation chemolysis has been in limited clinical use to dissolve struvite stones.	3
Uric acid stones can be dissolved based on oral alkalinisation of the urine above 7.0.	3
For obstructing uric acid stones, a combination of oral chemolysis with Tamsulosin is more effective than each substance alone, particularly in stones > 8 mm.	1b

Recommendations (oral chemolysis of uric acid stones)	Strength rating
Inform the patient how to monitor urine-pH by dipstick and to modify the dosage of alkalinising medication according to urine pH, as changes in urine pH are a direct consequence of such medication.	Strong
Carefully monitor patients during/after oral chemolysis of uric acid stones.	Strong
Combine oral chemolysis with Tamsulosin in case of (larger) ureteral stones (if active intervention is not indicated).	Weak

3.4.5 Extracorporeal shock wave lithotripsy (SWL)

The success of SWL depends on the efficacy of the lithotripter and the following factors:

- size, location (ureteral, pelvic or calyceal), and composition (hardness) of the stones (Section 3.4.3.2);
- patient's habitus (Section 3.4.2.2);
- performance of SWL (best practice, see below).

Each of these factors significantly influence the retreatment rate and final outcome of SWL.

Best clinical practice

Stenting

Routine use of internal stents before SWL does not improve stone free rates (SFRs), nor lowers the number of auxiliary treatments. It may, however, reduce formation of steinstrasse [124-127].

Pacemaker

Patients with a pacemaker can be treated with SWL, provided that appropriate technical precautions are taken; patients with implanted cardioverter defibrillators must be managed with special care (firing mode temporarily reprogrammed during SWL treatment). However, this might not be necessary with new-generation lithotripters [128].

Shock wave rate

Lowering shock wave frequency from 120 to 60-90 shock waves/min improves SFRs [129-134]. Tissue damage increases with shock wave frequency [135-140].

Number of shock waves, energy setting and repeat treatment sessions

The number of shock waves that can be delivered at each session depends on the type of lithotripter and shock wave power. There is no consensus on the maximum number of shock waves.

Starting SWL on a lower energy setting with stepwise power (and SWL sequence) ramping can achieve vasoconstriction during treatment [137], which prevents renal injury [141-143]. Animal studies [144] and

a prospective randomised study [145] have shown better SFRs (96% vs. 72%) using stepwise power ramping, but no difference has been found for fragmentation or evidence of complications after SWL, irrespective of whether ramping was used [146].

There are no conclusive data on the intervals required between repeated SWL sessions. However, clinical experience indicates that repeat sessions are feasible (within 1 day for ureteral stones).

Improvement of acoustic coupling

Proper acoustic coupling between the cushion of the treatment head and the patient's skin is important. Defects (air pockets) in the coupling gel deflect 99% of shock waves [147]. Ultrasound gel is probably the most widely used agent available for use as a lithotripsy coupling agent [148].

Procedural control

Results of treatment are operator dependent, and better results are obtained by experienced clinicians. During the procedure, careful imaging control of localisation contributes to outcome quality [149].

Pain control

Careful control of pain during treatment is necessary to limit pain-induced movements and excessive respiratory excursions [150-153].

Antibiotic prophylaxis

No standard antibiotic prophylaxis before SWL is recommended. However, prophylaxis is recommended in the case of internal stent placement ahead of anticipated treatments and in the presence of increased bacterial burden (e.g., indwelling catheter, nephrostomy tube, or infectious stones) [57, 154, 155].

Medical therapy after extracorporeal shock wave lithotripsy

In spite of conflicting results, most RCTs and several MAs support MET after SWL for ureteral or renal stones as adjunct to expedite expulsion and to increase SFRs. Medical expulsion therapy might also reduce analgesic requirements [156-163].

Complications of extracorporeal shock wave lithotripsy

Compared to PNL and ureterorenoscopy (URS), there are fewer overall complications with SWL [164, 165] (Table 3.4.1).

Table 3.4.1: Shock wave lithotripsy-related complications [166-180]

Complications			%	Ref.
Related to stone fragments	Steinstrasse		4 - 7	[166-168]
	Regrowth of residual fragments		21 - 59	[169, 170]
	Renal colic		2 - 4	[171]
Infectious	Bacteriuria in non-infection stones		7.7 - 23	[169, 172]
	Sepsis		1 - 2.7	[169, 172]
Tissue effect	Renal	Haematoma, symptomatic	< 1	[173]
		Haematoma, asymptomatic	4 - 19	[173]
	Cardiovascular	Dysrhythmia	11 - 59	[169, 174]
		Morbid cardiac events	Case reports	[169, 174]
	Gastrointestinal	Bowel perforation	Case reports	[175-177]
		Liver, spleen haematoma	Case reports	[177-180]

The relationship between SWL and hypertension or diabetes is unclear. Published data are contradictory; however, no evidence exists supporting the hypothesis that SWL may cause long-term adverse effects [181-186].

3.4.5.1 Summary of evidence and guidelines for SWL

Summary of evidence	LE
Stepwise power ramping prevents renal injury.	1b
Clinical experience has shown that repeat sessions are feasible (within one day for ureteral stones).	4
Optimal shock wave frequency is 1.0 to 1.5 Hz.	1a

Recommendation	Strength rating
Ensure correct use of the coupling agent because this is crucial for effective shock wave transportation.	Strong
Maintain careful fluoroscopic and/or ultrasonographic monitoring during shock wave lithotripsy (SWL).	Strong
Use proper analgesia because it improves treatment results by limiting pain-induced movements and excessive respiratory excursions.	Strong
In the case of infected stones or bacteriuria, prescribe antibiotics prior to SWL.	Strong

3.4.6 Ureterorenoscopy (URS) (retrograde and antegrade, RIRS)

The current standard for rigid ureterorenoscopes are tip diameters of < 8 F. Rigid URS can be used for the whole ureter [186]. However, technical improvements, as well as the availability of digital scopes, also favour the use of flexible ureteroscopes in the ureter [187].

Percutaneous antegrade removal of ureteral stones is a consideration in selected cases, i.e. large, impacted proximal ureteral calculi in a dilated renal collecting system [188-190], or when the ureter is not amenable to retrograde manipulation [191-195].

Ureterorenoscopy for renal stones (RIRS)

Technical improvements including endoscope miniaturisation, improved deflection mechanism, enhanced optical quality and tools, and introduction of disposables have led to an increased use of URS for both renal and ureteral stones. Major technological progress has been achieved for RIRS. A recent SR addressing renal stones > 2 cm showed a cumulative SFR of 91% with 1.45 procedures/patient; 4.5% of the complications were ≥ Clavien 3 [187, 196, 197]. Digital scopes demonstrate shorter operation times due to the improvement in image quality [196].

Stones that cannot be extracted directly must be disintegrated. If it is difficult to access stones within the lower renal pole that need disintegration; it may help to displace them into a more accessible calyx [198].

Best clinical practice in ureterorenoscopy

Access to the upper urinary tract

Most interventions are performed under general anaesthesia, although local or spinal anaesthesia is possible. Intravenous sedation is suitable for female patients with distal ureteral stones [199].

Antegrade URS is an option for large, impacted, proximal ureteral calculi [188-191] (Section 3.4.3.1.4.2).

Safety aspects

Fluoroscopic equipment must be available in the OR. We recommend placement of a safety wire, even though some groups have demonstrated that URS can be performed without it [200-202]. Balloon and plastic dilators should be available, if necessary.

Prior rigid URS can be helpful for optical dilatation followed by flexible URS, if necessary. If ureteral access is not possible, insertion of a JJ stent followed by URS after seven to fourteen days offers an alternative [203]. Bilateral URS during the same session is feasible resulting in equivalent-to-lower SFRs, but slightly higher overall complication rates (mostly minor, Clavien I and II) [204, 205].

Ureteral access sheaths

Hydrophilic-coated ureteral access sheaths, which are available in different calibres (inner diameter from 9 F upwards), can be inserted via a guide wire, with the tip placed in the proximal ureter.

Ureteral access sheaths allow easy, multiple, access to the UUT and therefore significantly facilitate URS. The use of ureteral access sheaths improves vision by establishing a continuous outflow, decrease intra-renal pressure, and potentially reduce operating time [206, 207].

The insertion of ureteral access sheaths may lead to ureteral damage, whereas the risk is lowest in pre-stented systems [208]. No data on long-term side effects are available [208, 209]. Whilst larger cohort series showed no difference in SFRs and ureteral damage, they did show lower post-operative infectious complications [210].

Use of ureteral access sheaths depends on the surgeon's preference.

Stone extraction

The aim of URS is complete stone removal. "Dust and go" strategies should be limited to the treatment of large (renal) stones [211]. Stones can be extracted by endoscopic forceps or baskets. Only baskets made of nitinol can be used for flexible URS [212].

Intracorporeal lithotripsy

The most effective lithotripsy system is the holmium:yttrium-aluminium-garnet (Ho:YAG) laser, which is currently the optimum standard for URS and flexible nephroscopy (Section 3.4.6), because it is effective in all stone types [213, 214]. Pneumatic and US systems can be used with high disintegration efficacy in rigid URS [215, 216].

However, stone migration into the kidney is a common problem, which can be prevented by placement of special anti-migration tools proximal of the stone [217]. Medical expulsion therapy following Ho:YAG laser lithotripsy increases SFRs and reduces colic episodes [218].

Stenting before and after URS

Routine stenting is not necessary before URS. However, pre-stenting facilitates ureteroscopic management of stones, improves the SFR, and reduces intra-operative complications [219, 220].

Randomised prospective trials have found that routine stenting after uncomplicated URS (complete stone removal) is not necessary; stenting might be associated with higher post-operative morbidity [221-223]. A ureteral catheter with a shorter indwelling time (one day) may also be used, with similar results [224].

Stents should be inserted in patients who are at increased risk of complications (e.g., ureteral trauma, residual fragments, bleeding, perforation, UTIs, or pregnancy), and in all doubtful cases, to avoid stressful emergencies. The ideal duration of stenting is not known. Most urologists favour 1-2 weeks after URS. α -blockers reduce the morbidity of ureteral stents and increase tolerability [225, 226].

Medical expulsive therapy after ureterorenoscopy

Medical expulsion therapy following Ho:YAG laser lithotripsy accelerates the spontaneous passage of fragments and reduces episodes of colic [218].

Complications of ureterorenoscopy

The overall complication rate after URS is 9-25% [186, 227, 228]. Most complications are minor and do not require intervention. Ureteral avulsion and strictures are rare (< 1%). Previous perforations are the most important risk factor for complications.

3.4.6.1 Summary of evidence and guidelines for retrograde URS, RIRS and antegrade ureteroscopy

Summary of evidence	LE
In uncomplicated URS, a stent need not be inserted.	1a
In URS (in particular for renal stones), pre-stenting has been shown to improve outcome.	1b
An α -blocker can reduce stent-related symptoms and colic episodes.	1a
Medical expulsion therapy following Ho:YAG laser lithotripsy accelerates the spontaneous passage of fragments and reduces episodes of colic.	1b
The most effective lithotripsy system for flexible ureteroscopy is the Ho:YAG laser.	2a
Pneumatic and US systems can be used with high disintegration efficacy in rigid URS.	2a
Medical expulsion therapy following Ho:YAG laser lithotripsy increases SFRs and reduces colic episodes.	1b
Percutaneous antegrade removal of proximal ureter stones or laparoscopic ureterolithotomy are feasible alternatives to retrograde ureteroscopy, in selected cases.	1a

Recommendations	Strength rating
Use holmium: yttrium-aluminium-garnet (Ho:YAG) laser lithotripsy for (flexible) ureterorenoscopy (URS).	Strong
Perform stone extraction only under direct endoscopic visualisation of the stone.	Strong
Do not insert a stent in uncomplicated cases.	Strong
Pre-stenting facilitates URS and improves outcomes of URS (in particular for renal stones).	Strong
Offer medical expulsive therapy for patients suffering from stent-related symptoms and after Ho:YAG laser lithotripsy for the passage of fragments.	Strong
Use percutaneous antegrade removal of ureteral stones as an alternative when shock wave lithotripsy is not indicated or has failed, and when the upper urinary tract is not amenable to retrograde ureterorenoscopy.	Strong
Use flexible ureterorenoscopy in case percutaneous nephrolithotomy or shock wave lithotripsy are not an option (even for stones > 2 cm). However, in that case there is a higher risk that a follow-up procedure and placement of a ureteral stent may be needed. In complex stone cases, use open or laparoscopic approaches as possible alternatives.	Strong

3.4.7 Percutaneous nephrolithotomy (PNL)

Percutaneous nephrolithotripsy remains the standard procedure for large renal calculi. Different rigid and flexible endoscopes are available and the selection is mainly based on the surgeon's own preference. Standard access tracts are 24-30 F. Smaller access sheaths, < 18 French, were initially introduced for paediatric use, but are now increasingly utilised in the adult population [229].

Contraindications

Patients receiving anti-coagulant therapy must be monitored carefully pre- and post-operatively. Anti-coagulant therapy must be discontinued before PNL [230].

Other important contraindications include:

- untreated UTI;
- tumour in the presumptive access tract area;
- potential malignant kidney tumour;
- pregnancy (Section 3.4.14.1).

Best clinical practice

Intracorporeal lithotripsy

Several methods for intracorporeal lithotripsy during PNL are available. Ultrasonic and pneumatic systems are most commonly used for rigid nephroscopy, whilst laser is increasingly used for miniaturised instruments [231]. Flexible endoscopes also require laser lithotripsy to maintain tip deflection, with the Ho:YAG laser having become the standard.

Pre-operative imaging

Pre-procedural evaluations are summarised in Section 3.3.1. In particular, US or CT of the kidney and the surrounding structures can provide information regarding interpositioned organs within the planned percutaneous path (e.g., spleen, liver, large bowel, pleura, and lung) [232].

Positioning of the patient

Both prone and supine positions are equally safe, although the supine position confers some advantages, it depends on appropriate equipment being available to position the patient correctly, for example, X-ray devices and an operating table. Most studies cannot demonstrate an advantage of supine PNL in terms of OR time. Prone position offers more options for puncture and is therefore preferred for upper pole or multiple access [233-235]. On the other hand, supine position allows simultaneous retrograde access to the collecting system, using flexible ureteroscope [236].

Puncture

Although fluoroscopy is the most common intra-operative imaging method, the (additional) use of US reduces radiation exposure [232, 237].

Pre-operative CT or intra-operative US allows identification of the tissue between the skin and kidney and lowers the incidence of visceral injury. The calyceal puncture may be done under direct visualisation using simultaneous flexible URS [237-241].

Dilatation

Dilatation of the percutaneous access tract can be achieved using a metallic telescope, single (serial) dilators, or a balloon dilatator. Although there are papers demonstrating that single step dilation is equally effective as other methods, the difference in outcomes is most likely related to surgeon experience rather than to the technology used.

Choice of instruments

The Urolithiasis Panel performed a SR assessing the outcomes of PNL using smaller tract sizes (< 22 Fr, mini-PNL) for removing renal calculi [229]. Stone-free rates were comparable in miniaturised and standard PNL procedures. Procedures performed with small instruments tended to be associated with significantly lower blood loss, but the duration of procedure tended to be significantly longer. There were no significant differences in any other complications. However, the quality of the evidence was poor with only two RCTs and the majority of the remaining studies were single-arm case series only. Furthermore, the tract sizes used, and types of stones treated, were heterogeneous; therefore, the risk of bias and confounding were high.

Nephrostomy and stents

The decision on whether, or not, to place a nephrostomy tube at the conclusion of the PNL procedure depends on several factors, including:

- presence of residual stones;
- likelihood of a second-look procedure;
- significant intra-operative blood loss;
- urine extravasation;
- ureteral obstruction;
- potential persistent bacteriuria due to infected stones;
- solitary kidney;
- bleeding diathesis;
- planned percutaneous chemolitholysis.

Small bore nephrostomies seem to have advantages in terms of post-operative pain [242-244]. Tubeless PNL is performed without a nephrostomy tube. When neither a nephrostomy tube nor a ureteral stent is introduced, the procedure is known as totally tubeless PNL. In uncomplicated cases, the latter procedure results in a shorter hospital stay, with no disadvantages reported [245-247].

Complications of percutaneous nephrolithotomy

A systematic review of almost 12,000 patients shows the incidence of complications associated with PNL; fever 10.8%, transfusion 7%, thoracic complication 1.5%, sepsis 0.5%, organ injury 0.4%, embolisation 0.4%, urinoma 0.2%, and death 0.05% [248].

Peri-operative fever can occur, even with a sterile pre-operative urinary culture and peri-operative antibiotic prophylaxis, because the renal stones themselves may be a source of infection. Intra-operative renal stone culture may therefore help to select post-operative antibiotics [249, 250]. Intra-operative irrigation pressure < 30 mmHg and unobstructed post-operative urinary drainage may be important factors in preventing postoperative sepsis. Bleeding after PNL may be treated by briefly clamping of the nephrostomy tube. Superselective embolic occlusion of the arterial branch may become necessary in the case of severe bleeding.

3.4.7.1 Summary of evidence and guidelines for endourology techniques for renal stone removal

Summary of evidence	LE
Imaging of the kidney with US or CT can provide information regarding interpositioned organs within the planned percutaneous path (e.g., spleen, liver, large bowel, pleura, and lung).	1a
Both prone and supine positions are equally safe, but neither has a proven advantage in operating time or SFR.	1a
Percutaneous nephrolithotomy performed with small instruments tends to be associated with significantly lower blood loss, but the duration of procedure tended to be significantly longer. There are no significant differences in SFR or any other complications.	1a
In uncomplicated cases, a totally tubeless PNL results in a shorter hospital stay, with no increase in complication rate.	1a

Recommendations	Strength rating
Perform pre-procedural imaging, including contrast medium where possible or retrograde study when starting the procedure, to assess stone comprehensiveness and anatomy of the collecting system to ensure safe access to the renal stone.	Strong
In uncomplicated cases, perform a tubeless (without nephrostomy tube) or totally tubeless (without nephrostomy tube and ureteral stent) percutaneous nephrolithotomy procedure.	Strong

3.4.8 General recommendations and precautions for stone removal

3.4.8.1 Antibiotic therapy

Urinary tract infections should always be treated if stone removal is planned. In patients with clinically significant infection and obstruction, drainage should be performed for several days before starting stone removal. A urine culture or urinary microscopy should be performed before treatment [251].

Perioperative antibiotic prophylaxis

For prevention of infection following URS and percutaneous stone removal, no clear-cut evidence exists [252]. In a review of a large database of patients undergoing PNL, it was found that in patients with negative baseline urine culture, antibiotic prophylaxis significantly reduced the rate of post-operative fever and other complications [253]. Single dose administration was found to be sufficient [254].

Recommendations	Strength rating
Obtain a urine culture or perform urinary microscopy before any treatment is planned.	Strong
Exclude or treat urinary tract infections prior to stone removal.	Strong
Offer peri-operative antibiotic prophylaxis to all patients undergoing endourological treatment.	Strong

3.4.8.2 Antithrombotic therapy and stone treatment

Patients with a bleeding diathesis, or receiving antithrombotic therapy, should be referred to an internist for appropriate therapeutic measures before deciding on stone management [255-259]. In patients with an uncorrected bleeding diathesis, the following are at elevated risk of haemorrhage or perinephric haematoma (PNH) (high-risk procedures):

- SWL (hazard ratio of PNH up to 4.2 during anti-coagulant/anti-platelet medication [260] [LE: 2]);
- PNL;
- percutaneous nephrostomy;
- laparoscopic surgery;
- open surgery [255, 261, 262].

Shock wave lithotripsy is feasible and safe after correction of the underlying coagulopathy [263-267]. In the case of an uncorrected bleeding disorder or continued antithrombotic therapy, URS, in contrast to SWL and PNL, might offer an alternative approach since it is associated with less morbidity [268-272]. Despite appropriate cessation of anti-platelet agents, following standardised protocols, prolonged haematuria in tube drainage after PNL has been reported [273]. Only data on flexible URS are available which support the superiority of URS in the treatment of proximal ureteral stones [269, 274, 275].

Table 3.4.2: Risk stratification for bleeding [257-259, 276]

Low-risk bleeding procedures	Cystoscopy Flexible cystoscopy Ureteral catheterisation Extraction of ureteral stent Ureterorenoscopy
High-risk bleeding procedures	Shock wave lithotripsy Percutaneous nephrostomy Percutaneous nephrolithotripsy

Table 3.4.3: Suggested strategy for antithrombotic therapy in stone removal [257-259]

(In collaboration with a cardiologist/internist weigh the risks and benefits of discontinuation of therapy, vs. delaying elective surgical procedures).

	Bleeding risk of planned procedure	Risk of thromboembolism		
		Low risk	Intermediate risk	High risk
Warfarin Dabigatran Rivaroxaban Apixaban	Low-risk procedure	May be continued	Bridging therapy	Bridging therapy
	High-risk procedure	May be temporarily discontinued at appropriate interval. Bridging therapy is strongly recommended.	Bridging therapy	Bridging therapy
Aspirin	Low-risk procedure	Continue	Continue	Elective surgery: postpone. Non-deferrable surgery: continue
	High-risk procedure	Discontinue	Elective surgery: postpone. Non-deferrable surgery: continue, if is possible.	Elective surgery: postpone. Non-deferrable surgery: continue.
Thienopyridine agents (P2Y12 receptor inhibitors)	Low-risk procedure	Discontinue five days before intervention. Resume within 24-72 hours with a loading dose.	Continue	Elective surgery: postpone. Non-deferrable surgery: continue.
	High-risk procedure	Discontinue five days before intervention and resume within 24-72 hours with a loading dose.	Elective surgery: postpone. Non-deferrable surgery: discontinue five days before procedure and resume within 24-72 hours with a loading dose. Bridging therapy -GPIIb/IIIa inhibitors if aspirin is discontinued.	Elective surgery: postpone. Non-deferrable surgery: discontinue five days before procedure and resume within 24-72 hours, with a loading dose. Bridging therapy -GPIIb/IIIa inhibitors.

3.4.8.2.1 Summary of evidence and guidelines for antithrombotic therapy and stone treatment

Summary of evidence	LE
Active surveillance is indicated in patients at high risk for thrombotic complications in the presence of an asymptomatic calyceal stone.	4
The temporary discontinuation, or bridging of antithrombotic therapy in high-risk patients, should be discussed with the internist.	3
Retrograde (flexible) URS stone removal is associated with less morbidity in patients when antithrombotic therapy cannot be discontinued.	2a

Recommendations	Strength rating
Offer active surveillance to patients at high risk of thrombotic complications in the presence of an asymptomatic calyceal stone.	Weak
Decide on temporary discontinuation, or bridging of antithrombotic therapy in high-risk patients, in consultation with the internist.	Strong
Retrograde (flexible) URS is the preferred intervention if stone removal is essential and antithrombotic therapy cannot be discontinued, since it is associated with less morbidity.	Strong

3.4.8.3 Obesity

A high BMI can pose a higher anaesthetic risk, and a lower success rate after SWL [277].

3.4.8.4 Stone composition

Stones composed of brushite, calcium oxalate monohydrate, or cystine are particularly hard, as well as stones with a high density on NCCT [35]. Percutaneous nephrolithotomy or RIRS and URS are alternatives for removal of large SWL-resistant stones.

Recommendations	Strength rating
Consider the stone composition before deciding on the method of removal, based on patient history, former stone analysis of the patient or Hounsfield unit (HU) on unenhanced computed tomography (CT). Stones with density > 1,000 HU on non-contrast-enhanced CT are less likely to be disintegrated by shock wave lithotripsy.	Strong
Attempt to dissolve radiolucent stones (See Section 3.4.4.)	Strong

3.4.8.5 Contraindications of procedures

Contraindications of extracorporeal SWL

There are several contraindications to the use of extracorporeal SWL, including:

- pregnancy, due to the potential effects on the foetus [278];
- bleeding diatheses, which should be compensated for at least 24 hours before and 48 hours after treatment [279];
- uncontrolled UTIs;
- severe skeletal malformations and severe obesity, which prevent targeting of the stone;
- arterial aneurysm in the vicinity of the stone [280];
- anatomical obstruction distal to the stone.

Contraindications of URS

Apart from general problems, for example, with general anaesthesia or untreated UTIs, URS can be performed in all patients without any specific contraindications.

Contraindications of PNL

Patients receiving anti-coagulant therapy must be monitored carefully pre- and post-operatively. Anti-coagulant therapy must be discontinued before PNL [268]. Other important contraindications include:

- untreated UTI;
- tumour in the presumptive access tract area;
- potential malignant kidney tumour;
- pregnancy (Section 3.4.3.1).

3.4.9 Specific stone management of ureteral stones

3.4.9.1 Conservative treatment/observation

There are only limited data regarding spontaneous stone passage according to stone size [281]. It is estimated that 95% of stones up to 4 mm pass within 40 days [186].

Based on an analysis of available evidence, an exact cut-off size for stones that are likely to pass spontaneously cannot be provided; < 10 mm may be considered a best estimate [186]. Therefore, the Panel decided not to include stone size but rather recommend “small”, suggesting < 6 mm. The Panel is aware of the fact that spontaneous stone expulsion decreases with increasing stone size and that there are differences between individual patients.

3.4.9.2 Pharmacological treatment, medical expulsive therapy

Medical expulsive therapy should only be used in informed patients if active stone removal is not indicated. Treatment should be discontinued if complications develop (infection, refractory pain, deterioration of renal function). In case of known uric acid stones in the distal ureter, a combination of alkalinisation with tamsulosin can increase the frequency of spontaneous passage. For details see Sections 3.4.3 and 3.4.4

3.4.9.3 Indications for active removal of ureteral stones [186, 281, 282]

Indications for active removal of ureteral stones are:

- stones with a low likelihood of spontaneous passage;
- persistent pain despite adequate analgesic medication;
- persistent obstruction;
- renal insufficiency (renal failure, bilateral obstruction, or single kidney).

For general recommendations and precautions see Section 3.4.8

3.4.9.4 Selection of procedure for active removal of ureteral stones

Overall SFRs after URS or SWL for ureteral stones are comparable. However, larger stones achieve earlier stone-free status with URS. Although URS is effective for ureteral calculi, it has greater potential for complications. However, in the current endourological era, the complication rate and morbidity of URS have been significantly reduced [283]. It has been demonstrated that URS is a safe option in obese patients (BMI > 30 kg/m²) with comparable SFRs and complication rates. However, in morbidly obese patients (BMI > 35 kg/m²) the overall complication rates double [284].

The Panel performed an SR to assess the benefits and harms of URS compared to SWL [285]. Compared with SWL, URS was associated with a significantly greater SFR up to four weeks, but the difference was not significant at three months in the included studies. Ureterorenoscopy was associated with fewer re-treatments and need for secondary procedures, but with a higher need for adjunctive procedures, greater complication rates and longer hospital stay. Counterbalancing for URS's higher SFRs, SWL is associated with least morbidity. Clavien-Dindo grade complications were, if reported, less frequent in patients treated with SWL.

Obesity can cause a lower success rate after SWL and PNL and may influence the choice of treatment.

Bleeding disorder

Ureterorenoscopy can be performed in patients with bleeding disorders, with a moderate increase in complications (see also Section 3.4.8.2) [268, 271].


3.4.9.4.1 Summary of evidence and guidelines for selection of procedure for active removal of ureteral stones

Summary of evidence	LE
Observation is feasible in informed patients who develop no complications (infection, refractory pain, deterioration of renal function).	1a
Medical expulsive therapy seems to be efficacious treating patients with ureteral stones who are amenable to conservative management. The greatest benefit might be among those with > 5 mm (distal) stones.	1a
Compared with SWL, URS was associated with significantly greater SFRs up to four weeks, but the difference was not significant at three months in the included studies.	1a
Ureterorenoscopy was associated with fewer re-treatments and need for secondary procedures, but with a higher need for adjunctive procedures, greater complication rates and longer hospital stay.	1a
In the case of severe obesity, URS is a more promising therapeutic option than SWL.	2b

Recommendations	Strength rating
In patients with newly diagnosed small* ureteral stones, if active removal is not indicated (Section 3.4.2.2), observe patient initially with periodic evaluation.	Strong
Offer α -blockers as medical expulsive therapy as one of the treatment options for (distal) ureteral stones ≥ 5 mm.	Strong
Inform patients that ureterorenoscopy (URS) has a better chance of achieving stone-free status with a single procedure.	Strong
Inform patients that URS has higher complication rate when compared to shock wave lithotripsy.	Strong
In cases of severe obesity use ureterorenoscopy as first-line therapy for ureteral (and renal) stones.	Strong

*See stratification data [186].

Figure 3.4.9.5: Treatment algorithm for ureteral stones (if active stone removal is indicated)



SWL = shock wave lithotripsy; URS = Ureterorenoscopy.

3.4.10 Specific stone management of renal stones

The natural history of small, non-obstructing asymptomatic calculi is not well defined, and the risk of progression is unclear. There is still no consensus on the follow-up duration, timing and type of intervention. Treatment options are chemolysis or active stone removal.

3.4.10.1 Conservative treatment (observation)

Observation of renal stones, especially in calices, depends on their natural history (Section 3.4.2.2). The recommendations provided are not supported by high level literature. There is a prospective trial supporting annual observation for asymptomatic inferior calyceal stones, ≤ 10 mm. In case stone growth is detected, the follow-up interval should be lowered. Intervention is advised for growing stones > 5 mm [286].

3.4.10.2 Pharmacological treatment of renal stones

Dissolution of stones through pharmacological treatment is an option for uric acid stones only, but information on the composition of the stone will need to guide the type of treatment selected. See Section 3.4.4. and 3.4.8.4.

3.4.10.3 Indications for active stone removal of renal stones [287]

Indications for the removal of renal stones, include:

- stone growth;
- stones in high-risk patients for stone formation;
- obstruction caused by stones;
- infection;
- symptomatic stones (e.g., pain or haematuria);
- stones > 15 mm;
- stones < 15 mm if observation is not the option of choice.
- patient preference;
- comorbidity;
- social situation of the patient (e.g., profession or travelling);
- choice of treatment.

The risk of a symptomatic episode or need for intervention of patients with asymptomatic renal stones seems to be ~10-25% per year, with a cumulative five-year event probability of 48.5% [286, 288, 289]. A prospective RCT with > 2 year clinical follow-up reported no significant difference between SWL and observation when comparing asymptomatic calyceal stones < 15 mm in terms of SFR, symptoms, requirement for additional treatment, quality of life (QoL), renal function, or hospital admission [290]. Although some have recommended prophylaxis for these stones to prevent renal colic, haematuria, infection, or stone growth, conflicting data have been reported [289, 291, 292]. In a follow-up period of almost five years after SWL, two series have demonstrated that up to 25% of patients with small residual fragments needed treatment [170, 293]. Although the question of whether calyceal stones should be treated is still unanswered, stone growth, *de novo* obstruction, associated infection, and acute and/or chronic pain are indications for treatment [287, 294, 295].

3.4.10.4 Selection of procedure for active removal of renal stones

For general recommendations and precautions see Section 3.4.8.

3.4.10.4.1 Stones in renal pelvis or upper/middle calices

Shock wave lithotripsy, PNL and RIRS are available treatment modalities for renal calculi. While PNL efficacy is hardly affected by stone size, the SFRs after SWL or URS are inversely proportional to stone size [296-299]. Shock wave lithotripsy achieves good SFRs for stones up to 20 mm, except for those at the lower pole [298, 300, 301]. Endourology is considered an alternative because of the reduced need of repeated procedures and consequently a shorter time until stone-free status is achieved. Stones > 20 mm should be treated primarily by PNL, because SWL often requires multiple treatments, and is associated with an increased risk of ureteral obstruction (colic or steinstrasse) with a need for adjunctive procedures (Figure 3.4.1) [164]. Retrograde renal surgery cannot be recommended as first-line treatment for stones > 20 mm in uncomplicated cases as SFRs decrease, and staged procedures will be required [302-304]. However, it may be a first-line option in patients where PNL is not an option or contraindicated.

3.4.10.4.2 Stones in the lower renal pole

The stone clearance rate after SWL seems to be lower for stones in the inferior calyx than for other intra-renal locations. Although the disintegration efficacy of SWL is not limited compared to other locations, the fragments often remain in the calyx and cause recurrent stone formation. The reported SFR of SWL for lower pole calculi is 25-95%. The preferential use of endoscopic procedures is supported by some current reports, even for stones smaller than 1 cm [164, 296, 297, 299, 300, 304-312].

The following can impair successful stone treatment by SWL [307, 313-317]:

- steep infundibular-pelvic angle;
- long calyx;
- long skin-to-stone distance;
- narrow infundibulum (Table 3.4.4);
- Shock wave-resistant stones (calcium oxalate monohydrate, brushite, or cystine).

Further anatomical parameters cannot yet be established. Supportive measures such as inversion, vibration or hydration may facilitate stone clearance [318].

If there are negative predictors for SWL, PNL and RIRS might be reasonable alternatives, even for smaller calculi [305]. Retrograde renal surgery seems to have comparable efficacy to SWL [164, 297, 300, 319]. Recent clinical experience has suggested a higher SFR of RIRS compared to SWL, but at the expense of greater invasiveness. Depending on operator skills, stones up to 3 cm can be treated by RIRS [197, 320-322].

However, staged procedures are frequently required.


In complex stone cases, open or laparoscopic approaches are possible alternatives (see appropriate chapters).

3.4.10.5 Summary of evidence and guidelines for the management of renal stones

Summary of evidence	LE
It is still debatable whether renal stones should be treated, or whether annual follow-up is sufficient for asymptomatic calyceal stones that have remained stable for six months.	4
Although the question of whether calyceal stones should be treated is still unanswered, stone growth, <i>de novo</i> obstruction, associated infection, and acute and/or chronic pain are indications for treatment.	3
Percutaneous nephrolithotomy is indicated in renal stones > 2 cm as primary option.	1a

Recommendations	Strength rating
Follow-up periodically in cases where renal stones are not treated (initially after six months then yearly, evaluating symptoms and stone status [either by ultrasound, kidney-ureter-bladder radiography or computed tomography]).	Strong
Offer active treatment for renal stones in case of stone growth, <i>de novo</i> obstruction, associated infection, and acute and/or chronic pain.	Weak
Assess comorbidity and patient preference when making treatment decisions.	Weak
Offer shock wave lithotripsy (SWL) and endourology (percutaneous nephrolithotomy [PNL], retrograde renal surgery [RIRS]) as treatment options for stones < 2 cm within the renal pelvis and upper or middle calices.	Strong
Perform PNL as first-line treatment of larger stones > 2 cm.	Strong
In case PNL is not an option, treat larger stones (> 2 cm) with flexible ureterorenoscopy or SWL. However, in such instances there is a higher risk that a follow-up procedure and placement of a ureteral stent may be needed.	Strong
For the lower pole, perform PNL or RIRS, even for stones > 1 cm, as the efficacy of SWL is limited (depending on favourable and unfavourable factors for SWL).	Strong

Figure 3.4.10.6: Treatment algorithm for renal stones (of active treatment is indicated)



*The term 'Endourology' encompasses all PNL and URS interventions.

PNL = percutaneous nephrolithotomy; RIRS = retrograde renal surgery; SWL = shock wave lithotripsy; URS = ureterorenoscopy.

3.4.11 Laparoscopy and open surgery

Advances in SWL and endourological surgery (URS and PNL) have significantly decreased the indications for open or laparoscopic stone surgery [323-328]. There is a consensus that most complex stones, including partial and complete staghorn stones, should be approached primarily with PNL. Additionally, a combined approach with PNL and RIRS may also be an appropriate alternative. However, if percutaneous approaches are not likely to be successful, or if multiple endourological approaches have been performed unsuccessfully; open or laparoscopic surgery may be a valid treatment option [329-335].

Few studies have reported laparoscopic stone removal. These procedures are usually reserved for special cases. When expertise is available, laparoscopic ureterolithotomy can be performed for large proximal ureteral stones as an alternative to URS or SWL [336, 337]. These more invasive procedures have yielded high SFRs and lower auxiliary procedure rates [188-190].

3.4.11.1 Summary of evidence and guidelines for laparoscopy and open surgery

Recommendations	Strength rating
Offer laparoscopic or open surgical stone removal in rare cases in which shock wave lithotripsy (SWL), (flexible) ureterorenoscopy and percutaneous nephrolithotomy fail, or are unlikely to be successful.	Strong
Perform surgery laparoscopically before proceeding to open surgery.	Strong
For ureterolithotomy, perform laparoscopy for large impacted stones when endoscopic lithotripsy or SWL has failed or is contraindicated.	Strong

3.4.12 Steinstrasse

Steinstrasse is an accumulation of stone fragments or stone gravel in the ureter and may interfere with the passage of urine [338]. Steinstrasse occurs in 4-7% cases of SWL [166], and the major factor in the development of steinstrasse formation is stone size [339].

A major problem of steinstrasse is ureteral obstruction, which may be silent in up to 23% of cases. A MA including eight RCTs (n = 876) suggests a benefit of stenting before SWL in terms of steinstrasse formation, but does not result in a benefit on SFRs or less auxiliary treatments [125].

When steinstrasse is asymptomatic, conservative treatment is an initial option. Medical expulsion therapy increases stone expulsion and reduces the need for endoscopic intervention [340, 341]. In the event of UTI or fever, the urinary systems should be decompressed, preferably by percutaneous nephrostomy [128, 131].

3.4.12.1 Summary of evidence and guidelines for steinstrasse

Summary of evidence	LE
Medical expulsion therapy increases the stone expulsion rate of steinstrasse [340].	1b
Ureterorenoscopy is effective for the treatment of steinstrasse [342].	3
Only low level evidence is available, supporting SWL or URS for the treatment of steinstrasse.	4

Recommendations	Strength rating
Treat steinstrasse associated with urinary tract infection/fever preferably with percutaneous nephrostomy.	Weak
Treat steinstrasse when large stone fragments are present with shock wave lithotripsy or ureterorenoscopy.	Weak

3.4.13 Management of patients with residual stones

Following initial treatment with SWL, URS or PNL residual fragments may remain and require additional intervention [293, 343, 344]. Most of the studies indicate that initial imaging is performed on the first day or the first week after treatment. However, false positive results from dust or residual fragments that will pass spontaneously without causing any stone related event might lead to overtreatment. As a consequence, imaging at four weeks seems most appropriate [345-347]. Compared to US, KUB and IVU, NCCT scan has a higher sensitivity to detect small residual fragments after definitive treatment of ureteral or kidney stones [348, 349]. However, more than half of the patients with a residual fragment in NCCT images may not experience a stone-related event [350].

It is clear that NCCT has the highest sensitivity to detect residual fragments; however, this must be balanced with the increased detection of clinically insignificant fragments and the exposure to ionising radiation when compared with KUB and US. In the absence of high level supporting evidence, the timing of follow-up imaging studies and need for secondary intervention is left to the discretion of the treating physician.

Recurrence risk in patients with residual fragments after treatment of infection stones is higher than for other stones [351]. For all stone compositions, 21-59% of patients with residual stones required treatment within five years. Fragments > 5 mm are more likely than smaller ones to require intervention [170, 352, 353]. There is evidence that fragments > 2 mm are more likely to grow, although this is not associated with increased re-intervention rates at one year follow up [343].

3.4.13.1 Summary of evidence and guideline for management of patients with residual stones

Summary of Evidence	LE
To detect residual fragments after SWL, URS or PNL, deferred imaging is more appropriate than immediate imaging post intervention.	3

Recommendation	Strength rating
Perform imaging after shock wave lithotripsy, ureterorenoscopy or percutaneous antegrade ureterorenoscopy to determine presence of residual fragments.	Strong

3.4.14 Management of specific patient groups

3.4.14.1 Management of urinary stones and related problems during pregnancy

Clinical management of a pregnant urolithiasis patient is complex and demands close collaboration between patient, radiologist, obstetrician and urologist. For diagnostic imaging see Section 3.3.1.

If spontaneous passage does not occur, or if complications develop (e.g., intractable symptoms, severe hydronephrosis or induction of premature labour), placement of a ureteral stent or a percutaneous nephrostomy tube is necessary as it is more effective to conservative treatment for symptom relief (LE: 1b) [354, 355].

Unfortunately, these temporising therapies are often associated with poor tolerance, and they require multiple exchanges during pregnancy, due to the potential for rapid encrustation [356].

Ureterorenoscopy has become a reasonable alternative in these situations [357, 358] (LE: 1a). When compared to temporary ureteral JJ stenting until after delivery, ureteroscopy resulted in fewer needs for stent exchange, less irritative LUTS and better patient satisfaction [359](LE: 1b).

Non-urgent ureterorenoscopy in pregnant women should be best performed during the second trimester, by an experienced urologist. Counselling of the patient should include access to neonatal and obstetric services [66].

Although feasible, percutaneous removal of renal stones during pregnancy remain an individual decision and should be performed only in experienced centres [360]. Pregnancy remains an absolute contraindication for SWL.

3.4.14.1.1 Summary of evidence and guidelines for the management of urinary stones and related problems during pregnancy

Summary of evidence	LE
Stent insertion seems to be more effective than conservative treatment in the management of symptomatic moderate to severe hydronephrosis during pregnancy.	1b
Ureterorenoscopy is a reasonable alternative to avoid long-term stenting/drainage.	1a
There is a higher tendency for stent encrustation during pregnancy.	3

Recommendations	Strength rating
Treat all uncomplicated cases of urolithiasis in pregnancy conservatively (except those that have clinical indications for intervention).	Strong

3.4.14.2 Management of stones in patients with urinary diversion

Aetiology

Patients with urinary diversion are at high risk for stone formation in the renal collecting system and ureter or in the conduit or continent reservoir [361-363]. Metabolic factors (hypercalciuria, hyperoxaluria and hypocitraturia), infection with urease-producing bacteria, foreign bodies, mucus secretion, and urinary stasis are responsible for stone formation [364] (Section 3.1.3). One study has shown that the risk for recurrent uppertract stones in patients with urinary diversion subjected to PNL was 63% at five years [365].

Management

Smaller upper-tract stones can be treated effectively with SWL [193, 366]. In the majority, endourological techniques are necessary to achieve stone-free status [192]. In individuals with long, tortuous conduits or with invisible ureter orifices, a retrograde endoscopic approach might be difficult or impossible.

3.4.14.2.1 Summary of evidence and guidelines for the management of stones in patients with urinary diversion

Summary of evidence	LE
The choice of access depends on the feasibility of orifice identification in the conduit or bowel reservoir. Whenever a retrograde approach is impossible, percutaneous access with antegrade ureterorenoscopy is the alternative.	4

Recommendations	Strength rating
Perform percutaneous lithotomy to remove large renal stones in patients with urinary diversion, as well as for ureteral stones that cannot be accessed via a retrograde approach, or that are not amenable to shock wave lithotripsy.	Strong

For stones in the conduit, a trans-stomal approach can be used to remove all stone material (along with the foreign body) using standard techniques, including intracorporeal lithotripsy and flexible endoscopes. Trans-stomal manipulations in continent urinary diversion must be performed carefully to avoid disturbance of the continence mechanism [367].

Before considering any percutaneous approach in these cases, CT should be undertaken to assess the presence of an overlying bowel, which could make this approach unsafe [368], and if present, an open surgical approach should be considered.

Prevention

Recurrence risk is high in these patients [365]. Metabolic evaluation and close follow-up are necessary to obtain the risk parameters for effective long-term prevention. Preventive measures include medical management of metabolic abnormalities, appropriate therapy of urinary infections, and hyperdiuresis or regular irrigation of continent reservoirs [369].

3.4.14.3 Management of stones in patients with neurogenic bladder

Aetiology, clinical presentation and diagnosis

Patients with neurogenic bladder develop urinary calculi because of additional risk factors such as bacteriuria, hydronephrosis, VUR, renal scarring, lower urinary tract reconstruction, and thoracic spinal defect [370]. The most common causes are urinary stasis and infection (Section 3.1.3). Indwelling catheters and surgical interposition of bowel segments for treatment of bladder dysfunction both facilitate UTI. Although calculi can form at any level of the urinary tract, they occur more frequently in the bladder; especially if bladder augmentation has been performed [371, 372].

Diagnosis of stones may be difficult and delayed in the absence of clinical symptoms due to sensory impairment and vesicourethral dysfunction. Difficulties in self-catheterisation should lead to suspicion of bladder calculi. Imaging studies are needed (US, CT) to confirm the clinical diagnosis prior to surgical intervention.

Management

Management of calculi in patients with neurogenic bladder is similar to that described in Section 3.3.3. In myelomeningocele patients, latex allergy is common; therefore, appropriate measures need to be taken regardless of the treatment [373]. Any surgery in these patients must be performed under general anaesthesia because of the impossibility of using spinal anaesthesia. Bone deformities often complicate positioning on the operating table [374]. The risk of stone formation after augmentation cystoplasty in immobile patients with sensory impairment can be significantly reduced by irrigation protocols [369].

For efficient long-term stone prevention in patients with neurogenic bladder, correction of the metabolic disorder, appropriate infection control, and restoration of normal storing/voiding function of the bladder are needed.

3.4.14.3.1 Summary of evidence and guidelines for the management of stones in patients with neurogenic bladder

Summary of evidence	LE
Patients undergoing urinary diversion and/or suffering from neurogenic bladder dysfunction are at risk for recurrent stone formation.	3

Recommendations	Strength rating
Take appropriate measures regardless of the treatment provided since in myelomeningocele patients latex allergy is common.	Strong

3.4.14.4 Management of stones in patients with transplanted kidneys

Aetiology

Transplant patients depend on their solitary kidney for renal function. Impairment causing urinary stasis/obstruction therefore requires immediate intervention or drainage of the transplanted kidney. Risk factors in these patients are multifold:

- Immunosuppression increases the infection risk, resulting in recurrent UTIs.
- Hyper filtration, excessively alkaline urine, renal tubular acidosis, and increased serum calcium caused by persistent tertiary hyperparathyroidism [375] are biochemical risk factors. Stones in kidney allografts have an incidence of 1% [376].

Management

Selecting the appropriate technique for stone removal in a transplanted kidney is difficult, although management principles are similar to those applied in other single renal units [377-380]. Additional factors such as transplant function, coagulative status, and anatomical obstacles due to the iliacal position of the organ, directly influence the surgical strategy.

For large or ureteral stones, careful percutaneous access and subsequent antegrade endoscopy are more favourable. The introduction of small flexible ureteroscopes and the holmium laser has made URS a valid treatment option for transplant calculi. However, one must be aware of potential injury to adjacent organs [381-383]. Retrograde access to transplanted kidneys is difficult due to the anterior location of the ureteral anastomosis, and ureteral tortuosity [384-386].

3.4.14.4.1 Summary of evidence and guidelines for the management of stones in patients with transplanted kidneys.

Summary of evidence	LE
Conservative treatment for small asymptomatic stones is only possible under close surveillance and in absolutely compliant patients.	3
Shock wave lithotripsy for small calyceal stones is an option with minimal complication risk, but localisation of the stone can be challenging and SFRs are poor [387, 388].	4

Recommendation	Strength rating
Perform ultrasound or non-contrast-enhanced computed tomography to rule out calculi in patients with transplanted kidneys, unexplained fever, or unexplained failure to thrive (particularly in children) [389].	Strong
Offer patients with transplanted kidneys, any of the contemporary management options, including shock wave lithotripsy, flexible ureteroendoscopy and percutaneous nephrolithotomy.	Weak

3.4.14.5 Special problems in stone removal

Table 3.4.14.1: Special problems in stone removal

Calyceal diverticulum stones	<ul style="list-style-type: none"> • SWL, PNL [390] (if possible) or RIRS [390, 391]. • Can also be removed using laparoscopic retroperitoneal surgery [392-396]. • Patients may become asymptomatic due to stone disintegration (SWL), whilst well-disintegrated stone material remains in the original position due to narrow calyceal neck.
Horseshoe kidneys	<ul style="list-style-type: none"> • Can be treated in line with the options described above [397]. • Passage of fragments after SWL might be poor. • Acceptable SFRs can be achieved with flexible ureteroscopy.
Stones in pelvic kidneys	<ul style="list-style-type: none"> • SWL, RIRS, PNL or laparoscopic surgery. • In obese patients, the options are RIRS, PNL or open surgery.
Stones formed in a continent reservoir	<ul style="list-style-type: none"> • Each stone must be considered and treated individually.
Patients with obstruction of the UPJ	<ul style="list-style-type: none"> • When outflow abnormality requires correction, stones can be removed by PNL together with percutaneous endopyelotomy or open/laparoscopic reconstructive surgery. • URS together with endopyelotomy with Ho:YAG laser. • Incision with an Acucise® balloon catheter might be considered, provided the stones can be prevented from falling into the pelvi-ureteral incision [398-401]. • Open surgery with correction of the UPJ obstruction (pyeloplasty) and stone removal is a feasible option [402].

3.4.15 Management of stones in children

Rates of urolithiasis have increased in developed countries, and there has been a shift in the age group experiencing a first stone episode [9, 403, 404]. More than 1% of all urinary stones are seen in patients aged < 18 years. As a result of malnutrition and racial factors, paediatric urolithiasis remains an endemic disease in some areas (e.g., Turkey and the Far East); elsewhere, the rates are similar to those observed in developed countries [405-408].

For diagnostic procedures see Section 3.3.3.2, for acute decompression see Section 3.4.2. and for metabolic evaluation see chapter 4.

Several factors must be considered when selecting treatment procedures for children. Compared to adults, children pass fragments more rapidly after SWL [53]. For endourological procedures, the smaller caliber urinary organs in children must be considered when selecting instruments for PNL or URS. However, improvement in intracorporeal lithotripsy devices and development of smaller instruments now facilitate the use of PNL and URS in children. Stone composition should be taken into account when selecting the appropriate procedure for stone removal (cystine stones are more resistant to SWL).

3.4.15.1 Medical expulsive therapy in children

Medical expulsive therapy has already been discussed in Section 3.4.3.1.2 but not addressing children. Current literature, including a recent SR, seems to support their safety and efficacy in children; however, this is now a controversial area in adult patients following recent publications [75, 409-413].

3.4.15.2 Extracorporeal shock wave lithotripsy

Extracorporeal shock wave lithotripsy remains the least-invasive procedure for stone management in children [414-417].

Stone-free-rates of 67-93% in short-term and 57-92% in long-term follow-up studies have been reported. In children, compared with adults, SWL can achieve more effective disintegration of large stones, together with swifter and uncomplicated discharge of large fragments [414, 418]. Tamsulosin has not been found to improve stone clearance. As in adults, the slow delivery rate of shock waves may improve the stone clearance rates [418]. Stones located in calices, as well as in abnormal kidneys, and large stones, are more difficult to disintegrate and clear. The likelihood of urinary obstruction is higher in such cases, and children should be followed closely for the prolonged risk of urinary tract obstruction. The retreatment rate is 13.9-53.9%, and the need for ancillary procedures and/or additional interventions is 7-33% [414, 416].

The need for general anaesthesia during SWL depends on patient age and the lithotripter used. General or dissociative anaesthesia is administered in most children aged < 10 years, to prevent patient and stone motion and the need for repositioning [414, 416]. With modern lithotripters, intravenous sedation or patient-controlled analgesia have been used in selected co-operative older children [419] (LE: 2b). There are concerns regarding the safety and potential biological effects of SWL on immature kidneys and surrounding organs in children. However, during short- and long-term follow-up, no irreversible functional or morphological side effects of high-energy shock waves have been demonstrated. In addition, when the potential deterioration of renal function is taken into account (although transient), restricting the number of shock waves and the energy used during each treatment session helps protect the kidneys [420-423].

If the stone burden requires a ureteral stent, alternative procedures should be considered. Ureteral stents are seldom needed following SWL of upper tract stones, ureteral pre-stenting decreases the SFR after initial treatment [414, 424, 425].

3.4.15.3 *Endourological procedures*

Percutaneous nephrolithotomy

Pre-operative evaluation and indications for PNL in children are similar to those in adults. Provided appropriate size instruments and US guidance are used, age is not a limiting factor, and PNL can be performed safely by experienced operators, with less radiation exposure, even for large and complex stones [426-430]. Stone-free rates are between 68% and 100% after a single session, and increase with ancillary procedures, such as second-look PNL, SWL and URS [426]. As for adults, tubeless PNL is safe in children, in well-selected cases [431, 432].

Ureterorenoscopy

Although SWL is still the first-line treatment for most ureteral stones, it is unlikely to be successful for stones > 10 mm in diameter, or for impacted stones, calcium oxalate monohydrate or cystine stones, or stones in children with unfavourable anatomy and in whom localisation is difficult [433, 434].

If SWL is not promising, URS can be used. With the clinical introduction of smaller calibre instruments, this modality has become the treatment of choice for medium and larger distal ureteral stones in children [433-437].

Different lithotripsy techniques, including ultrasonic, pneumatic and laser lithotripsy, are all safe and effective (Section 3.4.6) [438, 439].

Flexible Ureterorenoscopy

Despite concerns about the potential risks and complications related to endoscopic surgery of children's delicate ureter and collecting system, with the development of smaller size endoscopes, flexible Ureterorenoscopy (RIRS) has become an efficacious treatment modality for renal and ureteral stones [433, 439-441] and might be a particularly effective treatment option for lower calyx stones in the presence of unfavourable factors for SWL.

Similar to adults, routine stenting is not necessary before URS. However, leaving a ureteral stent for the subsequent session must be considered in case of failure of URS. Pre-stenting facilitates URS, increases SFR and decreases complication rates [442].

For large and complex kidney stones PNL has a higher SFR compared to RIRS, but RIRS is associated with less radiation exposure, lower complication rates and a shorter hospital stay [443]. The experience of the surgical team is of the utmost importance for the success of both endourological techniques [444].

3.4.15.4 *Open or laparoscopic surgery*

Most stones in children can be managed by SWL and endoscopic techniques. Therefore, the rate of open procedures has dropped significantly [445-447]. Indications for surgery include: failure of primary therapy for stone removal; very young children with complex stones; congenital obstruction that requires simultaneous surgical correction; severe orthopaedic deformities that limit positioning for endoscopic procedures; and abnormal kidney position [427]. Open surgery can be replaced by laparoscopic procedures in experienced hands [446, 447].

3.4.15.5 *Special considerations on recurrence prevention*

All paediatric stone formers need metabolic evaluation and recurrence prevention with respect to the detected stone type. In radiolucent stones, oral chemolysis may be considered as an alternative to SWL [448]. In the case of obstructive pathology in association with the established metabolic abnormalities, treatment should not be delayed. Children are in the high-risk group for stone recurrence [75, 449] (See chapter 4).

3.4.15.6 Summary of evidence and guidelines for the management of stones in children

Summary of evidence	LE
In children, the indications for SWL are similar to those in adults; however, children pass fragments more easily.	3
Children with renal stones of a diameter up to 20 mm (~300 mm ²) are ideal candidates for SWL.	1b
Ureterorenoscopy has become the treatment of choice for larger distal ureteral stones in children.	1a
In children, the indications for PNL are similar to those in adults.	1a

Recommendations	Strength rating
Offer children with ureteral stones shockwave lithotripsy as first line option but consider uretero-rensoscopy if SWL is not possible and larger distal ureteral stones.	Strong
Offer children with renal stones with a diameter of up to 20 mm (~300 mm ²) shockwave lithotripsy.	Strong
Offer children with renal pelvic or calyceal stones with a diameter > 20 mm (~300 mm ²) percutaneous nephrolithotomy.	Strong

4. FOLLOW UP: METABOLIC EVALUATION AND RECURRENCE PREVENTION

4.1 General metabolic considerations for patient work-up

4.1.1 Evaluation of patient risk


After stone passage, every patient should be assigned to a low- or high-risk group for stone formation (Figure 4.1). For correct classification, two items are mandatory:

- reliable stone analysis by infrared spectroscopy or X-ray diffraction;
- basic analysis (Section 3.3.2).

Only high-risk stone formers require specific metabolic evaluation. Stone type is the deciding factor for further diagnostic tests. The different stone types include:

- calcium oxalate;
- calcium phosphate;
- uric acid;
- ammonium urate;
- struvite (and infection stones);
- cystine;
- xanthine;
- 2,8-Dihydroxyadenine;
- drug stones;
- stones of unknown composition.

Figure 4.1 Assignment of patients to low- or high-risk groups for stone formation



4.1.2 Urine sampling

Specific metabolic evaluation requires collection of two consecutive 24-hour urine samples [450, 451]. The collecting bottles should be prepared with 5% thymol in isopropanol or stored at < 8°C during collection to prevent the risk of spontaneous crystallisation in the urine [452, 453]. Pre-analytical errors can be minimised by carrying out urinalysis immediately after collection. Alternatively, boric acid (10 g powder per urine container) can also be used. The collecting method should be chosen in close cooperation with the particular laboratory. Urine pH should be assessed during collection of freshly voided urine four times daily [15, 452] using sensitive pH-dipsticks or a pH-meter.

Spot urine samples are an alternative method of sampling, particularly when 24-hour's urine collection is difficult, for example, in non-toilet trained children [454]. Spot urine studies normally link the excretion rates to creatinine [454], but these are of limited use because the results may vary with collection time and patients' sex, body weight and age.

4.1.3 Timing of specific metabolic work-up

For the initial specific metabolic work-up, the patient should stay on a self-determined diet under normal daily conditions and should ideally be stone free for at least twenty days [455].

Follow-up studies are necessary in patients taking medication for recurrence prevention [456]. The first follow-up 24-hour urine measurement is suggested eight to twelve weeks after starting pharmacological prevention

of stone recurrence. This enables drug dosage to be adjusted if urinary risk factors have not normalised, with further 24-hour urine measurements, if necessary. Once urinary parameters have been normalised, it is sufficient to perform 24-hour urine evaluation every twelve months. The Panel realise that on this issue there is only very limited published evidence, and aim to set up a SR on the ideal timing of the 24-hour urine collection.

4.1.4 Reference ranges of laboratory values

Tables 4.1 - 4.4 provide the internationally accepted reference ranges for the different laboratory values in serum and urine.

Table 4.1: Normal laboratory values for blood parameters in adults [457]

Blood parameter	Reference range	
Creatinine	20-100 µmol/L	
Sodium	135-145 mmol/L	
Potassium	3.5-5.5 mmol/L	
Calcium	2.0-2.5 mmol/L (total calcium)	
	1.12-1.32 mmol/L (ionised calcium)	
Uric acid	119-380 µmol/L	
Chloride	98-112 mmol/L	
Phosphate	0.81-1.29 mmol/L	
Blood gas analysis	pH	7.35-7.45
	pO ₂	80-90 mmHg
	pCO ₂	35-45 mmHg
	HCO ₃	22-26 mmol/L
	BE	± 2 mmol/L

BE = base excess (loss of buffer base to neutralise acid); HCO = bicarbonate; PCO = partial pressure of carbon dioxide; PO = partial pressure of oxygen.

4.1.5 Risk indices and additional diagnostic tools

Several risk indices have been developed to describe the crystallisation risk for calcium oxalate or calcium phosphate in urine [458-461]. However, clinical validation of these risk indices for recurrence prediction or therapy improvement is ongoing.

Table 4.2: Normal laboratory values for urinary parameters in adults

Urinary Parameters	Reference ranges and limits for medical attention
pH	Constantly > 5.8 (suspicious of renal tubular acidosis)
	Constantly > 7.0 (suspicious of infection)
	Constantly ≤ 5.8 (suspicious of acidic arrest)
Specific weight	> 1.010
Creatinine	7-13 mmol/day females
	13-18 mmol/day males
Calcium	> 5.0 mmol/day (see Fig. 4.2)
	≥ 8.0 mmol/day (see Fig. 4.2)
Oxalate	> 0.5 mmol/day (suspicious of enteric hyperoxaluria)
	≥ 1.0 mmol/day (suspicious of primary hyperoxaluria)
Uric acid	> 4.0 mmol/day (females), 5 mmol/day (males)
Citrate	< 2.5 mmol/day
Magnesium	< 3.0 mmol/day
Inorganic phosphate	> 35 mmol/day
Ammonium	> 50 mmol/day
Cystine	> 0.8 mmol/day

Table 4.3: Normal values for spot urine samples: creatinine ratios (solute/creatinine) in adults [462]

Parameter/Patient age	Ratio of solute to creatinine	Units
Calcium	mol/mol	mg/mg
< 12 months	< 2.0	0.81
1-3 years	< 1.5	0.53
1-5 years	< 1.1	0.39
5-7 years	< 0.8	0.28
> 7 years	< 0.6	0.21
Oxalate	mol/mol	mg/mg
0-6 months	< 325-360	288-260
7-24 months	< 132-174	110-139
2-5 years	< 98-101	80
5-14 years	< 70-82	60-65
> 16 years	< 40	32
Citrate	mol/mol	g/g
0-5 years	> 0.25	0.42
> 5 years	> 0.15	0.25
Magnesium	mol/mol	g/g
	> 0.63	> 0.13
Uric acid		
> 2 years	< 0.56 mg/dl (33 imol/L) per GFR (ratio x plasma creatinine)	

Table 4.4: Solute excretion in 24-hour urine samples in children [462]**

Calcium/24 hour	Citrate/24 hour		Cystine/24 hour		Oxalate/24 hour		Urate/24 hour	
	Boys	Girls	< 10 years	> 10 years	All age groups	< 1 year	1-5 years	> 5 years
< 0.1 mmol/kg/24 h	> 1.9 mmol/1.73 m ² /24 h	> 1.6 mmol/1.73 m ² /24 h	< 55 µmol/1.73 m ² /24 h	< 200 µmol/1.73 m ² /24 h	< 0.5 mmol/1.73 m ² /24 h	< 70 µmol/kg/24 h	< 65 µmol/kg/24 h	< 55 µmol/kg/24 h
< 4 mg/kg/24 h	> 365 mg/1.73 m ² /24 h	> 310 mg/1.73 m ² /24 h	< 13 mg/1.73 m ² /24 h	< 48 mg/1.73 m ² /24 h	< 45 mg/1.73 m ² /24 h	< 13 mg/kg/24 h	< 11 mg/kg/24 h	< 9.3 mg/kg/24 h

**24 hour urine parameters are diet and gender dependent and may vary geographically.

4.2 General considerations for recurrence prevention

All stone formers, independent of their individual risk, should follow the preventive measures in Table 4.5.

The main focus of these is normalisation of dietary habits and lifestyle risks. Stone formers at high risk need specific prophylaxis for recurrence, which is usually pharmacological treatment based on stone analysis.

Table 4.5: General preventive measures

Fluid intake (drinking advice)	Fluid amount: 2.5-3.0 L/day
	Circadian drinking
	Neutral pH beverages
	Diuresis: 2.0-2.5 L/day
	Specific weight of urine: < 1010
Nutritional advice for a balanced diet	Balanced diet*
	Rich in vegetables and fibre
	Normal calcium content: 1-1.2 g/day
	Limited NaCl content: 4-5 g/day
	Limited animal protein content: 0.8-1.0 g/kg/day
Lifestyle advice to normalise general risk factors	BMI: retain a normal BMI level
	Adequate physical activity
	Balancing of excessive fluid loss

Caution: Protein requirements are age dependent; therefore, protein restriction in childhood should be handled carefully.

* Avoid excessive consumption of vitamin supplements.

4.2.1 Fluid intake

An inverse relationship between high fluid intake and stone formation has been repeatedly demonstrated [463-465]. The effect of fruit juices is mainly determined by the presence of citrate or bicarbonate [466]. If hydrogen ions are present, the net result is neutralisation. However, if potassium is present, both pH and citrate are increased [467, 468]. One large fair-quality RCT randomly assigned men with more than one past renal stone of any type and soft drink consumption of at least 160 mL/day to reduced soft drink intake or no treatment. Although the intervention significantly reduced the risk for symptomatic recurrent stones (RR: 0.83; CI: 0.71-0.98), the level of evidence for this outcome is low because results were from only one trial [465, 469].

4.2.2 Diet

A common sense approach to diet should be taken, that is, a mixed, balanced diet with contributions from all food groups, without any excesses [465, 470, 471].

Fruits, vegetables and fibre: fruit and vegetable intake should be encouraged because of the beneficial effects of fibre, although the role of the latter in preventing stone recurrences is debatable [472-475]. The alkaline content of a vegetarian diet also increases urinary pH.

Oxalate: excessive intake of oxalate-rich products should be limited or avoided to prevent high oxalate load [466], particularly in patients who have high oxalate excretion.

Vitamin C: although vitamin C is a precursor of oxalate, its role as a risk factor in calcium oxalate stone formation remains controversial [476]. However, it seems wise to advise calcium oxalate stone formers to avoid excessive intake.

Animal protein: animal protein should not be consumed in excess [477, 478] and limited to 0.8-1.0 g/kg body weight. Excessive consumption of animal protein has several effects that favour stone formation, including hypocitraturia, low urine pH, hyperoxaluria and hyperuricosuria.

Calcium intake: calcium should not be restricted, unless there are strong reasons for doing so, due to the inverse relationship between dietary calcium and stone formation [473, 479]. The daily requirement for calcium is 1,000 to 1,200 mg [15]. Calcium supplements are not recommended except in enteric hyperoxaluria, when additional calcium should be taken with meals to bind intestinal oxalate [465, 478, 480]. Older adults who do not have a history of renal stones but who take calcium supplements should ensure adequate fluid intake since it may prevent increases in urine calcium concentration, and thereby reduce or eliminate any increased risk of renal stones formation associated with calcium supplement use [481].

Sodium: daily sodium (NaCl) intake should not exceed 3-5 g [15]. High intake adversely affects urine composition:

- calcium excretion is increased by reduced tubular reabsorption;
- urinary citrate is reduced due to loss of bicarbonate;
- increased risk of sodium urate crystal formation.

Calcium stone formation can be reduced by restricting sodium and animal protein [477, 478]. A positive correlation between sodium consumption and risk of first-time stone formation has been confirmed only in women [479, 482]. There have been no prospective clinical trials on the role of sodium restriction as an independent variable in reducing the risk of stone formation.

Urate: intake of purine-rich food should be restricted in patients with hyperuricosuric calcium oxalate [483, 484] and uric acid stones. Intake should not exceed 500 mg/day [15].

4.2.3 Lifestyle

Lifestyle factors may influence the risk of stone formation, for example, obesity [485] and arterial hypertension [486, 487].

4.2.4 Summary of evidence and guidelines for recurrence prevention

Summary of evidence	LE
Increasing fluid intake reduces the risk of stone recurrence.	1a

Recommendation	Strength rating
Advise patients that a generous fluid intake is to be maintained, allowing for a 24-hour urine volume > 2.5 L.	Strong

4.3 Stone-specific metabolic evaluation and pharmacological recurrence prevention

4.3.1 Introduction

Pharmacological treatment is necessary in patients at high risk for recurrent stone formation. The ideal drug should halt stone formation, have no side effects, and be easy to administer. Each of these aspects is important to achieve good compliance. Table 4.6 highlights the most important characteristics of commonly used medication.

Table 4.6: Pharmacological substances used for stone prevention - characteristics, specifics and dosage

Agent	Rationale	Dose	Specifics and side effects	Stone type	Ref
Alkaline citrates	Alkalinisation Hypocitraturia Inhibition of calcium oxalate crystallisation	5-12 g/d (14-36 mmol/d) Children: 0.1-0.15 g/kg/d	Daily dose for alkalinisation depends on urine pH	Calcium oxalate Uric acid Cystine	[50, 465, 488-495]
Allopurinol	Hyperuricosuria Hyperuricaemia	100-300 mg/d Children: 1-3 mg/kg/d	100 mg in isolated hyperuricosuria Renal insufficiency demands dose correction	Calcium oxalate Uric acid Ammonium urate 2,8-Dihydroxyadenine	[496-500]
Calcium	Enteric hyperoxaluria	1000 mg/d	Intake 30 min before meals	Calcium oxalate	[478-480]
Captopril	Cystinuria Active decrease of urinary cystine levels	75-150 mg	Second-line option due to significant side effects	Cystine	[501, 502]
Febuxostat	Hyperuricosuria Hyperuricaemia	80-120 mg/d	Acute gout contraindicated, pregnancy, xanthine stone formation	Calcium oxalate Uric acid	[503, 504]
L-Methionine	Acidification	600-1500 mg/d	Hypercalciuria, bone demineralisation, systemic acidosis. No long-term therapy	Infection stones Ammonium urate Calcium phosphate	[50, 505, 506]
Magnesium	Isolated hypomagnesiuria Enteric hyperoxaluria	200-400 mg/d Children: 6 mg/kg/d	Renal insufficiency demands dose correction. Diarrhoea, chronic alkali losses, hypocitraturia	Calcium oxalate	[507, 508] low evidence
Sodium bicarbonate	Alkalinisation Hypocitraturia	4.5 g/d		Calcium oxalate Uric acid, Cystine	[509]
Pyridoxine	Primary hyperoxaluria	Initial dose 5 mg/kg/d Max. 20 mg/kg/d	Polyneuropathia	Calcium oxalate	[510]
Thiazide (Hydrochlorothiazide)	Hypercalciuria	25-50 mg/d Children: 0.5-1 mg/kg/d	Risk for agent-induced hypotonic blood pressure, diabetes, hyperuricaemia, hypokalaemia, followed by intracellular acidosis and hypocitraturia	Calcium oxalate Calcium phosphate	[50, 507, 511-519]
Tiopronin	Cystinuria Active decrease of urinary cystine levels	Initial dose 250 mg/d	Max. 2000 mg/d Risk for tachyphylaxis and proteinuria	Cystine	[520-523]

4.4 Calcium oxalate stones

The criteria for identification of calcium oxalate stone formers with high recurrence risk are listed in Section 3.1.2.

4.4.1 *Diagnosis*

Blood analysis requires measurement of creatinine, sodium, potassium, chloride, ionised calcium (or total calcium + albumin), uric acid, and parathyroid hormone (PTH) (and vitamin D) in the case of increased calcium levels. Urinalysis requires measurement of urine volume, urine pH profile, specific weight, calcium, oxalate, uric acid, citrate, sodium and magnesium.


4.4.2 *Interpretation of results and aetiology*

The diagnostic and therapeutic algorithm for calcium oxalate stones is shown in Figure 4.2 [50, 465, 489-491, 496-498, 503, 507-509, 511-518, 524-528].

The most common metabolic abnormalities associated with calcium stone formation are hypercalciuria, which affects 30-60% of adult stone formers, and hyperoxaluria (26-67%), followed by hyperuricosuria (15-46%), hypomagnesiuria (7-23%), and hypocitraturia (5-29%). However, ranges tend to differ based on ethnicity [524].

- Elevated levels of ionised calcium in serum (or total calcium and albumin) require assessment of intact PTH to confirm or exclude suspected hyperparathyroidism (HPT).
- “Acidic arrest” (urine pH constantly < 5.8) may promote co-crystallisation of uric acid and calcium oxalate.
- Similarly, increased uric acid excretion (> 4 mmol/day in adults or > 12 mg/kg/day in children) can act as a promoter.
- Urine pH levels constantly > 5.8 in the day profile indicate renal tubular acidosis (RTA), provided UTI has been excluded. An ammonium chloride loading test confirms RTA and identifies RTA subtype (Section 4.6.5).
- Hypercalciuria may be associated with normocalcemia (idiopathic hypercalciuria, or granulomatous diseases) or hypercalcaemia (hyperparathyroidism, granulomatous diseases, vitamin D excess, or malignancy).
- Hypocitraturia (male < 1.7 mmol/d, female < 1.9 mmol/d) may be idiopathic or secondary to metabolic acidosis or hypokalaemia.
- Oxalate excretion > 0.5 mmol/day in adults (> 0.37 mmol/1.73 m²/day in children) confirms hyperoxaluria.
 - o primary hyperoxaluria (oxalate excretion mostly > 1 mmol/day), appears in three genetically determined forms;
 - o secondary hyperoxaluria (oxalate excretion > 0.5 mmol/day, usually < 1 mmol/day), occurs due to intestinal hyperabsorption of oxalate or extreme dietary oxalate intake;
 - o mild hyperoxaluria (oxalate excretion 0.45-0.85 mmol/day), commonly found in idiopathic calcium oxalate stone formers.
- Hypermagnesiuria (< 3.0 mmol/day) may be related to poor dietary intake or to reduced intestinal absorption (chronic diarrhoea).

Figure 4.2: Diagnostic and therapeutic algorithm for calcium oxalate stones



¹ Be aware of excess calcium excretion.

² tid = three times/day (24h).

³ No magnesium therapy for patients with renal insufficiency.

⁴ There is no evidence that combination therapy (thiazide + citrate) or (thiazide + allopurinol) is superior to thiazide therapy alone [511, 518].

⁵ Febuxostat 80 mg/d.

4.4.3 Specific treatment

General preventive measures are recommended for fluid intake and diet. Hyperoxaluric stone formers should consume foods with low oxalate content, whereas hyperuricosuric stone formers benefit from daily dietary reduction of purine. Figure 4.2 summarises the diagnostic algorithm and the pharmacological treatment of calcium oxalate stones [50, 465, 489-491, 496-498, 503, 507-509, 511-518, 524-528]. There is only low level evidence on the efficacy of preventing stone recurrence through pre-treatment stone composition and biochemistry measures, or on-treatment biochemistry measures [465].

4.4.4 Summary of evidence and guidelines for pharmacological treatments for patients with specific abnormalities in urine composition (based on 24-hour urine samples)

Summary of evidence	LE
Thiazide + potassium citrate can reduce stone formation.	1a
Oxalate restriction is beneficial if hyperoxaluria is present.	2b
Potassium citrate can reduce stone formation in enteric hyperoxaluria.	3-4
Calcium supplement can reduce stone formation in enteric hyperoxaluria.	2
Diet reduced in fat and oxalate can be beneficial in reducing stone formation.	3
Potassium citrate and sodium bicarbonate can be used to if hypocitraturia is present.	1b
Allopurinol is first-line treatment of hyperuricosuria.	1a
Febuxostat is second-line treatment of hyperuricosuria.	1b
Avoid excessive intake of animal protein in hyperuricosuria.	1b
Restricted intake of salt is beneficial if there is high urinary sodium excretion.	1b

Recommendations	Strength rating
Prescribe thiazide + potassium citrate in case of hypercalcaemia.	Strong
Advise oxalate restriction if hyperoxaluria is present.	Weak
Offer potassium citrate in enteric hyperoxaluria.	Weak
Offer calcium supplement in enteric hyperoxaluria.	Weak
Advise reduced dietary fat and oxalate in enteric hyperoxaluria.	Weak
Prescribe potassium citrate and sodium bicarbonate in case of hypocitraturia.	Strong
Prescribe allopurinol in case of hyperuricosuria.	Strong
Offer febuxostat as second-line treatment of hyperuricosuria.	Strong
Advise avoiding excessive intake of animal protein in hyperuricosuria.	Strong
Advise restricted intake of salt if there is high urinary sodium excretion.	Strong

4.5 Calcium phosphate stones

Some calcium phosphate stone formers are at high risk of recurrence. Further information on identifying high-risk patients is provided in Section 3.1.2.

Calcium phosphate mainly appears in two completely different minerals: carbonate apatite and brushite. Carbonate apatite crystallisation occurs at a pH > 6.8 and may be associated with infection.

Brushite crystallises at an optimum pH of 6.5-6.8, at high urinary concentrations of calcium (> 8 mmol/day) and phosphate (> 35 mmol/day). Its occurrence is not related to UTI.

Possible causes of calcium phosphate stones include HPT, RTA and UTI; each of which requires different therapy.


4.5.1 *Diagnosis*

Diagnosis requires blood analysis for: creatinine, sodium, potassium, chloride, ionised calcium (or total calcium + albumin), and PTH (in the case of increased calcium levels). Urinalysis includes measurement of: volume, urine pH profile, specific weight, calcium, phosphate and citrate.

4.5.2 *Interpretation of results and aetiology*

General preventive measures are recommended for fluid intake and diet. The diagnostic and therapeutic algorithm for calcium phosphate stones is shown in Figure 4.3.

Figure 4.3: Diagnostic and therapeutic algorithm for calcium phosphate stones



HPT = hyperparathyroidism; RTA = renal tubular acidosis; UTI = urinary tract infection.

4.5.3 Pharmacological therapy [50, 465, 511, 512, 516, 528]

Hyperparathyroidism and RTA are common causes of calcium phosphate stone formation. Although most patients with primary HPT require surgery, RTA can be corrected pharmacologically. If primary HPT and RTA have been excluded, pharmacotherapy for calcium phosphate calculi depends on effective reduction of urinary calcium levels using thiazides. If urine pH remains constantly > 6.2, urinary acidification with L-methionine may be beneficial; however, it is not commonly used and needs monitoring for systemic acidosis development. For infection-associated calcium phosphate stones, it is important to consider the guidance given for infection stones.

4.5.4 Summary of evidence and guidelines for the management of calcium phosphate stones

Summary of evidence	LE
Thiazide is beneficial in case of hypercalciuria.	1a
Acidification of urine can be beneficial in case of high urine pH.	3-4

Recommendations	Strength rating
Prescribe thiazide in case of hypercalciuria.	Strong
Advise patients to acidify their urine in case of high urine pH.	Weak

4.6 Disorders and diseases related to calcium stones

4.6.1 Hyperparathyroidism [529-532]

Primary HPT is responsible for an estimated 5% of all calcium stone formation. Renal stones occur in approximately 20% of patients with primary HPT. Elevated levels of parathyroid hormone (PTH) significantly increase calcium turnover, leading to hypercalcaemia and hypercalciuria. Serum calcium may be mildly elevated and serum PTH may be within the upper normal limits, therefore, repeated measurements may be needed; preferably with the patient fasting. Stones of HPT patients may contain both calcium oxalate and calcium phosphate.

If HPT is suspected, neck exploration should be performed to confirm the diagnosis. Primary HPT can only be cured by surgery.

4.6.2 Granulomatous diseases [532]

Granulomatous diseases, such as sarcoidosis, may be complicated by hypercalcaemia and hypercalciuria secondary to increased calcitriol production. The latter is independent of PTH control, leading to increased calcium absorption in the gastrointestinal tract and suppression of PTH. Treatment focuses on the activity of the granulomatous diseases and may require steroids, hydroxychloroquine or ketoconazole. Treatment should be reserved for a specialist.

4.6.3 Primary hyperoxaluria [510]

Patients with primary hyperoxaluria (PH) should be referred to specialised centres, as successful management requires an experienced interdisciplinary team. The main therapeutic aim is to reduce endogenous oxalate production, which is increased in patients with PH. In approximately one-third of patients with PH type I, pyridoxine therapy normalises or significantly reduces urinary oxalate excretion. The goal of adequate urine dilution is achieved by adjusting fluid intake to 3.5-4.0 L/day in adults (children 1.5 L/m² body surface area) and following a circadian drinking regimen.

Therapeutic options for preventing calcium oxalate crystallisation include hyperdiuresis, alkaline citrates and magnesium. However, in end-stage renal failure, PH requires simultaneous liver-kidney transplantation.

Treatment regimens are:

- pyridoxine in PH type I: 5-20 mg/kg/day according to urinary oxalate excretion and patient tolerance;
- alkaline citrate: 9-12 g/day in adults, 0.1-0.15 meq/kg/day in children;
- magnesium: 200-400 mg/day (no magnesium in the case of renal insufficiency).

4.6.3.1 Summary of evidence and guidelines for the management of primary hyperoxaluria

Summary of evidence	LE
Pyridoxine can reduce the urinary oxalate excretion in primary hyperoxaluria.	3

Recommendation	Strength rating
Prescribe pyridoxine for primary hyperoxaluria.	Strong

4.6.4 Enteric hyperoxaluria [480, 533]

Enteric hyperoxaluria is a particularly problematic condition in patients with intestinal malabsorption of fat. This abnormality is associated with a high risk of stone formation, and is seen after intestinal resection and malabsorptive bariatric surgery as well as in Crohn's disease and pancreas insufficiency. In addition to hyperoxaluria, these patients usually present with hypocitraturia due to loss of alkali. Urine pH is usually low, as are urinary calcium and urine volume. All these abnormalities contribute to high levels of supersaturation with calcium oxalate, crystalluria, and stone formation. Specific preventive measures are:

- restricted intake of oxalate-rich foods;
- restricted fat intake;
- calcium supplementation at meal times to enable calcium oxalate complex formation in the intestine [480, 533];
- sufficient fluid intake to balance intestinal loss of water caused by diarrhoea;
- alkaline citrates to raise urinary pH and citrate.

4.6.4.1 Summary of evidence and guidelines for the management of enteric hyperoxaluria


Summary of evidence	LE
Potassium citrate can be beneficial to replace citrate loss and raise urine pH.	3
Calcium supplements with meals can enable calcium oxalate complex formation in the intestine.	2
Reduction in dietary fat and oxalate can be beneficial in intestinal malabsorption.	3

Recommendations	Strength rating
Prescribe potassium citrate.	Weak
Advise patients to take calcium supplements with meals.	Strong
Advise patients to follow a diet with a low fat and oxalate content.	Weak

4.6.5 Renal tubular acidosis [534, 535]

Renal tubular acidosis is caused by severe impairment of proton or bicarbonate handling along the nephron. Kidney stone formation most probably occurs in patients with distal RTA type I. Figure 4.4 outlines the diagnosis of RTA. Table 4.7 shows acquired and inherited causes of RTA [513-515].

Figure 4.4: Diagnosis of renal tubular acidosis



BGA = blood gas analysis; RTA = renal tubular acidosis

** An alternative Ammonium Chloride loading test using NH_4Cl load with 0.05 g/kg body weight over three days might provide similar results and may be better tolerated by the patient. A second alternative in these cases could be the furosemide acidification test.

Renal tubular acidosis can be acquired or inherited. Reasons for acquired RTA can be obstructive uropathy, recurrent pyelonephritis, acute tubular necrosis, renal transplantation, analgesic nephropathy, sarcoidosis,

idiopathic hypercalciuria, and primary parathyroidism; it may also be drug-induced (e.g. zonisamide). Table 4.7 shows the inherited causes of RTA.

Table 4.7: Inherited causes of renal tubular acidosis

Type - inheritance	Gene/gene product/function	Phenotype
Autosomal dominant	<i>SLC4A1/AE1/Cl-bicarbonate exchanger</i>	Hypercalciuria, hypokalaemia, osteomalacia
Autosomal recessive with hearing loss	<i>ATP6V1B1/B1</i> subunit of vacuolar H-ATPase/proton secretion	Hypercalciuria, hypokalaemia, rickets
Autosomal recessive	<i>ATP6V0A4/A4</i> subunit of vacuolar H-ATPase/proton secretion	Hypercalciuria, hypokalaemia, rickets

The main therapeutic aim of RTA treatment is restoring a normal acid-base equilibrium. Despite the alkaline pH of urine in RTA, alkalinisation using alkaline citrates or sodium bicarbonate is key to normalising the metabolic changes (intracellular acidosis) responsible for stone formation (Table 4.8). The alkali load reduces tubular reabsorption of citrate, which in turn normalises citrate excretion and simultaneously reduces calcium turnover.

Therapeutic success can be monitored by venous blood gas analysis (base excess: ± 2.0 mmol/L) in complete RTA. If excessive calcium excretion (> 8 mmol/day) persists after re-establishing acid-base equilibrium, thiazides may lower urinary calcium excretion.

Table 4.8: Pharmacological treatment of renal tubular acidosis

Biochemical risk factor	Rationale for pharmacological therapy	Medication
Hypercalciuria	Calcium excretion > 8 mmol/day	Hydrochlorothiazide, - in adults: 25 mg/day initially, up to 50 mg/day - in children: 0.5-1 mg/kg/day Alternatives in adults: Chlorthalidone 25 mg/d Indapamide 2.5 mg/d
Inadequate urine pH	Intracellular acidosis in nephron	Alkaline citrate, 9-12 g/day divided in three doses OR Sodium bicarbonate, 1.5 g, three times daily

4.6.5.1 Summary of evidence and guidelines for the management of tubular acidosis

Summary of evidence	LE
Potassium citrate can be beneficial in distal renal tubular acidosis to correct the intracellular acidosis.	2b
Thiazide and potassium citrate are beneficial for hypercalciuria.	1a

Recommendation	Strength rating
Prescribe potassium citrate for distal renal tubular acidosis.	Weak
Prescribe thiazide and potassium citrate for hypercalciuria.	Strong

4.6.6 Nephrocalcinosis [462]

Nephrocalcinosis (NC) refers to increased crystal deposition within the renal cortex or medulla, and occurs alone or in combination with renal stones. There are various metabolic causes. The main risk factors are: HPT, PH, RTA, vitamin D metabolic disorders, idiopathic hypercalciuria and hypocitraturia, and genetic disorders, including Dent's disease, Bartter's syndrome and Medullary sponge kidney. The many causes of NC means there is no single standard therapy. Therapeutic attention must focus on the underlying metabolic or genetic disease, while minimising the biochemical risk factors.

4.6.6.1 *Diagnosis*

Diagnosis requires the following blood analysis: PTH (in the case of increased calcium levels), vitamin D and metabolites, vitamin A, sodium, potassium, magnesium, chloride, and blood gas analysis. Urinalysis should investigate: urine pH profile (minimum four times daily), daily urine volume, specific weight of urine, and levels of calcium, oxalate, phosphate, uric acid, magnesium and citrate.

4.7 **Uric acid and ammonium urate stones**

All uric acid and ammonium urate stone formers are considered to be at high risk of recurrence [15]. Uric acid nephrolithiasis is responsible for approximately 10% of renal stones [536] and associated with hyperuricosuria or low urinary pH. Hyperuricosuria may be a result of dietary excess, endogenous overproduction (enzyme defects), myeloproliferative disorders, tumour lysis syndrome, drugs, gout or catabolism [537]. Low urinary pH may be caused by decreased urinary ammonium excretion (insulin resistance or gout), increased endogenous acid production (insulin resistance, metabolic syndrome, or exercise-induced lactic acidosis), increased acid intake (high animal protein intake), or increased base loss (diarrhoea) [537].

Ammonium urate stones are extremely rare, comprising < 1% of all types of urinary stones. They are associated with UTI, malabsorption (inflammatory bowel disease and ileostomy diversion or laxative abuse), potassium deficiency, hypokalaemia and malnutrition. Suggestions on uric acid and ammonium urate nephrolithiasis are based on level 3 and 4 evidence.

4.7.1 *Diagnosis*

Figure 4.5 shows the diagnostic and therapeutic algorithm for uric acid and ammonium urate stones. Blood analysis requires measurement of creatinine, potassium and uric acid levels. Urinalysis requires measurement of urine volume, urine pH profile, specific weight of urine, and uric acid level. Urine culture is needed in the case of ammonium urate stones.

4.7.2 *Interpretation of results*

Uric acid and ammonium urate stones form under completely different biochemical conditions. Acidic arrest (urine pH constantly < 5.8) promotes uric acid crystallisation.

Hyperuricosuria is defined as uric acid excretion > 4 mmol/day in adults or > 0.12 mmol/kg/day in children.


Hyperuricaemia may be present, but there is only weak evidence for its association with stone formation.

Hyperuricosuric calcium oxalate stone formation can be distinguished from uric acid stone formation by: urinary pH, which is usually > 5.5 in calcium oxalate stone formation and < 5.5 in uric acid stone formation and occasional absence of hyperuricosuria in patients with pure uric acid stones [538, 539]. Ammonium urate crystals form in urine at pH > 6.5, high uric acid concentration when ammonium is present serves as a cation [540-542].

4.7.3 *Specific treatment*

General preventive measures are recommended for fluid intake and diet. Hyperuricosuric stone formers benefit from purine reduction in their daily diet. Figure 4.5 describes pharmacological treatment [15, 454, 536-548]. For uric acid stones, allopurinol may change the stone composition distribution in patients with gout to a pattern similar to that in stone formers without gout [549].

Figure 4.5: Diagnostic and therapeutic algorithm for uric acid- and ammonium urate stones



¹ d: day.

² tid: three times a day.

³ A higher pH may lead to calcium phosphate stone formation.

⁴ In patients with high uric acid excretion, allopurinol may be helpful.

4.7.4 Summary of evidence and guideline for the management of uric acid- and ammonium urate stones

Summary of evidence	LE
Potassium citrate can be beneficial to alkalinise the urine in urate stone formers.	3
Allopurinol can be beneficial in hyperuricosuric urate stone formers.	1b

Recommendations	Strength rating
Prescribe potassium citrate to alkalinise the urine in urate stone formers.	Strong
Prescribe allopurinol in hyperuricosuric urate stone formers.	Strong

4.8 Struvite and infection stones

All infection-stone formers are deemed at high risk of recurrence. Struvite stones represent 2-15% of the stones sent for analysis. Stones that contain struvite may originate *de novo* or grow on pre-existing stones,

which are infected with urea-splitting bacteria [550]. There are several factors predisposing patients to struvite stone formation (Table 4.8) [551].

4.8.1 Diagnosis

Blood analysis requires measurement of creatinine, and urinalysis requires repeat urine pH measurements and urine culture.

Interpretation

Infection stones contain the following minerals: struvite and/or carbonate apatite and/or ammonium urate. Urine culture typically provides evidence for urease-producing bacteria, which increase ammonia ions and develop alkaline urine (Table 4.10). Carbonate apatite starts to crystallise at a urine pH level of 6.8. Struvite only precipitates at pH > 7.2 [552, 553]. *Proteus mirabilis* accounts for more than half of all urease-positive UTIs [554, 555].

4.8.2 Specific treatment

General preventive measures are recommended for fluid intake and diet. Specific measures include complete surgical stone removal [551], short- or long-term antibiotic treatment [556], urinary acidification using methionine [505] or ammonium chloride [557], and advice to restrict intake of urease [558, 559]. For severe infections, acetohydroxamic acid may be an option [558, 559] (Figure 4.6); however, it is not licensed/available in all European countries.

Eradication of infection after complete stone removal is desirable. The evidence regarding the duration of post-operative antibiotic administration is inconclusive.

4.8.3 Summary of evidence and guidelines for the management of infection stones

Summary of evidence	LE
Removing the stone material as completely as possible with surgery can reduce ongoing infection.	3-4
Antibiotics are beneficial after complete stone removal.	3
Ammonium chloride, 1 g, two or three times daily, can ensure urinary acidification to prevent recurrent infection.	3
Methionine, 200-500 mg, one to three times daily, can be used as an alternative to ammonium chloride, to ensure urinary acidification.	3
Urease inhibitors in case of severe infection are occasionally used (if licensed).	1b

Recommendations	Strength rating
Surgically remove the stone material as completely as possible.	Strong
Prescribe antibiotics in case of persistent bacteriuria.	Strong
Prescribe ammonium chloride, 1 g, two or three times daily to ensure urinary acidification.	Weak
Prescribe methionine, 200-500 mg, one to three times daily, as an alternative, to ensure urinary acidification.	Weak


Table 4.8: Factors predisposing to struvite stone formation

<ul style="list-style-type: none"> • Neurogenic bladder • Spinal cord injury/paralysis • Continent urinary diversion • Ileal conduit • Foreign body • Stone disease • Indwelling urinary catheter 	<ul style="list-style-type: none"> • Urethral stricture • Benign prostatic hyperplasia • Bladder diverticulum • Cystocele • Calyceal diverticulum • UPJ obstruction
--	---

Table 4.9: Most important species of urease-producing bacteria

Obligate urease-producing bacteria (> 98%)
<ul style="list-style-type: none"> • <i>Proteus spp.</i> • <i>Providencia rettgeri</i> • <i>Morganella morganii</i> • <i>Corynebacterium urealyticum</i> • <i>Ureaplasma urealyticum</i>
Facultative urease-producing bacteria
<ul style="list-style-type: none"> • <i>Enterobacter gergoviae</i> • <i>Klebsiella spp.</i> • <i>Providencia stuartii</i> • <i>Serratia marcescens</i> • <i>Staphylococcus spp.</i>
CAUTION: 0-5% of <i>Escherichia coli</i> , <i>Enterococcus spp.</i> and <i>Pseudomonas aeruginosa</i> strains may produce urease.

Figure 4.6: Diagnostic and therapeutic algorithm for infection stones



¹ Discussed with uric acid stones,

² Acetohydroxamic acid

* When nationally available.

bid = twice a day; tid = three times a day.

4.9 Cystine stones

Cystine stones account for 1-2% of all urinary stones in adults and 6-8% of the stones reported in paediatric studies [25, 560]. All cystine stone formers are deemed at high risk of recurrence.

4.9.1 Diagnosis

Blood analysis includes measurement of creatinine, and urinalysis includes measurement of urine volume, pH profile, specific weight, and cystine.

Interpretation

- Cystine is poorly soluble in urine and crystallises spontaneously within the physiological urinary pH range.
- Cystine solubility depends strongly on urine pH: at pH 6.0, the limit of solubility is 1.33 mmol/L.
- Routine analysis of cystine is not suitable for therapeutic monitoring.
- Regardless of phenotype or genotype of the cystinuric patient, the clinical manifestations are the same [561].
- There is no role for genotyping patients in the routine management of cystinuria [562, 563].
- Reductive therapy targets the disulphide binding in the cysteine molecule. For therapy monitoring, it is essential to differentiate between cystine, cysteine and drug-cysteine complexes. Only high-performance liquid chromatography (HPLC)-based analysis differentiates between the different complexes formed by therapy.
- Diagnosis is established by stone analysis. The typical hexagonal crystals are detectable in only 20-25% of urine specimens from patients with cystinuria [564].
- The cyanide nitroprusside colorimetric qualitative test detects the presence of cystine at a threshold concentration of 75 mg/L, with a sensitivity of 72% and specificity of 95%. False-positive results in patients with Fanconi's syndrome, homocystinuria, or those taking various drugs, including infection stones [565].
- Quantitative 24-hour urinary cystine excretion confirms the diagnosis in the absence of stone analysis.
- Levels above 30 mg/day are considered abnormal [566, 567].

4.9.2 Specific treatment

General preventative measures for fluid intake and diet are recommended. A diet low in methionine may theoretically reduce urinary excretion of cystine; however, patients are unlikely to comply sufficiently with such a diet. A restricted intake of sodium is more easily achieved and is more effective in reducing urinary cystine. Patients are usually advised to avoid sodium consumption > 2 g/day [568]. A high level of diuresis is of fundamental importance, aiming for a 24-hour urine volume of > 3 L [569]. A considerable fluid intake evenly distributed throughout the day is necessary.


4.9.2.1 Pharmacological treatment of cystine stones

The main therapeutic option for avoiding cystine crystallisation is to maintain urine pH > 7.5, to improve cystine solubility and ensure appropriate hydration with a minimum of 3.5 L/day in adults, or 1.5 L/m² body surface area in children.

Free cystine concentration can be decreased by reductive substances, which act by splitting the disulphide binding of cysteine.

Tiopronin is currently the best choice for cystine reduction. However, side effects often lead to treatment termination, for example, when nephrotic syndrome develops, or poor compliance, especially with long-term use. After carefully considering the risk of early tachyphylaxis, putting into place a dose-escape phenomenon for long-term use, and recurrence risk, tiopronin is recommended at cystine levels > 3.0 mmol/day or in the case of recurring stone formation, notwithstanding other preventive measures.

Figure 4.7: Metabolic management of cystine stones



4.9.3 Summary of evidence and guidelines for the management of cystine stones

Summary of evidence	LE
Increasing fluid intake so that 24-hour urine volume exceeds 3 L is used to dilute the cystine.	3
Potassium citrate 3-10 mmol two or three times daily can be used to achieve pH > 7.5.	3
Tiopronin, 250-2,000 mg/day can be used to reduce stone formation in patients with cystine excretion, > 3 mmol/day, or when other measures are insufficient.	3

Recommendations	
Therapeutic measures	Strength rating
Urine dilution Advise patients to increase their fluid intake so that 24-hour urine volume exceeds 3 L.	Strong
Alkalinisation For patients with cystine excretion < 3 mmol/day, prescribe potassium citrate 3-10 mmol two or three times daily, to achieve pH > 7.5.	Strong
Complex formation with cystine For patients with cystine excretion, > 3 mmol/day, or when other measures are insufficient: prescribe in addition to other measures tiopronin, 250-2,000 mg/day.	Strong

4.10 2,8-Dihydroxyadenine stones and xanthine stones [15]

All 2,8-Dihydroxyadenine and xanthine stone formers are considered to be at high risk of recurrence. Both stone types are rare. Diagnosis and specific prevention are similar to those for uric acid stones.

4.10.1 2,8-Dihydroxyadenine stones

A genetically determined defect of adenine phosphoribosyl transferase causes high urinary excretion of poorly soluble 2,8-Dihydroxyadenine. High-dose allopurinol or febuxostat are important options, but should be given with regular monitoring.

4.10.2 Xanthine stones

Patients who form xanthine stones usually show decreased levels of serum uric acid. There is no available pharmacological intervention.

4.10.3 Fluid intake and diet

Recommendations for general preventive measures apply. Pharmacological intervention is difficult, therefore, high fluid intake ensures optimal specific weight levels of urine < 1.010. A purine-reduced diet decreases the risk of spontaneous crystallisation in urine.

4.11 Drug stones [50]

Drug stones are induced by pharmacological treatment [570] (Table 4.11). Two types exist:

- stones formed by crystallised compounds of the drug;
- stones formed due to unfavourable changes in urine composition under drug therapy.

Table 4.10: Compounds that cause drug stones

Active compounds crystallising in urine	Substances impairing urine composition
<ul style="list-style-type: none">• Allopurinol/oxypurinol• Amoxicillin/ampicillin• Ceftriaxone• Quinolones• Ephedrine• Indinavir• Magnesium trisilicate• Sulphonamides• Triamterene• Zonisamide	<ul style="list-style-type: none">• Acetazolamide• Allopurinol• Aluminium magnesium hydroxide• Ascorbic acid• Calcium• Furosemide• Laxatives• Methoxyflurane• Vitamin D• Topiramate

4.12 Matrix Stones

Pure matrix stones are extremely rare with less than 70 cases described in the literature. They are more prevalent in females. The main risk factors are recurrent UTIs, especially due to *Proteus mirabilis* or *Escherichia coli*, previous surgery for stone disease, chronic renal failure and haemodialysis. Complete endourological removal, frequently via the percutaneous approach, is critical. Given the rarity of matrix calculi a specific prophylactic regimen to minimise recurrence cannot be recommended. Eliminating infections and prophylactic use of antibiotics are most commonly proposed [571].

4.13 Unknown stone composition [14]

An accurate medical history is the first step towards identifying risk factors as summarised below (see section 4.13.1).

Diagnostic imaging begins with US examination of both kidneys to establish whether the patient is stone free. Stone detection by US should be followed by KUB and unenhanced multislice CT in adults to differentiate between calcium-containing and non-calcium stones.

Blood analysis demonstrates severe metabolic and organic disorders, such as renal insufficiency, HPT or other hypercalcaemic states and hyperuricaemia. In children, hyperoxalaemia is additionally screened for.

Urinalysis is performed routinely with a dipstick test as described above. Urine culture is required if there are signs of infection. Constant urine pH < 5.8 in the daily profile indicates acidic arrest, which may promote uric acid crystallisation. Persistent urine pH > 5.8 in the daily profile indicates RTA, if UTI is excluded.

Microscopy of urinary sediment can help to discover rare stone types, because crystals of 2,8-Dihydroxyadenine, cystine and xanthine are pathognomonic for the corresponding disease. In cases in which the presence of cystine is doubtful, a cyanide nitroprusside colorimetric qualitative test can be used to detect the presence of cystine in urine, with a sensitivity of 72% and specificity of 95%. False-positive results are possible in patients with Fanconi's syndrome or homocystinuria, or in those taking various drugs, including ampicillin or sulfa-containing medication [565, 572].

Following this programme, the most probable stone type can be assumed and specific patient evaluation can follow. However, if any expelled stone material is available, it should be analysed by diagnostic confirmation or correction.

4.13.1 **Guidelines for investigations for the assessment of patients with stones of unknown composition**

Investigation	Rationale for investigation [14, 15, 50, 57]	Strength rating
Take a medical history	<ul style="list-style-type: none"> Stone history (former stone events, family history) Dietary habits Medication chart 	Strong
Perform diagnostic imaging	<ul style="list-style-type: none"> Ultrasound in the case of a suspected stone Unenhanced helical computed tomography Determination of Hounsfield units provides information about the possible stone composition 	Strong
Perform a blood analysis	<ul style="list-style-type: none"> Creatinine Calcium (ionised calcium or total calcium + albumin) Uric acid 	Strong
Perform a urinalysis	<ul style="list-style-type: none"> Urine pH profile (measurement after each voiding, minimum four times daily) Dipstick test: leukocytes, erythrocytes, nitrite, protein, urine pH, specific weight Urine cultures Microscopy of urinary sediment (morning urine) Cyanide nitroprusside test (cystine exclusion) <p>Further examinations depend on the results of the investigations listed above.</p>	Strong

5. REFERENCES

- Skolarikos, A., et al. Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines. *Eur Urol*, 2015. 67: 750.
<https://www.ncbi.nlm.nih.gov/pubmed/25454613>
- Turk, C., et al. EAU Guidelines on Diagnosis and Conservative Management of Urolithiasis. *Eur Urol*, 2016. 69: 468.
<https://www.ncbi.nlm.nih.gov/pubmed/26318710>
- Turk, C., et al. EAU Guidelines on Interventional Treatment for Urolithiasis. *Eur Urol*, 2016. 69: 475.
<https://www.ncbi.nlm.nih.gov/pubmed/26344917>
- Phillips, B., et al. Oxford Centre for Evidence-based Medicine Levels of Evidence. Updated by Jeremy Howick March 2009.
<https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/>
- Guyatt, G.H., et al. What is "quality of evidence" and why is it important to clinicians? *BMJ*, 2008. 336: 995.
<https://www.ncbi.nlm.nih.gov/pubmed/18456631>
- Guyatt, G.H., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*, 2008. 336: 924.
<https://www.ncbi.nlm.nih.gov/pubmed/18436948>

7. Trinchieri A CG, *et al.*, Epidemiology, in Stone Disease, K.S. C.P. Segura JW, Pak CY, Preminger GM, Tolley D., Eds. 2003, Health Publications: Paris.
8. Stamatelou, K.K., *et al.* Time trends in reported prevalence of kidney stones in the United States: 1976-1994. *Kidney Int*, 2003. 63: 1817.
<https://www.ncbi.nlm.nih.gov/pubmed/12675858>
9. Hesse, A., *et al.* Study on the prevalence and incidence of urolithiasis in Germany comparing the years 1979 vs. 2000. *Eur Urol*, 2003. 44: 709.
<https://www.ncbi.nlm.nih.gov/pubmed/14644124>
10. Sanchez-Martin, F.M., *et al.* [Incidence and prevalence of published studies about urolithiasis in Spain. A review]. *Actas Urol Esp*, 2007. 31: 511.
<https://www.ncbi.nlm.nih.gov/pubmed/17711170>
11. Yasui, T., *et al.* 2082 Association of the loci 5q35.3, 7q14.3, and 13q14.1 with urolithiasis: A case-control study in the Japanese population, involving genome-wide association study. *J Urol*, 2013. 189: e854.
[http://www.jurology.com/article/S0022-5347\(13\)02777-8/abstract](http://www.jurology.com/article/S0022-5347(13)02777-8/abstract)
12. Strohmaier, W.L. Course of calcium stone disease without treatment. What can we expect? *Eur Urol*, 2000. 37: 339.
<https://www.ncbi.nlm.nih.gov/pubmed/10720863>
13. Keoghane, S., *et al.* The natural history of untreated renal tract calculi. *BJU Int*, 2010. 105: 1627.
<https://www.ncbi.nlm.nih.gov/pubmed/20438563>
14. Straub, M., *et al.* Diagnosis and metaphylaxis of stone disease. Consensus concept of the National Working Committee on Stone Disease for the upcoming German Urolithiasis Guideline. *World J Urol*, 2005. 23: 309.
<https://www.ncbi.nlm.nih.gov/pubmed/16315051>
15. Hesse, A.T., *et al.* (Eds.), *Urinary Stones, Diagnosis, Treatment and Prevention of Recurrence*. 3rd edition. 2009, Basel.
<https://www.karger.com/Article/Pdf/232951>
16. Basiri, A., *et al.* Familial relations and recurrence pattern in nephrolithiasis: new words about old subjects. *Urol J*, 2010. 7: 81.
<https://www.ncbi.nlm.nih.gov/pubmed/20535692>
17. Goldfarb, D.S., *et al.* A twin study of genetic and dietary influences on nephrolithiasis: a report from the Vietnam Era Twin (VET) Registry. *Kidney Int*, 2005. 67: 1053.
<https://www.ncbi.nlm.nih.gov/pubmed/15698445>
18. Asplin, J.R., *et al.* Hyperoxaluria in kidney stone formers treated with modern bariatric surgery. *J Urol*, 2007. 177: 565.
<https://www.ncbi.nlm.nih.gov/pubmed/17222634>
19. Gonzalez, R.D., *et al.* Kidney stone risk following modern bariatric surgery. *Curr Urol Rep*, 2014. 15: 401.
<https://www.ncbi.nlm.nih.gov/pubmed/24658828>
20. Rendina, D., *et al.* Metabolic syndrome and nephrolithiasis: a systematic review and meta-analysis of the scientific evidence. *J Nephrol*, 2014. 27: 371.
<https://www.ncbi.nlm.nih.gov/pubmed/24696310>
21. Dell'Orto, V.G., *et al.* Metabolic disturbances and renal stone promotion on treatment with topiramate: a systematic review. *Br J Clin Pharmacol*, 2014. 77: 958.
<https://www.ncbi.nlm.nih.gov/pubmed/24219102>
22. Mufti, U.B., *et al.* Nephrolithiasis in autosomal dominant polycystic kidney disease. *J Endourol*, 2010. 24: 1557.
<https://www.ncbi.nlm.nih.gov/pubmed/20818989>
23. Chen, Y., *et al.* Current trend and risk factors for kidney stones in persons with spinal cord injury: a longitudinal study. *Spinal Cord*, 2000. 38: 346.
<https://www.ncbi.nlm.nih.gov/pubmed/10889563>
24. Hara, A., *et al.* Incidence of nephrolithiasis in relation to environmental exposure to lead and cadmium in a population study. *Environ Res*, 2016. 145: 1.
<https://www.ncbi.nlm.nih.gov/pubmed/26613344>
25. Leusmann, D.B., *et al.* Results of 5,035 stone analyses: a contribution to epidemiology of urinary stone disease. *Scand J Urol Nephrol*, 1990. 24: 205.
<https://www.ncbi.nlm.nih.gov/pubmed/2237297>
26. Leusmann, D.B. Whewellite, weddellite and company: where do all the strange names originate? *BJU Int*, 2000. 86: 411.
<https://www.ncbi.nlm.nih.gov/pubmed/10971263>

27. Kim, S.C., *et al.* Cystine calculi: correlation of CT-visible structure, CT number, and stone morphology with fragmentation by shock wave lithotripsy. *Urol Res*, 2007. 35: 319.
<https://www.ncbi.nlm.nih.gov/pubmed/17965956>
28. Wimpissinger, F., *et al.* The silence of the stones: asymptomatic ureteral calculi. *J Urol*, 2007. 178: 1341.
<https://www.ncbi.nlm.nih.gov/pubmed/17706721>
29. Ray, A.A., *et al.* Limitations to ultrasound in the detection and measurement of urinary tract calculi. *Urology*, 2010. 76: 295.
<https://www.ncbi.nlm.nih.gov/pubmed/20206970>
30. Smith-Bindman, R., *et al.* Ultrasonography versus computed tomography for suspected nephrolithiasis. *N Engl J Med*, 2014. 371: 1100.
<https://www.ncbi.nlm.nih.gov/pubmed/25229916>
31. Heidenreich, A., *et al.* Modern approach of diagnosis and management of acute flank pain: review of all imaging modalities. *Eur Urol*, 2002. 41: 351.
<https://www.ncbi.nlm.nih.gov/pubmed/12074804>
32. Kennish, S.J., *et al.* Is the KUB radiograph redundant for investigating acute ureteric colic in the non-contrast enhanced computed tomography era? *Clin Radiol*, 2008. 63: 1131.
<https://www.ncbi.nlm.nih.gov/pubmed/18774360>
33. Worster, A., *et al.* The accuracy of noncontrast helical computed tomography versus intravenous pyelography in the diagnosis of suspected acute urolithiasis: a meta-analysis. *Ann Emerg Med*, 2002. 40: 280.
<https://www.ncbi.nlm.nih.gov/pubmed/12192351>
34. Wu, D.S., *et al.* Indinavir urolithiasis. *Curr Opin Urol*, 2000. 10: 557.
<https://www.ncbi.nlm.nih.gov/pubmed/11148725>
35. El-Nahas, A.R., *et al.* A prospective multivariate analysis of factors predicting stone disintegration by extracorporeal shock wave lithotripsy: the value of high-resolution noncontrast computed tomography. *Eur Urol*, 2007. 51: 1688.
<https://www.ncbi.nlm.nih.gov/pubmed/17161522>
36. Patel, T., *et al.* Skin to stone distance is an independent predictor of stone-free status following shockwave lithotripsy. *J Endourol*, 2009. 23: 1383.
<https://www.ncbi.nlm.nih.gov/pubmed/19694526>
37. Zarse, C.A., *et al.* CT visible internal stone structure, but not Hounsfield unit value, of calcium oxalate monohydrate (COM) calculi predicts lithotripsy fragility in vitro. *Urol Res*, 2007. 35: 201.
<https://www.ncbi.nlm.nih.gov/pubmed/17565491>
38. Kluner, C., *et al.* Does ultra-low-dose CT with a radiation dose equivalent to that of KUB suffice to detect renal and ureteral calculi? *J Comput Assist Tomogr*, 2006. 30: 44.
<https://www.ncbi.nlm.nih.gov/pubmed/16365571>
39. Caoili, E.M., *et al.* Urinary tract abnormalities: initial experience with multi-detector row CT urography. *Radiology*, 2002. 222: 353.
<https://www.ncbi.nlm.nih.gov/pubmed/11818599>
40. Van Der Molen, A.J., *et al.* CT urography: definition, indications and techniques. A guideline for clinical practice. *Eur Radiol*, 2008. 18: 4.
<https://www.ncbi.nlm.nih.gov/pubmed/17973110>
41. Thomson, J.M., *et al.* Computed tomography versus intravenous urography in diagnosis of acute flank pain from urolithiasis: a randomized study comparing imaging costs and radiation dose. *Australas Radiol*, 2001. 45: 291.
<https://www.ncbi.nlm.nih.gov/pubmed/11531751>
42. Smith-Bindman, R., *et al.* Computed Tomography Radiation Dose in Patients With Suspected Urolithiasis. *JAMA Intern Med*, 2015. 175: 1413.
<https://www.ncbi.nlm.nih.gov/pubmed/26121191>
43. Jellison, F.C., *et al.* Effect of low dose radiation computerized tomography protocols on distal ureteral calculus detection. *J Urol*, 2009. 182: 2762.
<https://www.ncbi.nlm.nih.gov/pubmed/19837431>
44. Xiang, H., *et al.* Systematic review and meta-analysis of the diagnostic accuracy of low-dose computed tomography of the kidneys, ureters and bladder for urolithiasis. *J Med Imaging Radiat Oncol*, 2017. 61: 582.
<https://www.ncbi.nlm.nih.gov/pubmed/28139077>
45. Poletti, P.A., *et al.* Low-dose versus standard-dose CT protocol in patients with clinically suspected renal colic. *AJR Am J Roentgenol*, 2007. 188: 927.
<https://www.ncbi.nlm.nih.gov/pubmed/17377025>

46. Zheng, X., *et al.* Dual-energy computed tomography for characterizing urinary calcified calculi and uric acid calculi: A meta-analysis. *Eur J Radiol*, 2016. 85: 1843.
<https://www.ncbi.nlm.nih.gov/pubmed/>
47. Niemann, T., *et al.* Diagnostic performance of low-dose CT for the detection of urolithiasis: a meta-analysis. *AJR Am J Roentgenol*, 2008. 191: 396.
<https://www.ncbi.nlm.nih.gov/pubmed/18647908>
48. El-Wahab, O.A., *et al.* Multislice computed tomography vs. intravenous urography for planning supine percutaneous nephrolithotomy: A randomised clinical trial. *Arab J Urol*, 2014. 12: 162.
<https://www.ncbi.nlm.nih.gov/pubmed/26019942>
49. Thiruchelvam, N., *et al.* Planning percutaneous nephrolithotomy using multidetector computed tomography urography, multiplanar reconstruction and three-dimensional reformatting. *BJU Int*, 2005. 95: 1280.
<https://www.ncbi.nlm.nih.gov/pubmed/15892817>
50. Pearle, M.S., *et al.*, Medical management of urolithiasis. 2nd International consultation on Stone Disease, ed. K.S. Denstedt J. 2008.
51. Mandel, N., *et al.* Conversion of calcium oxalate to calcium phosphate with recurrent stone episodes. *J Urol*, 2003. 169: 2026.
<https://www.ncbi.nlm.nih.gov/pubmed/12771710>
52. Kourambas, J., *et al.* Role of stone analysis in metabolic evaluation and medical treatment of nephrolithiasis. *J Endourol*, 2001. 15: 181.
<https://www.ncbi.nlm.nih.gov/pubmed/>
53. Hesse, A., *et al.* Quality control in urinary stone analysis: results of 44 ring trials (1980-2001). *Clin Chem Lab Med*, 2005. 43: 298.
<https://www.ncbi.nlm.nih.gov/pubmed/15843235>
54. Sutor, D.J., *et al.* Identification standards for human urinary calculus components, using crystallographic methods. *Br J Urol*, 1968. 40: 22.
<https://www.ncbi.nlm.nih.gov/pubmed/5642759>
55. Abdel-Halim, R.E., *et al.* A review of urinary stone analysis techniques. *Saudi Med J*, 2006. 27: 1462.
<https://www.ncbi.nlm.nih.gov/pubmed/17013464>
56. Gilad, R., *et al.* Interpreting the results of chemical stone analysis in the era of modern stone analysis techniques. *J Nephrol*, 2017. 30: 135.
<https://www.ncbi.nlm.nih.gov/pubmed/26956131>
57. Bonkat, G., *et al.*, EAU Guidelines on Urological Infections, in EAU Guidelines, Edn. published as the 32nd EAU Annual Meeting, London, E.A.o.U.G. Office, Editor. 2017, European Association of Urology Guidelines Office: Arnhem, The Netherlands.
58. Somani, B.K., *et al.* Review on diagnosis and management of urolithiasis in pregnancy: an ESUT practical guide for urologists. *World J Urol*, 2017. 35: 1637.
<https://www.ncbi.nlm.nih.gov/pubmed/28424869>
59. Asrat, T., *et al.* Ultrasonographic detection of ureteral jets in normal pregnancy. *Am J Obstet Gynecol*, 1998. 178: 1194.
<https://www.ncbi.nlm.nih.gov/pubmed/9662301>
60. Swartz, M.A., *et al.* Admission for nephrolithiasis in pregnancy and risk of adverse birth outcomes. *Obstet Gynecol*, 2007. 109: 1099.
<https://www.ncbi.nlm.nih.gov/pubmed/17470589>
61. Patel, S.J., *et al.* Imaging the pregnant patient for nonobstetric conditions: algorithms and radiation dose considerations. *Radiographics*, 2007. 27: 1705.
<https://www.ncbi.nlm.nih.gov/pubmed/18025513>
62. Roy, C., *et al.* Assessment of painful ureterohydronephrosis during pregnancy by MR urography. *Eur Radiol*, 1996. 6: 334.
<https://www.ncbi.nlm.nih.gov/pubmed/8798002>
63. Juan, Y.S., *et al.* Management of symptomatic urolithiasis during pregnancy. *Kaohsiung J Med Sci*, 2007. 23: 241.
<https://www.ncbi.nlm.nih.gov/pubmed/17525006>
64. Masselli, G., *et al.* Stone disease in pregnancy: imaging-guided therapy. *Insights Imaging*, 2014. 5: 691.
<https://www.ncbi.nlm.nih.gov/pubmed/25249333>
65. Safety Guidelines for Magnetic Resonance Imaging Equipment in Clinical Use, MHRA, Editor. 2015, MHRA.
<http://www.ismrm.org/smrt/files/con2033065.pdf>

66. Committee Opinion No. 723: Guidelines for Diagnostic Imaging During Pregnancy and Lactation. *Obstet Gynecol*, 2017. 130: e210.
<https://www.acog.org/-/media/Committee-Opinions/Committee-on-Obstetric-Practice/co723.pdf?dmc=1&ts=20171118T0801492910>
67. AIUM Practice parameter for the performance of obstetric ultrasound examinations 2013, Examinations, 2013, AIUM.
<http://www.aium.org/resources/guidelines/obstetric.pdf>
68. F.D.A., Avoid Fetal “Keepsake” Images, Heartbeat Monitors. 2014.
<https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm095508.htm>
69. Sharp, C., *et al.*, Diagnostic Medical Exposures: Advice on Exposure to Ionising Radiation during Pregnancy. 1998, [No abstract available].
70. Kanal, E., *et al.* ACR guidance document for safe MR practices: 2007. *AJR Am J Roentgenol*, 2007. 188: 1447.
<https://www.ncbi.nlm.nih.gov/pubmed/17515363>
71. White, W.M., *et al.* Predictive value of current imaging modalities for the detection of urolithiasis during pregnancy: a multicenter, longitudinal study. *J Urol*, 2013. 189: 931.
<https://www.ncbi.nlm.nih.gov/pubmed/23017526>
72. Sternberg, K., *et al.* Pediatric stone disease: an evolving experience. *J Urol*, 2005. 174: 1711.
<https://www.ncbi.nlm.nih.gov/pubmed/16148688>
73. Palmer, L.S. Pediatric urologic imaging. *Urol Clin North Am*, 2006. 33: 409.
<https://www.ncbi.nlm.nih.gov/pubmed/16829274>
74. Passerotti, C., *et al.* Ultrasound versus computerized tomography for evaluating urolithiasis. *J Urol*, 2009. 182: 1829.
<https://www.ncbi.nlm.nih.gov/pubmed/19692054>
75. Tasian, G.E., *et al.* Evaluation and medical management of kidney stones in children. *J Urol*, 2014. 192: 1329.
<https://www.ncbi.nlm.nih.gov/pubmed/24960469>
76. Riccabona, M., *et al.* Imaging recommendations in paediatric urology. Minutes of the ESPR urology task force session on childhood obstructive uropathy, high-grade fetal hydronephrosis, childhood haematuria, and urolithiasis in childhood. ESPR Annual Congress, Edinburgh, UK, June 2008. *Pediatr Radiol*, 2009. 39: 891.
<https://www.ncbi.nlm.nih.gov/pubmed/19565235>
77. Darge, K., *et al.* [Modern ultrasound technologies and their application in pediatric urinary tract imaging]. *Radiologe*, 2005. 45: 1101.
<https://www.ncbi.nlm.nih.gov/pubmed/16086170>
78. Pepe, P., *et al.* Functional evaluation of the urinary tract by color-Doppler ultrasonography (CDU) in 100 patients with renal colic. *Eur J Radiol*, 2005. 53: 131.
<https://www.ncbi.nlm.nih.gov/pubmed/15607864>
79. Oner, S., *et al.* Comparison of spiral CT and US in the evaluation of pediatric urolithiasis. *Jbr-btr*, 2004. 87: 219.
<https://www.ncbi.nlm.nih.gov/pubmed/15587558>
80. Palmer, J.S., *et al.* Diagnosis of pediatric urolithiasis: role of ultrasound and computerized tomography. *J Urol*, 2005. 174: 1413.
<https://www.ncbi.nlm.nih.gov/pubmed/16145452>
81. Riccabona, M., *et al.* Conventional imaging in paediatric urology. *Eur J Radiol*, 2002. 43: 100.
<https://www.ncbi.nlm.nih.gov/pubmed/12127207>
82. Chateil, J.F., *et al.* [Practical measurement of radiation dose in pediatric radiology: use of the dose surface product in digital fluoroscopy and for neonatal chest radiographs]. *J Radiol*, 2004. 85: 619.
<https://www.ncbi.nlm.nih.gov/pubmed/15205653>
83. Stratton, K.L., *et al.* Implications of ionizing radiation in the pediatric urology patient. *J Urol*, 2010. 183: 2137.
<https://www.ncbi.nlm.nih.gov/pubmed/20399463>
84. Tamm, E.P., *et al.* Evaluation of the patient with flank pain and possible ureteral calculus. *Radiology*, 2003. 228: 319.
<https://www.ncbi.nlm.nih.gov/pubmed/12819343>
85. Cody, D.D., *et al.* Strategies for formulating appropriate MDCT techniques when imaging the chest, abdomen, and pelvis in pediatric patients. *AJR Am J Roentgenol*, 2004. 182: 849.
<https://www.ncbi.nlm.nih.gov/pubmed/15039151>

86. Leppert, A., *et al.* Impact of magnetic resonance urography on preoperative diagnostic workup in children affected by hydronephrosis: should IVU be replaced? *J Pediatr Surg*, 2002. 37: 1441.
<https://www.ncbi.nlm.nih.gov/pubmed/12378450>
87. Engeler, D.S., *et al.* The ideal analgesic treatment for acute renal colic--theory and practice. *Scand J Urol Nephrol*, 2008. 42: 137.
<https://www.ncbi.nlm.nih.gov/pubmed/17899475>
88. Shokeir, A.A., *et al.* Resistive index in renal colic: the effect of nonsteroidal anti-inflammatory drugs. *BJU Int*, 1999. 84: 249.
<https://www.ncbi.nlm.nih.gov/pubmed/10468715>
89. Pathan, S.A., *et al.* Delivering safe and effective analgesia for management of renal colic in the emergency department: a double-blind, multigroup, randomised controlled trial. *Lancet*, 2016. 387: 1999.
<https://www.ncbi.nlm.nih.gov/pubmed/26993881>
90. Afshar, K., *et al.* Nonsteroidal anti-inflammatory drugs (NSAIDs) and non-opioids for acute renal colic. *Cochrane Database Syst Rev*, 2015: CD006027.
<https://www.ncbi.nlm.nih.gov/pubmed/26120804>
91. Krum, H., *et al.* Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs. *Cardiovasc Ther*, 2012. 30: 342.
<https://www.ncbi.nlm.nih.gov/pubmed/21884017>
92. Bhala, N., *et al.* Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. *Lancet*, 2013. 382: 769.
<https://www.ncbi.nlm.nih.gov/pubmed/23726390>
93. Holdgate, A., *et al.* Nonsteroidal anti-inflammatory drugs (NSAIDs) versus opioids for acute renal colic. *Cochrane Database Syst Rev*, 2005: CD004137.
<https://www.ncbi.nlm.nih.gov/pubmed/15846699>
94. Holdgate, A., *et al.* Systematic review of the relative efficacy of non-steroidal anti-inflammatory drugs and opioids in the treatment of acute renal colic. *BMJ*, 2004. 328: 1401.
<https://www.ncbi.nlm.nih.gov/pubmed/15178585>
95. Seitz, C., *et al.* Medical therapy to facilitate the passage of stones: what is the evidence? *Eur Urol*, 2009. 56: 455.
<https://www.ncbi.nlm.nih.gov/pubmed/19560860>
96. Lee, A., *et al.* Effects of nonsteroidal anti-inflammatory drugs on postoperative renal function in adults with normal renal function. *Cochrane Database Syst Rev*, 2007: CD002765.
<https://www.ncbi.nlm.nih.gov/pubmed/17443518>
97. Hollingsworth, J.M., *et al.* Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis. *BMJ*, 2016. 355: i6112.
<https://www.ncbi.nlm.nih.gov/pubmed/27908918>
98. Guercio, S., *et al.* Randomized prospective trial comparing immediate versus delayed ureteroscopy for patients with ureteral calculi and normal renal function who present to the emergency department. *J Endourol*, 2011. 25: 1137.
<https://www.ncbi.nlm.nih.gov/pubmed/21682597>
99. Ramsey, S., *et al.* Evidence-based drainage of infected hydronephrosis secondary to ureteric calculi. *J Endourol*, 2010. 24: 185.
<https://www.ncbi.nlm.nih.gov/pubmed/20063999>
100. Lynch, M.F., *et al.* Percutaneous nephrostomy and ureteric stent insertion for acute renal deobstruction: Consensus based guidance. *British Journal of Medical & Surgical Urology*, 2008. 1: 120.
<http://www.sciencedirect.com/science/article/pii/S1875974208000955>
101. Pearle, M.S., *et al.* Optimal method of urgent decompression of the collecting system for obstruction and infection due to ureteral calculi. *J Urol*, 1998. 160: 1260.
<https://www.ncbi.nlm.nih.gov/pubmed/9751331>
102. Wang, C.J., *et al.* Percutaneous nephrostomy versus ureteroscopic management of sepsis associated with ureteral stone impaction: a randomized controlled trial. *Urolithiasis*, 2016. 44: 415.
<https://www.ncbi.nlm.nih.gov/pubmed/26662171>
103. Marien, T., *et al.* Antimicrobial resistance patterns in cases of obstructive pyelonephritis secondary to stones. *Urology*, 2015. 85: 64.
<https://www.ncbi.nlm.nih.gov/pubmed/25530365>
104. Dellabella, M., *et al.* Randomized trial of the efficacy of tamsulosin, nifedipine and phloroglucinol in medical expulsive therapy for distal ureteral calculi. *J Urol*, 2005. 174: 167.
<https://www.ncbi.nlm.nih.gov/pubmed/15947613>

105. Borghi, L., *et al.* Nifedipine and methylprednisolone in facilitating ureteral stone passage: a randomized, double-blind, placebo-controlled study. *J Urol*, 1994. 152: 1095.
<https://www.ncbi.nlm.nih.gov/pubmed/8072071>
106. Porpiglia, F., *et al.* Effectiveness of nifedipine and deflazacort in the management of distal ureter stones. *Urology*, 2000. 56: 579.
<https://www.ncbi.nlm.nih.gov/pubmed/11018608>
107. Dellabella, M., *et al.* Medical-expulsive therapy for distal ureterolithiasis: randomized prospective study on role of corticosteroids used in combination with tamsulosin-simplified treatment regimen and health-related quality of life. *Urology*, 2005. 66: 712.
<https://www.ncbi.nlm.nih.gov/pubmed/16230122>
108. Campschroer, T., *et al.* Alpha-blockers as medical expulsive therapy for ureteral stones. *Cochrane Database Syst Rev*, 2014. 4: CD008509.
<https://www.ncbi.nlm.nih.gov/pubmed/24691989>
109. Bai, Y., *et al.* Tadalafil Facilitates the Distal Ureteral Stone Expulsion: A Meta-Analysis. *J Endourol*, 2017. 31: 557.
<https://www.ncbi.nlm.nih.gov/pubmed/28384011>
110. Porpiglia, F., *et al.* Corticosteroids and tamsulosin in the medical expulsive therapy for symptomatic distal ureter stones: single drug or association? *Eur Urol*, 2006. 50: 339.
<https://www.ncbi.nlm.nih.gov/pubmed/16574310>
111. Yilmaz, E., *et al.* The comparison and efficacy of 3 different alpha1-adrenergic blockers for distal ureteral stones. *J Urol*, 2005. 173: 2010.
<https://www.ncbi.nlm.nih.gov/pubmed/15879806>
112. Wang, H., *et al.* Comparative efficacy of tamsulosin versus nifedipine for distal ureteral calculi: a meta-analysis. *Drug Des Devel Ther*, 2016. 10: 1257.
<https://www.ncbi.nlm.nih.gov/pubmed/27099471>
113. Liu, X.J., *et al.* Role of silodosin as medical expulsive therapy in ureteral calculi: a meta-analysis of randomized controlled trials. *Urolithiasis*, 2017.
<https://www.ncbi.nlm.nih.gov/pubmed/28365782>
114. Pickard, R., *et al.* Medical expulsive therapy in adults with ureteric colic: a multicentre, randomised, placebo-controlled trial. *Lancet*, 2015. 386: 341.
<https://www.ncbi.nlm.nih.gov/pubmed/25998582>
115. Furyk, J.S., *et al.* Distal Ureteric Stones and Tamsulosin: A Double-Blind, Placebo-Controlled, Randomized, Multicenter Trial. *Ann Emerg Med*, 2016. 67: 86.
<https://www.ncbi.nlm.nih.gov/pubmed/26194935>
116. Sur, R.L., *et al.* Silodosin to facilitate passage of ureteral stones: a multi-institutional, randomized, double-blinded, placebo-controlled trial. *Eur Urol*, 2015. 67: 959.
<https://www.ncbi.nlm.nih.gov/pubmed/25465978>
117. Turk, C., *et al.* Medical Expulsive Therapy for Ureterolithiasis: The EAU Recommendations in 2016. *Eur Urol*, 2016.
<https://www.ncbi.nlm.nih.gov/pubmed/27506951>
118. Kachrilas, S., *et al.* The current role of percutaneous chemolysis in the management of urolithiasis: review and results. *Urolithiasis*, 2013. 41: 323.
<https://www.ncbi.nlm.nih.gov/pubmed/>
119. Bernardo, N.O., *et al.* Chemolysis of urinary calculi. *Urol Clin North Am*, 2000. 27: 355.
<https://www.ncbi.nlm.nih.gov/pubmed/10778477>
120. Tiselius, H.G., *et al.* Minimally invasive treatment of infection staghorn stones with shock wave lithotripsy and chemolysis. *Scand J Urol Nephrol*, 1999. 33: 286.
<https://www.ncbi.nlm.nih.gov/pubmed/10572989>
121. Rodman, J.S., *et al.* Dissolution of uric acid calculi. *J Urol*, 1984. 131: 1039.
<https://www.ncbi.nlm.nih.gov/pubmed/6726897>
122. Becker, G. Uric acid stones. *Nephrology*, 2007. 12: S21.
<https://www.ncbi.nlm.nih.gov/pubmed/17316272>
123. El-Gamal, O., *et al.* Role of combined use of potassium citrate and tamsulosin in the management of uric acid distal ureteral calculi. *Urol Res*, 2012. 40: 219.
<https://www.ncbi.nlm.nih.gov/pubmed/21858663>
124. Musa, A.A. Use of double-J stents prior to extracorporeal shock wave lithotripsy is not beneficial: results of a prospective randomized study. *Int Urol Nephrol*, 2008. 40: 19.
<https://www.ncbi.nlm.nih.gov/pubmed/17394095>

125. Shen, P., *et al.* Use of ureteral stent in extracorporeal shock wave lithotripsy for upper urinary calculi: a systematic review and meta-analysis. *J Urol*, 2011. 186: 1328.
<https://www.ncbi.nlm.nih.gov/pubmed/21855945>
126. Wang, H., *et al.* Meta-Analysis of Stenting versus Non-Stenting for the Treatment of Ureteral Stones. *PLoS One*, 2017. 12: e0167670.
<https://www.ncbi.nlm.nih.gov/pubmed/28068364>
127. Ghoneim, I.A., *et al.* Extracorporeal shock wave lithotripsy in impacted upper ureteral stones: a prospective randomized comparison between stented and non-stented techniques. *Urology*, 2010. 75: 45.
<https://www.ncbi.nlm.nih.gov/pubmed/19811806>
128. Platonov, M.A., *et al.* Pacemakers, implantable cardioverter/defibrillators, and extracorporeal shockwave lithotripsy: evidence-based guidelines for the modern era. *J Endourol*, 2008. 22: 243.
<https://www.ncbi.nlm.nih.gov/pubmed/18294028>
129. Li, W.M., *et al.* Clinical predictors of stone fragmentation using slow-rate shock wave lithotripsy. *Urol Int*, 2007. 79: 124.
<https://www.ncbi.nlm.nih.gov/pubmed/17851280>
130. Yilmaz, E., *et al.* Optimal frequency in extracorporeal shock wave lithotripsy: prospective randomized study. *Urology*, 2005. 66: 1160.
<https://www.ncbi.nlm.nih.gov/pubmed/16006908>
131. Pace, K.T., *et al.* Shock wave lithotripsy at 60 or 120 shocks per minute: a randomized, double-blind trial. *J Urol*, 2005. 174: 595.
<https://www.ncbi.nlm.nih.gov/pubmed/16006908>
132. Madbouly, K., *et al.* Slow versus fast shock wave lithotripsy rate for urolithiasis: a prospective randomized study. *J Urol*, 2005. 173: 127.
<https://www.ncbi.nlm.nih.gov/pubmed/15592053>
133. Semins, M.J., *et al.* The effect of shock wave rate on the outcome of shock wave lithotripsy: a meta-analysis. *J Urol*, 2008. 179: 194.
<https://www.ncbi.nlm.nih.gov/pubmed/18001796>
134. Li, K., *et al.* Optimal frequency of shock wave lithotripsy in urolithiasis treatment: a systematic review and meta-analysis of randomized controlled trials. *J Urol*, 2013. 190: 1260.
<https://www.ncbi.nlm.nih.gov/pubmed/23538240>
135. Nguyen, D.P., *et al.* Optimization of Extracorporeal Shock Wave Lithotripsy Delivery Rates Achieves Excellent Outcomes for Ureteral Stones: Results of a Prospective Randomized Trial. *J Urol*, 2015. 194: 418.
<https://www.ncbi.nlm.nih.gov/pubmed/25661296>
136. Pishchalnikov, Y.A., *et al.* Why stones break better at slow shockwave rates than at fast rates: in vitro study with a research electrohydraulic lithotripter. *J Endourol*, 2006. 20: 537.
<https://www.ncbi.nlm.nih.gov/pubmed/16903810>
137. Connors, B.A., *et al.* Extracorporeal shock wave lithotripsy at 60 shock waves/min reduces renal injury in a porcine model. *BJU Int*, 2009. 104: 1004.
<https://www.ncbi.nlm.nih.gov/pubmed/19338532>
138. Moon, K.B., *et al.* Optimal shock wave rate for shock wave lithotripsy in urolithiasis treatment: a prospective randomized study. *Korean J Urol*, 2012. 53: 790.
<https://www.ncbi.nlm.nih.gov/pubmed/23185672>
139. Ng, C.F., *et al.* A prospective, randomized study of the clinical effects of shock wave delivery for unilateral kidney stones: 60 versus 120 shocks per minute. *J Urol*, 2012. 188: 837.
<https://www.ncbi.nlm.nih.gov/pubmed/22819406>
140. Kang, D.H., *et al.* Comparison of High, Intermediate, and Low Frequency Shock Wave Lithotripsy for Urinary Tract Stone Disease: Systematic Review and Network Meta-Analysis. *PLoS One*, 2016. 11: e0158661.
<https://www.ncbi.nlm.nih.gov/pubmed/27387279>
141. Connors, B.A., *et al.* Effect of initial shock wave voltage on shock wave lithotripsy-induced lesion size during step-wise voltage ramping. *BJU Int*, 2009. 103: 104.
<https://www.ncbi.nlm.nih.gov/pubmed/18680494>
142. Handa, R.K., *et al.* Optimising an escalating shockwave amplitude treatment strategy to protect the kidney from injury during shockwave lithotripsy. *BJU Int*, 2012. 110: E1041.
<https://www.ncbi.nlm.nih.gov/pubmed/22612388>

143. Skuginna, V., *et al.* Does Stepwise Voltage Ramping Protect the Kidney from Injury During Extracorporeal Shockwave Lithotripsy? Results of a Prospective Randomized Trial. *Eur Urol*, 2016. 69: 267.
<https://www.ncbi.nlm.nih.gov/pubmed/26119561>
144. Maloney, M.E., *et al.* Progressive increase of lithotripter output produces better in-vivo stone comminution. *J Endourol*, 2006. 20: 603.
<https://www.ncbi.nlm.nih.gov/pubmed/16999607>
145. Demirci, D., *et al.* Comparison of conventional and step-wise shockwave lithotripsy in management of urinary calculi. *J Endourol*, 2007. 21: 1407.
<https://www.ncbi.nlm.nih.gov/pubmed/18044996>
146. Honey, R.J., *et al.* Shock wave lithotripsy: a randomized, double-blind trial to compare immediate versus delayed voltage escalation. *Urology*, 2010. 75: 38.
<https://www.ncbi.nlm.nih.gov/pubmed/19896176>
147. Pishchalnikov, Y.A., *et al.* Air pockets trapped during routine coupling in dry head lithotripsy can significantly decrease the delivery of shock wave energy. *J Urol*, 2006. 176: 2706.
<https://www.ncbi.nlm.nih.gov/pubmed/17085200>
148. Jain, A., *et al.* Effect of air bubbles in the coupling medium on efficacy of extracorporeal shock wave lithotripsy. *Eur Urol*, 2007. 51: 1680.
<https://www.ncbi.nlm.nih.gov/pubmed/17112655>
149. Logarakis, N.F., *et al.* Variation in clinical outcome following shock wave lithotripsy. *J Urol*, 2000. 163: 721.
<https://www.ncbi.nlm.nih.gov/pubmed/10687964>
150. Eichel, L., *et al.* Operator experience and adequate anesthesia improve treatment outcome with third-generation lithotripters. *J Endourol*, 2001. 15: 671.
<https://www.ncbi.nlm.nih.gov/pubmed/11697394>
151. Sorensen, C., *et al.* Comparison of intravenous sedation versus general anesthesia on the efficacy of the Doli 50 lithotripter. *J Urol*, 2002. 168: 35.
<https://www.ncbi.nlm.nih.gov/pubmed/12050487>
152. Cleveland, R.O., *et al.* Effect of stone motion on in vitro comminution efficiency of Storz Modulith SLX. *J Endourol*, 2004. 18: 629.
<https://www.ncbi.nlm.nih.gov/pubmed/15597649>
153. Aboumarzouk, O.M., *et al.* Analgesia for patients undergoing shockwave lithotripsy for urinary stones - a systematic review and meta-analysis. *Int Braz J Urol*, 2017. 43: 394.
<https://www.ncbi.nlm.nih.gov/pubmed/28338301>
154. Honey, R.J., *et al.* A prospective study examining the incidence of bacteriuria and urinary tract infection after shock wave lithotripsy with targeted antibiotic prophylaxis. *J Urol*, 2013. 189: 2112.
<https://www.ncbi.nlm.nih.gov/pubmed/23276509>
155. Lu, Y., *et al.* Antibiotic prophylaxis for shock wave lithotripsy in patients with sterile urine before treatment may be unnecessary: a systematic review and meta-analysis. *J Urol*, 2012. 188: 441.
<https://www.ncbi.nlm.nih.gov/pubmed/22704118>
156. Chen, K., *et al.* The Efficacy and Safety of Tamsulosin Combined with Extracorporeal Shockwave Lithotripsy for Urolithiasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *J Endourol*, 2015. 29: 1166.
<https://www.ncbi.nlm.nih.gov/pubmed/25915454>
157. Naja, V., *et al.* Tamsulosin facilitates earlier clearance of stone fragments and reduces pain after shockwave lithotripsy for renal calculi: results from an open-label randomized study. *Urology*, 2008. 72: 1006.
<https://www.ncbi.nlm.nih.gov/pubmed/18799202>
158. Zhu, Y., *et al.* alpha-Blockers to assist stone clearance after extracorporeal shock wave lithotripsy: a meta-analysis. *BJU Int*, 2010. 106: 256.
<https://www.ncbi.nlm.nih.gov/pubmed/19889063>
159. Zheng, S., *et al.* Tamsulosin as adjunctive treatment after shockwave lithotripsy in patients with upper urinary tract stones: a systematic review and meta-analysis. *Scand J Urol Nephrol*, 2010. 44: 425.
<https://www.ncbi.nlm.nih.gov/pubmed/21080841>
160. Schuler, T.D., *et al.* Medical expulsive therapy as an adjunct to improve shockwave lithotripsy outcomes: a systematic review and meta-analysis. *J Endourol*, 2009. 23: 387.
<https://www.ncbi.nlm.nih.gov/pubmed/19245302>

161. Li, M., *et al.* Adjunctive medical therapy with alpha-blocker after extracorporeal shock wave lithotripsy of renal and ureteral stones: a meta-analysis. *PLoS One*, 2015. 10: e0122497.
<https://www.ncbi.nlm.nih.gov/pubmed/25860144>
162. Skolarikos, A., *et al.* The Efficacy of Medical Expulsive Therapy (MET) in Improving Stone-free Rate and Stone Expulsion Time, After Extracorporeal Shock Wave Lithotripsy (SWL) for Upper Urinary Stones: A Systematic Review and Meta-analysis. *Urology*, 2015. 86: 1057.
<https://www.ncbi.nlm.nih.gov/pubmed/26383613>
163. De Nunzio, C., *et al.* Tamsulosin or Silodosin Adjuvant Treatment Is Ineffective in Improving Shockwave Lithotripsy Outcome: A Short-Term Follow-Up Randomized, Placebo-Controlled Study. *J Endourol*, 2016. 30: 817.
<https://www.ncbi.nlm.nih.gov/pubmed/27080916>
164. Pearle, M.S., *et al.* Prospective, randomized trial comparing shock wave lithotripsy and ureteroscopy for lower pole caliceal calculi 1 cm or less. *J Urol*, 2005. 173: 2005.
<https://www.ncbi.nlm.nih.gov/pubmed/15879805>
165. Lingeman, J.E., *et al.* Comparison of results and morbidity of percutaneous nephrostolithotomy and extracorporeal shock wave lithotripsy. *J Urol*, 1987. 138: 485.
<https://www.ncbi.nlm.nih.gov/pubmed/3625845>
166. Ather, M.H., *et al.* Does ureteral stenting prior to shock wave lithotripsy influence the need for intervention in steinstrasse and related complications? *Urol Int*, 2009. 83: 222.
<https://www.ncbi.nlm.nih.gov/pubmed/19752621>
167. Madbouly, K., *et al.* Risk factors for the formation of a steinstrasse after extracorporeal shock wave lithotripsy: a statistical model. *J Urol*, 2002. 167: 1239.
<https://www.ncbi.nlm.nih.gov/pubmed/11832705>
168. Sayed, M.A., *et al.* Steinstrasse after extracorporeal shockwave lithotripsy: aetiology, prevention and management. *BJU Int*, 2001. 88: 675.
<https://www.ncbi.nlm.nih.gov/pubmed/11890235>
169. Skolarikos, A., *et al.* Extracorporeal shock wave lithotripsy 25 years later: complications and their prevention. *Eur Urol*, 2006. 50: 981.
<https://www.ncbi.nlm.nih.gov/pubmed/16481097>
170. Osman, M.M., *et al.* 5-year-follow-up of patients with clinically insignificant residual fragments after extracorporeal shockwave lithotripsy. *Eur Urol*, 2005. 47: 860.
<https://www.ncbi.nlm.nih.gov/pubmed/15925084>
171. Tan, Y.M., *et al.* Clinical experience and results of ESWL treatment for 3,093 urinary calculi with the Storz Modulith SL 20 lithotripter at the Singapore general hospital. *Scand J Urol Nephrol*, 2002. 36: 363.
<https://www.ncbi.nlm.nih.gov/pubmed/12487741>
172. Muller-Mattheis, V.G., *et al.* Bacteremia during extracorporeal shock wave lithotripsy of renal calculi. *J Urol*, 1991. 146: 733.
<https://www.ncbi.nlm.nih.gov/pubmed/1875482>
173. Dhar, N.B., *et al.* A multivariate analysis of risk factors associated with subcapsular hematoma formation following electromagnetic shock wave lithotripsy. *J Urol*, 2004. 172: 2271.
<https://www.ncbi.nlm.nih.gov/pubmed/15538247>
174. Zanetti, G., *et al.* Cardiac dysrhythmias induced by extracorporeal shockwave lithotripsy. *J Endourol*, 1999. 13: 409.
<https://www.ncbi.nlm.nih.gov/pubmed/10479005>
175. Rodrigues Netto, N., Jr., *et al.* Small-bowel perforation after shockwave lithotripsy. *J Endourol*, 2003. 17: 719.
<https://www.ncbi.nlm.nih.gov/pubmed/14642028>
176. Holmberg, G., *et al.* Perforation of the bowel during SWL in prone position. *J Endourol*, 1997. 11: 313.
<https://www.ncbi.nlm.nih.gov/pubmed/9355944>
177. Maker, V., *et al.* Gastrointestinal injury secondary to extracorporeal shock wave lithotripsy: a review of the literature since its inception. *J Am Coll Surg*, 2004. 198: 128.
<https://www.ncbi.nlm.nih.gov/pubmed/14698320>
178. Kim, T.B., *et al.* Life-threatening complication after extracorporeal shock wave lithotripsy for a renal stone: a hepatic subcapsular hematoma. *Korean J Urol*, 2010. 51: 212.
<https://www.ncbi.nlm.nih.gov/pubmed/20414400>
179. Ng, C.F., *et al.* Hepatic haematoma after shockwave lithotripsy for renal stones. *Urol Res*, 2012. 40: 785.
<https://www.ncbi.nlm.nih.gov/pubmed/22782117>

180. Chen, C.S., *et al.* Subcapsular hematoma of spleen--a complication following extracorporeal shock wave lithotripsy for ureteral calculus. *Changgeng Yi Xue Za Zhi*, 1992. 15: 215.
<https://www.ncbi.nlm.nih.gov/pubmed/1295657>
181. Lingeman, J.E., *et al.* Blood pressure changes following extracorporeal shock wave lithotripsy and other forms of treatment for nephrolithiasis. *JAMA*, 1990. 263: 1789.
<https://www.ncbi.nlm.nih.gov/pubmed/2313851>
182. Krambeck, A.E., *et al.* Diabetes mellitus and hypertension associated with shock wave lithotripsy of renal and proximal ureteral stones at 19 years of followup. *J Urol*, 2006. 175: 1742.
<https://www.ncbi.nlm.nih.gov/pubmed/16600747>
183. Eassa, W.A., *et al.* Prospective study of the long-term effects of shock wave lithotripsy on renal function and blood pressure. *J Urol*, 2008. 179: 964.
<https://www.ncbi.nlm.nih.gov/pubmed/24162890>
184. Yu, C., *et al.* A systematic review and meta-analysis of new onset hypertension after extracorporeal shock wave lithotripsy. *Int Urol Nephrol*, 2014. 46: 719.
<https://www.ncbi.nlm.nih.gov/pubmed/24162890>
185. Fankhauser, C.D., *et al.* Long-term Adverse Effects of Extracorporeal Shock-wave Lithotripsy for Nephrolithiasis and Ureterolithiasis: A Systematic Review. *Urology*, 2015. 85: 991.
<https://www.ncbi.nlm.nih.gov/pubmed/25917723>
186. Preminger, G.M., *et al.* 2007 Guideline for the management of ureteral calculi. *Eur Urol*, 2007. 52: 1610.
<https://www.ncbi.nlm.nih.gov/pubmed/17993340>
187. Wendt-Nordahl, G., *et al.* Do new generation flexible ureterorenoscopes offer a higher treatment success than their predecessors? *Urol Res*, 2011. 39: 185.
<https://www.ncbi.nlm.nih.gov/pubmed/21052986>
188. Wang, Q., *et al.* Rigid ureteroscopic lithotripsy versus percutaneous nephrolithotomy for large proximal ureteral stones: A meta-analysis. *PLoS One*, 2017. 12: e0171478.
<https://www.ncbi.nlm.nih.gov/pubmed/28182718>
189. Wang, Y., *et al.* Comparison of the efficacy and safety of URSL, RPLU, and MPCNL for treatment of large upper impacted ureteral stones: a randomized controlled trial. *BMC Urol*, 2017. 17: 50.
<https://www.ncbi.nlm.nih.gov/pubmed/28662708>
190. Wu, T., *et al.* Ureteroscopic Lithotripsy versus Laparoscopic Ureterolithotomy or Percutaneous Nephrolithotomy in the Management of Large Proximal Ureteral Stones: A Systematic Review and Meta-Analysis. *Urol Int*, 2017. 99: 308.
<https://www.ncbi.nlm.nih.gov/pubmed/28586770>
191. Sun, X., *et al.* Treatment of large impacted proximal ureteral stones: randomized comparison of percutaneous antegrade ureterolithotripsy versus retrograde ureterolithotripsy. *J Endourol*, 2008. 22: 913.
<https://www.ncbi.nlm.nih.gov/pubmed/18429682>
192. el-Nahas, A.R., *et al.* Percutaneous treatment of large upper tract stones after urinary diversion. *Urology*, 2006. 68: 500.
<https://www.ncbi.nlm.nih.gov/pubmed/16979745>
193. El-Assmy, A., *et al.* Extracorporeal shock wave lithotripsy of upper urinary tract calculi in patients with cystectomy and urinary diversion. *Urology*, 2005. 66: 510.
<https://www.ncbi.nlm.nih.gov/pubmed/16140067>
194. Moufid, K., *et al.* Large impacted upper ureteral calculi: A comparative study between retrograde ureterolithotripsy and percutaneous antegrade ureterolithotripsy in the modified lateral position. *Urol Ann*, 2013. 5: 140.
<https://www.ncbi.nlm.nih.gov/pubmed/24049373>
195. Topaloglu, H., *et al.* A comparison of antegrade percutaneous and laparoscopic approaches in the treatment of proximal ureteral stones. *Biomed Res Int*, 2014. 2014: 691946.
<https://www.ncbi.nlm.nih.gov/pubmed/25295266>
196. Binbay, M., *et al.* Is there a difference in outcomes between digital and fiberoptic flexible ureterorenoscopy procedures? *J Endourol*, 2010. 24: 1929.
<https://www.ncbi.nlm.nih.gov/pubmed/21043835>
197. Geraghty, R., *et al.* Evidence for Ureterorenoscopy and Laser Fragmentation (URSL) for Large Renal Stones in the Modern Era. *Curr Urol Rep*, 2015. 16: 54.
<https://www.ncbi.nlm.nih.gov/pubmed/26077357>
198. Auge, B.K., *et al.* Ureteroscopic management of lower-pole renal calculi: technique of calculus displacement. *J Endourol*, 2001. 15: 835.
<https://www.ncbi.nlm.nih.gov/pubmed/11724125>

199. Cybulski, P.A., *et al.* Ureteroscopy: anesthetic considerations. *Urol Clin North Am*, 2004. 31: 43.
<https://www.ncbi.nlm.nih.gov/pubmed/15040400>
200. Dickstein, R.J., *et al.* Is a safety wire necessary during routine flexible ureteroscopy? *J Endourol*, 2010. 24: 1589.
<https://www.ncbi.nlm.nih.gov/pubmed/20836719>
201. Eandi, J.A., *et al.* Evaluation of the impact and need for use of a safety guidewire during ureteroscopy. *J Endourol*, 2008. 22: 1653.
<https://www.ncbi.nlm.nih.gov/pubmed/18721045>
202. Ulvik, O., *et al.* Ureteroscopy with and without safety guide wire: should the safety wire still be mandatory? *J Endourol*, 2013. 27: 1197.
<https://www.ncbi.nlm.nih.gov/pubmed/23795760>
203. Ambani, S.N., *et al.* Ureteral stents for impassable ureteroscopy. *J Endourol*, 2013. 27: 549.
<https://www.ncbi.nlm.nih.gov/pubmed/23066997>
204. Pace, K.T., *et al.* Same Session Bilateral Ureteroscopy for Multiple Stones: Results from the CROES URS Global Study. *J Urol*, 2017. 198: 130.
<https://www.ncbi.nlm.nih.gov/pubmed/28163031>
205. Ge, H., *et al.* Bilateral Same-Session Ureteroscopy for Treatment of Ureteral Calculi: A Systematic Review and Meta-Analysis. *J Endourol*, 2016. 30: 1169.
<https://www.ncbi.nlm.nih.gov/pubmed/27626367>
206. Stern, J.M., *et al.* Safety and efficacy of ureteral access sheaths. *J Endourol*, 2007. 21: 119.
<https://www.ncbi.nlm.nih.gov/pubmed/17338606>
207. L'Esperance J, O., *et al.* Effect of ureteral access sheath on stone-free rates in patients undergoing ureteroscopic management of renal calculi. *Urology*, 2005. 66: 252.
<https://www.ncbi.nlm.nih.gov/pubmed/16040093>
208. Traxer, O., *et al.* Prospective evaluation and classification of ureteral wall injuries resulting from insertion of a ureteral access sheath during retrograde intrarenal surgery. *J Urol*, 2013. 189: 580.
<https://www.ncbi.nlm.nih.gov/pubmed/22982421>
209. Aboumarzouk, O.M., *et al.* Flexible ureteroscopy and laser lithotripsy for stones >2 cm: a systematic review and meta-analysis. *J Endourol*, 2012. 26: 1257.
<https://www.ncbi.nlm.nih.gov/pubmed/22642568>
210. Traxer, O., *et al.* Differences in renal stone treatment and outcomes for patients treated either with or without the support of a ureteral access sheath: The Clinical Research Office of the Endourological Society Ureteroscopy Global Study. *World J Urol*, 2015. 33: 2137.
<https://www.ncbi.nlm.nih.gov/pubmed/25971204>
211. Santiago, J.E., *et al.* To Dust or Not To Dust: a Systematic Review of Ureteroscopic Laser Lithotripsy Techniques. *Curr Urol Rep*, 2017. 18: 32.
<https://www.ncbi.nlm.nih.gov/pubmed/28271355>
212. Bach, T., *et al.* Working tools in flexible ureterorenoscopy--influence on flow and deflection: what does matter? *J Endourol*, 2008. 22: 1639.
<https://www.ncbi.nlm.nih.gov/pubmed/18620506>
213. Leijte, J.A., *et al.* Holmium laser lithotripsy for ureteral calculi: predictive factors for complications and success. *J Endourol*, 2008. 22: 257.
<https://www.ncbi.nlm.nih.gov/pubmed/18294030>
214. Pierre, S., *et al.* Holmium laser for stone management. *World J Urol*, 2007. 25: 235.
<https://www.ncbi.nlm.nih.gov/pubmed/17340157>
215. Garg, S., *et al.* Ureteroscopic laser lithotripsy versus ballistic lithotripsy for treatment of ureteric stones: a prospective comparative study. *Urol Int*, 2009. 82: 341.
<https://www.ncbi.nlm.nih.gov/pubmed/19440025>
216. Binbay, M., *et al.* Evaluation of pneumatic versus holmium:YAG laser lithotripsy for impacted ureteral stones. *Int Urol Nephrol*, 2011. 43: 989.
<https://www.ncbi.nlm.nih.gov/pubmed/21479563>
217. Ahmed, M., *et al.* Systematic evaluation of ureteral occlusion devices: insertion, deployment, stone migration, and extraction. *Urology*, 2009. 73: 976.
<https://www.ncbi.nlm.nih.gov/pubmed/19394493>
218. John, T.T., *et al.* Adjunctive tamsulosin improves stone free rate after ureteroscopic lithotripsy of large renal and ureteric calculi: a prospective randomized study. *Urology*, 2010. 75: 1040.
<https://www.ncbi.nlm.nih.gov/pubmed/19819530>

219. Assimos, D., *et al.* Preoperative JJ stent placement in ureteric and renal stone treatment: results from the Clinical Research Office of Endourological Society (CROES) ureteroscopy (URS) Global Study. *BJU Int*, 2016. 117: 648.
<https://www.ncbi.nlm.nih.gov/pubmed/26237735>
220. Jessen, J.P., *et al.* International Collaboration in Endourology: Multicenter Evaluation of Prestenting for Ureterorenoscopy. *J Endourol*, 2016. 30: 268.
<https://www.ncbi.nlm.nih.gov/pubmed/26582170>
221. Song, T., *et al.* Meta-analysis of postoperatively stenting or not in patients underwent ureteroscopic lithotripsy. *Urol Res*, 2012. 40: 67.
<https://www.ncbi.nlm.nih.gov/pubmed/21573923>
222. Haleblan, G., *et al.* Ureteral stenting and urinary stone management: a systematic review. *J Urol*, 2008. 179: 424.
<https://www.ncbi.nlm.nih.gov/pubmed/18076928>
223. Nabi, G., *et al.* Outcomes of stenting after uncomplicated ureteroscopy: systematic review and meta-analysis. *BMJ*, 2007. 334: 572.
<https://www.ncbi.nlm.nih.gov/pubmed/17311851>
224. Moon, T.D. Ureteral stenting--an obsolete procedure? *J Urol*, 2002. 167: 1984.
<https://www.ncbi.nlm.nih.gov/pubmed/11956423>
225. Wang, C.J., *et al.* Effects of specific alpha-1A/1D blocker on lower urinary tract symptoms due to double-J stent: a prospectively randomized study. *Urol Res*, 2009. 37: 147.
<https://www.ncbi.nlm.nih.gov/pubmed/19277623>
226. Lamb, A.D., *et al.* Meta-analysis showing the beneficial effect of alpha-blockers on ureteric stent discomfort. *BJU Int*, 2011. 108: 1894.
<https://www.ncbi.nlm.nih.gov/pubmed/21453351>
227. Geavlete, P., *et al.* Complications of 2735 retrograde semirigid ureteroscopy procedures: a single-center experience. *J Endourol*, 2006. 20: 179.
<https://www.ncbi.nlm.nih.gov/pubmed/16548724>
228. Perez Castro, E., *et al.* Differences in ureteroscopic stone treatment and outcomes for distal, mid-, proximal, or multiple ureteral locations: the Clinical Research Office of the Endourological Society ureteroscopy global study. *Eur Urol*, 2014. 66: 102.
<https://www.ncbi.nlm.nih.gov/pubmed/24507782>
229. Ruhayel, Y., *et al.* Tract Sizes in Miniaturized Percutaneous Nephrolithotomy: A Systematic Review from the European Association of Urology Urolithiasis Guidelines Panel. *Eur Urol*, 2017. 72: 220.
<https://www.ncbi.nlm.nih.gov/pubmed/28237786>
230. Tikkinen, K.A.O., *et al.*, EAU Guidelines on Thromboprophylaxis in Urological Surgery, in EAU Guidelines, Edn. published as the 32nd EAU Annual Meeting, London, 2017, European Association of Urology Guidelines Office: Arnhem, The Netherlands.
<http://uroweb.org/guideline/thromboprophylaxis/>
231. Ganesamoni, R., *et al.* Prospective randomized controlled trial comparing laser lithotripsy with pneumatic lithotripsy in miniperc for renal calculi. *J Endourol*, 2013. 27: 1444.
<https://www.ncbi.nlm.nih.gov/pubmed/24251428>
232. Zhu, W., *et al.* A prospective and randomised trial comparing fluoroscopic, total ultrasonographic, and combined guidance for renal access in mini-percutaneous nephrolithotomy. *BJU Int*, 2017. 119: 612.
<https://www.ncbi.nlm.nih.gov/pubmed/27862806>
233. Wang, Y., *et al.* Prone versus modified supine position in percutaneous nephrolithotomy: a prospective randomized study. *Int J Med Sci*, 2013. 10: 1518.
<https://www.ncbi.nlm.nih.gov/pubmed/24046526>
234. Mak, D.K., *et al.* What is better in percutaneous nephrolithotomy - Prone or supine? A systematic review. *Arab J Urol*, 2016. 14: 101.
<https://www.ncbi.nlm.nih.gov/pubmed/27489736>
235. Yuan, D., *et al.* Supine Versus Prone Position in Percutaneous Nephrolithotomy for Kidney Calculi: A Meta-Analysis. *J Endourol*, 2016. 30: 754.
<https://www.ncbi.nlm.nih.gov/pubmed/27072075>
236. Cracco, C.M., *et al.* ECIRS (Endoscopic Combined Intrarenal Surgery) in the Galdakao-modified supine Valdivia position: a new life for percutaneous surgery? *World J Urol*, 2011. 29: 821.
<https://www.ncbi.nlm.nih.gov/pubmed/22057344>
237. Osman, M., *et al.* Percutaneous nephrolithotomy with ultrasonography-guided renal access: experience from over 300 cases. *BJU Int*, 2005. 96: 875.
<https://www.ncbi.nlm.nih.gov/pubmed/16153221>

238. Isac, W., *et al.* Endoscopic-guided versus fluoroscopic-guided renal access for percutaneous nephrolithotomy: a comparative analysis. *Urology*, 2013. 81: 251.
<https://www.ncbi.nlm.nih.gov/pubmed/23374772>
239. Falahatkar, S., *et al.* Complete supine PCNL: ultrasound vs. fluoroscopic guided: a randomized clinical trial. *Int Braz J Urol*, 2016. 42: 710.
<https://www.ncbi.nlm.nih.gov/pubmed/27564281>
240. Jessen, J.P., *et al.* Percutaneous nephrolithotomy under combined sonographic/radiologic guided puncture: results of a learning curve using the modified Clavien grading system. *World J Urol*, 2013. 31: 1599.
<https://www.ncbi.nlm.nih.gov/pubmed/23283412>
241. Wang, K., *et al.* Ultrasonographic versus Fluoroscopic Access for Percutaneous Nephrolithotomy: A Meta-Analysis. *Urol Int*, 2015. 95: 15.
<https://www.ncbi.nlm.nih.gov/pubmed/25678305>
242. Lu, Y., *et al.* Randomized prospective trial of tubeless versus conventional minimally invasive percutaneous nephrolithotomy. *World J Urol*, 2013. 31: 1303.
<https://www.ncbi.nlm.nih.gov/pubmed/22903789>
243. Desai, M.R., *et al.* A prospective randomized comparison of type of nephrostomy drainage following percutaneous nephrostolithotomy: large bore versus small bore versus tubeless. *J Urol*, 2004. 172: 565.
<https://www.ncbi.nlm.nih.gov/pubmed/15247731>
244. Cormio, L., *et al.* Exit strategies following percutaneous nephrolithotomy (PCNL): a comparison of surgical outcomes in the Clinical Research Office of the Endourological Society (CROES) PCNL Global Study. *World J Urol*, 2013. 31: 1239.
<https://www.ncbi.nlm.nih.gov/pubmed/22752586>
245. Istanbuluoglu, M.O., *et al.* Effectiveness of totally tubeless percutaneous nephrolithotomy in selected patients: a prospective randomized study. *Int Urol Nephrol*, 2009. 41: 541.
<https://www.ncbi.nlm.nih.gov/pubmed/19165617>
246. Garofalo, M., *et al.* Tubeless procedure reduces hospitalization and pain after percutaneous nephrolithotomy: results of a multivariable analysis. *Urolithiasis*, 2013. 41: 347.
<https://www.ncbi.nlm.nih.gov/pubmed/23632910>
247. Gonen, M., *et al.* Tubeless and stentless percutaneous nephrolithotomy in patients requiring supracostal access. *Urol Int*, 2009. 82: 440.
<https://www.ncbi.nlm.nih.gov/pubmed/19506412>
248. Seitz, C., *et al.* Incidence, prevention, and management of complications following percutaneous nephrolitholapaxy. *Eur Urol*, 2012. 61: 146.
<https://www.ncbi.nlm.nih.gov/pubmed/21978422>
249. Zanetti, G., *et al.* Infections and urolithiasis: current clinical evidence in prophylaxis and antibiotic therapy. *Arch Ital Urol Androl*, 2008. 80: 5.
<https://www.ncbi.nlm.nih.gov/pubmed/18533618>
250. Gonen, M., *et al.* Factors affecting fever following percutaneous nephrolithotomy: a prospective clinical study. *J Endourol*, 2008. 22: 2135.
<https://www.ncbi.nlm.nih.gov/pubmed/19506412>
251. Mariappan, P., *et al.* Stone and pelvic urine culture and sensitivity are better than bladder urine as predictors of urosepsis following percutaneous nephrolithotomy: a prospective clinical study. *J Urol*, 2005. 173: 1610.
<https://www.ncbi.nlm.nih.gov/pubmed/15821509>
252. Lo, C.W., *et al.* Effectiveness of Prophylactic Antibiotics against Post-Ureteroscopic Lithotripsy Infections: Systematic Review and Meta-Analysis. *Surg Infect (Larchmt)*, 2015. 16: 415.
<https://www.ncbi.nlm.nih.gov/pubmed/26207401>
253. Gravas, S., *et al.* Postoperative infection rates in low risk patients undergoing percutaneous nephrolithotomy with and without antibiotic prophylaxis: a matched case control study. *J Urol*, 2012. 188: 843.
<https://www.ncbi.nlm.nih.gov/pubmed/22819398>
254. Chew, B.H., *et al.* A Single Dose of Intraoperative Antibiotics Is Sufficient to Prevent Urinary Tract Infection During Ureteroscopy. *J Endourol*, 2016. 30: 63.
<https://www.ncbi.nlm.nih.gov/pubmed/26413885>
255. Klingler, H.C., *et al.* Stone treatment and coagulopathy. *Eur Urol*, 2003. 43: 75.
<https://www.ncbi.nlm.nih.gov/pubmed/12507547>

256. Kefer, J.C., *et al.* Safety and efficacy of percutaneous nephrostolithotomy in patients on anticoagulant therapy. *J Urol*, 2009. 181: 144.
<https://www.ncbi.nlm.nih.gov/pubmed/18289567>
257. Baron, T.H., *et al.* Management of antithrombotic therapy in patients undergoing invasive procedures. *N Engl J Med*, 2013. 368: 2113.
<https://www.ncbi.nlm.nih.gov/pubmed/23718166>
258. Naspro, R., *et al.* Antiplatelet therapy in patients with coronary stent undergoing urologic surgery: is it still no man's land? *Eur Urol*, 2013. 64: 101.
<https://www.ncbi.nlm.nih.gov/pubmed/23428067>
259. Eberli, D., *et al.* Urological surgery and antiplatelet drugs after cardiac and cerebrovascular accidents. *J Urol*, 2010. 183: 2128.
<https://www.ncbi.nlm.nih.gov/pubmed/20399452>
260. Razvi, H., *et al.* Risk factors for perinephric hematoma formation after shockwave lithotripsy: a matched case-control analysis. *J Endourol*, 2012. 26: 1478.
<https://www.ncbi.nlm.nih.gov/pubmed/22712655>
261. Rassweiler, J.J., *et al.* Treatment of renal stones by extracorporeal shockwave lithotripsy: an update. *Eur Urol*, 2001. 39: 187.
<https://www.ncbi.nlm.nih.gov/pubmed/11223679>
262. Fischer, C., *et al.* [Extracorporeal shock-wave lithotripsy induced ultrastructural changes to the renal parenchyma under aspirin use. Electron microscopic findings in the rat kidney]. *Urologe A*, 2007. 46: 150.
<https://www.ncbi.nlm.nih.gov/pubmed/17221245>
263. Becopoulos, T., *et al.* Extracorporeal lithotripsy in patients with hemophilia. *Eur Urol*, 1988. 14: 343.
<https://www.ncbi.nlm.nih.gov/pubmed/3169076>
264. Ishikawa, J., *et al.* Extracorporeal shock wave lithotripsy in von Willebrand's disease. *Int J Urol*, 1996. 3: 58.
<https://www.ncbi.nlm.nih.gov/pubmed/8646601>
265. Zanetti, G., *et al.* Extracorporeal shockwave lithotripsy in patients treated with antithrombotic agents. *J Endourol*, 2001. 15: 237.
<https://www.ncbi.nlm.nih.gov/pubmed/11339387>
266. Schnabel, M.J., *et al.* Incidence and risk factors of renal hematoma: a prospective study of 1,300 SWL treatments. *Urolithiasis*, 2014. 42: 247.
<https://www.ncbi.nlm.nih.gov/pubmed/24419328>
267. Schnabel, M.J., *et al.* Antiplatelet and anticoagulative medication during shockwave lithotripsy. *J Endourol*, 2014. 28: 1034.
<https://www.ncbi.nlm.nih.gov/pubmed/24851726>
268. Turna, B., *et al.* Safety and efficacy of flexible ureterorenoscopy and holmium:YAG lithotripsy for intrarenal stones in anticoagulated cases. *J Urol*, 2008. 179: 1415.
<https://www.ncbi.nlm.nih.gov/pubmed/18289567>
269. Toepfer, N.J., *et al.* The effect of antiplatelet and anticoagulant therapy on the clinical outcome of patients undergoing ureteroscopy. *Urology*, 2013. 82: 773.
<https://www.ncbi.nlm.nih.gov/pubmed/23876586>
270. Aboumarzouk, O.M., *et al.* Flexible ureteroscopy and holmium:YAG laser lithotripsy for stone disease in patients with bleeding diathesis: a systematic review of the literature. *Int Braz J Urol*, 2012. 38: 298.
<https://www.ncbi.nlm.nih.gov/pubmed/22765861>
271. Watterson, J.D., *et al.* Safety and efficacy of holmium: YAG laser lithotripsy in patients with bleeding diatheses. *J Urol*, 2002. 168: 442.
<https://www.ncbi.nlm.nih.gov/pubmed/12131284>
272. Elkoushy, M.A., *et al.* Ureteroscopy in patients with coagulopathies is associated with lower stone-free rate and increased risk of clinically significant hematuria. *Int Braz J Urol*, 2012. 38: 195.
<https://www.ncbi.nlm.nih.gov/pubmed/22555043>
273. Sahin, C., *et al.* Transient cessation of antiplatelet medication before percutaneous stone surgery: does it have any safety concern on bleeding related problems? *Urolithiasis*, 2017. 45: 371.
<https://www.ncbi.nlm.nih.gov/pubmed/9763079>
274. Kuo, R.L., *et al.* Use of ureteroscopy and holmium:YAG laser in patients with bleeding diatheses. *Urology*, 1998. 52: 609.
<https://www.ncbi.nlm.nih.gov/pubmed/9763079>

275. Altay, B., *et al.* A review study to evaluate holmium:YAG laser lithotripsy with flexible ureteroscopy in patients on ongoing oral anticoagulant therapy. *Lasers Med Sci*, 2017. 32: 1615.
<https://www.ncbi.nlm.nih.gov/pubmed/28733910>
276. Gupta, A.D., *et al.* Coronary stent management in elective genitourinary surgery. *BJU Int*, 2012. 110: 480.
<https://www.ncbi.nlm.nih.gov/pubmed/22192977>
277. Delakas, D., *et al.* Independent predictors of failure of shockwave lithotripsy for ureteral stones employing a second-generation lithotripter. *J Endourol*, 2003. 17: 201.
<https://www.ncbi.nlm.nih.gov/pubmed/12816580>
278. Ohmori, K., *et al.* Effects of shock waves on the mouse fetus. *J Urol*, 1994. 151: 255.
<https://www.ncbi.nlm.nih.gov/pubmed/>
279. Stroom, S.B., *et al.* Extracorporeal shock wave lithotripsy in patients with bleeding diatheses. *J Urol*, 1990. 144: 1347.
<https://www.ncbi.nlm.nih.gov/pubmed/1613866>
280. Carey, S.W., *et al.* Extracorporeal shock wave lithotripsy for patients with calcified ipsilateral renal arterial or abdominal aortic aneurysms. *J Urol*, 1992. 148: 18.
<https://www.ncbi.nlm.nih.gov/pubmed/1613866>
281. Skolarikos, A., *et al.* The role for active monitoring in urinary stones: a systematic review. *J Endourol*, 2010. 24: 923.
<https://www.ncbi.nlm.nih.gov/pubmed/20482232>
282. Skolarikos, A., *et al.* Indications, prediction of success and methods to improve outcome of shock wave lithotripsy of renal and upper ureteral calculi. *Arch Ital Urol Androl*, 2010. 82: 56.
<https://www.ncbi.nlm.nih.gov/pubmed/20593724>
283. Cui, X., *et al.* Comparison between extracorporeal shock wave lithotripsy and ureteroscopic lithotripsy for treating large proximal ureteral stones: a meta-analysis. *Urology*, 2015. 85: 748.
<https://www.ncbi.nlm.nih.gov/pubmed/25681251>
284. Ishii, H., *et al.* Outcomes of Systematic Review of Ureteroscopy for Stone Disease in the Obese and Morbidly Obese Population. *J Endourol*, 2016. 30: 135.
<https://www.ncbi.nlm.nih.gov/pubmed/26415049>
285. Drake, T., *et al.* What are the Benefits and Harms of Ureteroscopy Compared with Shock-wave Lithotripsy in the Treatment of Upper Ureteral Stones? A Systematic Review. *Eur Urol*, 2017. 72: 772.
<https://www.ncbi.nlm.nih.gov/pubmed/28456350>
286. Inci, K., *et al.* Prospective long-term followup of patients with asymptomatic lower pole caliceal stones. *J Urol*, 2007. 177: 2189.
<https://www.ncbi.nlm.nih.gov/pubmed/17509315>
287. Brandt, B., *et al.* Painful caliceal calculi. The treatment of small nonobstructing caliceal calculi in patients with symptoms. *Scand J Urol Nephrol*, 1993. 27: 75.
<https://www.ncbi.nlm.nih.gov/pubmed/8493473>
288. Burgher, A., *et al.* Progression of nephrolithiasis: long-term outcomes with observation of asymptomatic calculi. *J Endourol*, 2004. 18: 534.
<https://www.ncbi.nlm.nih.gov/pubmed/15333216>
289. Hubner, W., *et al.* Treatment of caliceal calculi. *Br J Urol*, 1990. 66: 9.
<https://www.ncbi.nlm.nih.gov/pubmed/2393803>
290. Keeley, F.X., Jr., *et al.* Preliminary results of a randomized controlled trial of prophylactic shock wave lithotripsy for small asymptomatic renal calyceal stones. *BJU Int*, 2001. 87: 1.
<https://www.ncbi.nlm.nih.gov/pubmed/11121982>
291. Glowacki, L.S., *et al.* The natural history of asymptomatic urolithiasis. *J Urol*, 1992. 147: 319.
<https://www.ncbi.nlm.nih.gov/pubmed/1732583>
292. Collins, J.W., *et al.* Is there a role for prophylactic shock wave lithotripsy for asymptomatic calyceal stones? *Curr Opin Urol*, 2002. 12: 281.
<https://www.ncbi.nlm.nih.gov/pubmed/12072647>
293. Rebuck, D.A., *et al.* The natural history of renal stone fragments following ureteroscopy. *Urology*, 2011. 77: 564.
<https://www.ncbi.nlm.nih.gov/pubmed/21109293>
294. Andersson, L., *et al.* Small renal caliceal calculi as a cause of pain. *J Urol*, 1983. 130: 752.
<https://www.ncbi.nlm.nih.gov/pubmed/6887409>
295. Mee, S.L., *et al.* Small caliceal stones: is extracorporeal shock wave lithotripsy justified? *J Urol*, 1988. 139: 908.
<https://www.ncbi.nlm.nih.gov/pubmed/3361660>

296. Argyropoulos, A.N., *et al.* Evaluation of outcome following lithotripsy. *Curr Opin Urol*, 2010. 20: 154.
<https://www.ncbi.nlm.nih.gov/pubmed/19898239>
297. Srisubat, A., *et al.* Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy (PCNL) or retrograde intrarenal surgery (RIRS) for kidney stones. *Cochrane Database Syst Rev*, 2014. 11: CD007044.
<https://www.ncbi.nlm.nih.gov/pubmed/25418417>
298. Sahinkanat, T., *et al.* Evaluation of the effects of relationships between main spatial lower pole calyceal anatomic factors on the success of shock-wave lithotripsy in patients with lower pole kidney stones. *Urology*, 2008. 71: 801.
<https://www.ncbi.nlm.nih.gov/pubmed/18279941>
299. Danuser, H., *et al.* Extracorporeal shock wave lithotripsy of lower calyx calculi: how much is treatment outcome influenced by the anatomy of the collecting system? *Eur Urol*, 2007. 52: 539.
<https://www.ncbi.nlm.nih.gov/pubmed/17400366>
300. Preminger, G.M. Management of lower pole renal calculi: shock wave lithotripsy versus percutaneous nephrolithotomy versus flexible ureteroscopy. *Urol Res*, 2006. 34: 108.
<https://www.ncbi.nlm.nih.gov/pubmed/16463145>
301. Zheng, C., *et al.* Extracorporeal shock wave lithotripsy versus retrograde intrarenal surgery for treatment for renal stones 1-2 cm: a meta-analysis. *Urolithiasis*, 2015. 43: 549.
<https://www.ncbi.nlm.nih.gov/pubmed/26211003>
302. Zheng, C., *et al.* Retrograde intrarenal surgery versus percutaneous nephrolithotomy for treatment of renal stones >2 cm: a meta-analysis. *Urol Int*, 2014. 93: 417.
<https://www.ncbi.nlm.nih.gov/pubmed/25170589>
303. Karakoyunlu, N., *et al.* A comparison of standard PCNL and staged retrograde FURS in pelvis stones over 2 cm in diameter: a prospective randomized study. *Urolithiasis*, 2015. 43: 283.
<https://www.ncbi.nlm.nih.gov/pubmed/25295266>
304. Donaldson, J.F., *et al.* Systematic review and meta-analysis of the clinical effectiveness of shock wave lithotripsy, retrograde intrarenal surgery, and percutaneous nephrolithotomy for lower-pole renal stones. *Eur Urol*, 2015. 67: 612.
<https://www.ncbi.nlm.nih.gov/pubmed/25449204>
305. Kumar, A., *et al.* A prospective, randomized comparison of shock wave lithotripsy, retrograde intrarenal surgery and miniperc for treatment of 1 to 2 cm radiolucent lower calyceal renal calculi: a single center experience. *J Urol*, 2015. 193: 160.
<https://www.ncbi.nlm.nih.gov/pubmed/25177768>
306. Sener, N.C., *et al.* Prospective randomized trial comparing shock wave lithotripsy and flexible ureterorenoscopy for lower pole stones smaller than 1 cm. *Urolithiasis*, 2014. 42: 127.
<https://www.ncbi.nlm.nih.gov/pubmed/24220692>
307. Manikandan, R., *et al.* Do anatomic factors pose a significant risk in the formation of lower pole stones? *Urology*, 2007. 69: 620.
<https://www.ncbi.nlm.nih.gov/pubmed/17445636>
308. De, S., *et al.* Percutaneous nephrolithotomy versus retrograde intrarenal surgery: a systematic review and meta-analysis. *Eur Urol*, 2015. 67: 125.
<https://www.ncbi.nlm.nih.gov/pubmed/25064687>
309. Sener, N.C., *et al.* Asymptomatic lower pole small renal stones: shock wave lithotripsy, flexible ureteroscopy, or observation? A prospective randomized trial. *Urology*, 2015. 85: 33.
<https://www.ncbi.nlm.nih.gov/pubmed/25440816>
310. Kumar, A., *et al.* A Prospective Randomized Comparison Between Shock Wave Lithotripsy and Flexible Ureterorenoscopy for Lower Caliceal Stones \leq 2 cm: A Single-Center Experience. *J Endourol*, 2015. 29: 575.
<https://www.ncbi.nlm.nih.gov/pubmed/25203489>
311. Mi, Y., *et al.* Flexible ureterorenoscopy (F-URS) with holmium laser versus extracorporeal shock wave lithotripsy (ESWL) for treatment of renal stone <2 cm: a meta-analysis. *Urolithiasis*, 2016. 44: 353.
<https://www.ncbi.nlm.nih.gov/pubmed/26530230>
312. Zhang, W., *et al.* Retrograde Intrarenal Surgery Versus Percutaneous Nephrolithotomy Versus Extracorporeal Shockwave Lithotripsy for Treatment of Lower Pole Renal Stones: A Meta-Analysis and Systematic Review. *J Endourol*, 2015. 29: 745.
<https://www.ncbi.nlm.nih.gov/pubmed/25531986>
313. Sumino, Y., *et al.* Predictors of lower pole renal stone clearance after extracorporeal shock wave lithotripsy. *J Urol*, 2002. 168: 1344.
<https://www.ncbi.nlm.nih.gov/pubmed/12352389>

314. Torricelli, F.C., *et al.* Impact of renal anatomy on shock wave lithotripsy outcomes for lower pole kidney stones: results of a prospective multifactorial analysis controlled by computerized tomography. *J Urol*, 2015. 193: 2002.
<https://www.ncbi.nlm.nih.gov/pubmed/25524240>
315. Gupta, N.P., *et al.* Infundibulopelvic anatomy and clearance of inferior caliceal calculi with shock wave lithotripsy. *J Urol*, 2000. 163: 24.
<https://www.ncbi.nlm.nih.gov/pubmed/10604306>
316. Abdelhamid, M., *et al.* A Prospective Evaluation of High-Resolution CT Parameters in Predicting Extracorporeal Shockwave Lithotripsy Success for Upper Urinary Tract Calculi. *J Endourol*, 2016. 30: 1227.
<https://www.ncbi.nlm.nih.gov/pubmed/27597174>
317. Madbouly, K., *et al.* Impact of lower pole renal anatomy on stone clearance after shock wave lithotripsy: fact or fiction? *J Urol*, 2001. 165: 1415.
<https://www.ncbi.nlm.nih.gov/pubmed/11342888>
318. Chiong, E., *et al.* Randomized controlled study of mechanical percussion, diuresis, and inversion therapy to assist passage of lower pole renal calculi after shock wave lithotripsy. *Urology*, 2005. 65: 1070.
<https://www.ncbi.nlm.nih.gov/pubmed/15922429>
319. Chan, L.H., *et al.* Primary SWL Is an Efficient and Cost-Effective Treatment for Lower Pole Renal Stones Between 10 and 20 mm in Size: A Large Single Center Study. *J Endourol*, 2017. 31: 510.
<https://www.ncbi.nlm.nih.gov/pubmed/28355100>
320. Hyams, E.S., *et al.* Flexible ureterorenoscopy and holmium laser lithotripsy for the management of renal stone burdens that measure 2 to 3 cm: a multi-institutional experience. *J Endourol*, 2010. 24: 1583.
<https://www.ncbi.nlm.nih.gov/pubmed/20629566>
321. Riley, J.M., *et al.* Retrograde ureteroscopy for renal stones larger than 2.5 cm. *J Endourol*, 2009. 23: 1395.
<https://www.ncbi.nlm.nih.gov/pubmed/19694527>
322. Akman, T., *et al.* Comparison of percutaneous nephrolithotomy and retrograde flexible nephrolithotripsy for the management of 2-4 cm stones: a matched-pair analysis. *BJU Int*, 2012. 109: 1384.
<https://www.ncbi.nlm.nih.gov/pubmed/22093679>
323. Assimos, D.G., *et al.* The role of open stone surgery since extracorporeal shock wave lithotripsy. *J Urol*, 1989. 142: 263.
<https://www.ncbi.nlm.nih.gov/pubmed/2746742>
324. Segura, J.W. Current surgical approaches to nephrolithiasis. *Endocrinol Metab Clin North Am*, 1990. 19: 919.
<https://www.ncbi.nlm.nih.gov/pubmed/2081519>
325. Honeck, P., *et al.* Does open stone surgery still play a role in the treatment of urolithiasis? Data of a primary urolithiasis center. *J Endourol*, 2009. 23: 1209.
<https://www.ncbi.nlm.nih.gov/pubmed/19538063>
326. Bichler, K.H., *et al.* Indications for open stone removal of urinary calculi. *Urol Int*, 1997. 59: 102.
<https://www.ncbi.nlm.nih.gov/pubmed/9392057>
327. Paik, M.L., *et al.* Is there a role for open stone surgery? *Urol Clin North Am*, 2000. 27: 323.
<https://www.ncbi.nlm.nih.gov/pubmed/10778474>
328. Alivizatos, G., *et al.* Is there still a role for open surgery in the management of renal stones? *Curr Opin Urol*, 2006. 16: 106.
<https://www.ncbi.nlm.nih.gov/pubmed/>
329. Basiri, A., *et al.* Comparison of safety and efficacy of laparoscopic pyelolithotomy versus percutaneous nephrolithotomy in patients with renal pelvic stones: a randomized clinical trial. *Urol J*, 2014. 11: 1932.
<https://www.ncbi.nlm.nih.gov/pubmed/25433470>
330. Prakash, J., *et al.* Retroperitoneoscopic versus open mini-incision ureterolithotomy for upper- and mid-ureteric stones: a prospective randomized study. *Urolithiasis*, 2014. 42: 133.
<https://www.ncbi.nlm.nih.gov/pubmed/24272062>
331. Al-Hunayan, A., *et al.* Management of solitary renal pelvic stone: laparoscopic retroperitoneal pyelolithotomy versus percutaneous nephrolithotomy. *J Endourol*, 2011. 25: 975.
<https://www.ncbi.nlm.nih.gov/pubmed/21612433>

332. Skolarikos, A., *et al.* Laparoscopic urinary stone surgery: an updated evidence-based review. *Urol Res*, 2010. 38: 337.
<https://www.ncbi.nlm.nih.gov/pubmed/20396871>
333. Giedelman, C., *et al.* Laparoscopic anatomic nephrolithotomy: developments of the technique in the era of minimally invasive surgery. *J Endourol*, 2012. 26: 444.
<https://www.ncbi.nlm.nih.gov/pubmed/22142215>
334. Wang, X., *et al.* Laparoscopic pyelolithotomy compared to percutaneous nephrolithotomy as surgical management for large renal pelvic calculi: a meta-analysis. *J Urol*, 2013. 190: 888.
<https://www.ncbi.nlm.nih.gov/pubmed/23454154>
335. Singh, V., *et al.* Prospective randomized comparison of retroperitoneoscopic pyelolithotomy versus percutaneous nephrolithotomy for solitary large pelvic kidney stones. *Urol Int*, 2014. 92: 392.
<https://www.ncbi.nlm.nih.gov/pubmed/24135482>
336. Kumar, A., *et al.* A Prospective Randomized Comparison Between Laparoscopic Ureterolithotomy and Semirigid Ureteroscopy for Upper Ureteral Stones >2 cm: A Single-Center Experience. *J Endourol*, 2015. 29: 1248.
<https://www.ncbi.nlm.nih.gov/pubmed/25177768>
337. Torricelli, F.C., *et al.* Semi-rigid ureteroscopic lithotripsy versus laparoscopic ureterolithotomy for large upper ureteral stones: a meta - analysis of randomized controlled trials. *Int Braz J Urol*, 2016. 42: 645.
<https://www.ncbi.nlm.nih.gov/pubmed/27564273>
338. Coptcoat, M.J., *et al.* The steinstrasse: a legacy of extracorporeal lithotripsy? *Eur Urol*, 1988. 14: 93.
<https://www.ncbi.nlm.nih.gov/pubmed/3360043>
339. Lucio, J., 2nd, *et al.* Steinstrasse predictive factors and outcomes after extracorporeal shockwave lithotripsy. *Int Braz J Urol*, 2011. 37: 477.
<https://www.ncbi.nlm.nih.gov/pubmed/21888699>
340. Moursy, E., *et al.* Tamsulosin as an expulsive therapy for steinstrasse after extracorporeal shock wave lithotripsy: a randomized controlled study. *Scand J Urol Nephrol*, 2010. 44: 315.
<https://www.ncbi.nlm.nih.gov/pubmed/20560802>
341. Resim, S., *et al.* Role of tamsulosin in treatment of patients with steinstrasse developing after extracorporeal shock wave lithotripsy. *Urology*, 2005. 66: 945.
<https://www.ncbi.nlm.nih.gov/pubmed/16286100>
342. Rabbani, S.M. Treatment of steinstrasse by transureteral lithotripsy. *Urol J*, 2008. 5: 89.
<https://www.ncbi.nlm.nih.gov/pubmed/18592460>
343. Chew, B.H., *et al.* Natural History, Complications and Re-Intervention Rates of Asymptomatic Residual Stone Fragments after Ureteroscopy: a Report from the EDGE Research Consortium. *J Urol*, 2016. 195: 982.
<https://www.ncbi.nlm.nih.gov/pubmed/26585680>
344. Candau, C., *et al.* Natural history of residual renal stone fragments after ESWL. *Eur Urol*, 2000. 37: 18.
<https://www.ncbi.nlm.nih.gov/pubmed/10671779>
345. Olvera-Posada, D., *et al.* Natural History of Residual Fragments After Percutaneous Nephrolithotomy: Evaluation of Factors Related to Clinical Events and Intervention. *Urology*, 2016. 97: 46.
<https://www.ncbi.nlm.nih.gov/pubmed/27421779>
346. Portis, A.J., *et al.* Confident intraoperative decision making during percutaneous nephrolithotomy: does this patient need a second look? *Urology*, 2008. 71: 218.
<https://www.ncbi.nlm.nih.gov/pubmed/18308087>
347. Tokas, T., *et al.* Uncovering the real outcomes of active renal stone treatment by utilizing non-contrast computer tomography: a systematic review of the current literature. *World J Urol*, 2017. 35: 897.
<https://www.ncbi.nlm.nih.gov/pubmed/27738806>
348. Omar, M., *et al.* Contemporary Imaging Practice Patterns Following Ureteroscopy for Stone Disease. *J Endourol*, 2015. 29: 1122.
<https://www.ncbi.nlm.nih.gov/pubmed/25963170>
349. Rippel, C.A., *et al.* Residual fragments following ureteroscopic lithotripsy: incidence and predictors on postoperative computerized tomography. *J Urol*, 2012. 188: 2246.
<https://www.ncbi.nlm.nih.gov/pubmed/23083650>

350. Gokce, M.I., *et al.* Comparison of imaging modalities for detection of residual fragments and prediction of stone related events following percutaneous nephrolithotomy. *Int Braz J Urol*, 2015. 41: 86.
<https://www.ncbi.nlm.nih.gov/pubmed/25928513>
351. Beck, E.M., *et al.* The fate of residual fragments after extracorporeal shock wave lithotripsy monotherapy of infection stones. *J Urol*, 1991. 145: 6.
<https://www.ncbi.nlm.nih.gov/pubmed/1984100>
352. El-Nahas, A.R., *et al.* Predictors of clinical significance of residual fragments after extracorporeal shockwave lithotripsy for renal stones. *J Endourol*, 2006. 20: 870.
<https://www.ncbi.nlm.nih.gov/pubmed/17144853>
353. Buchholz, N.P., *et al.* Minor residual fragments after extracorporeal shockwave lithotripsy: spontaneous clearance or risk factor for recurrent stone formation? *J Endourol*, 1997. 11: 227.
<https://www.ncbi.nlm.nih.gov/pubmed/9376838>
354. Tsai, Y.L., *et al.* Comparative study of conservative and surgical management for symptomatic moderate and severe hydronephrosis in pregnancy: a prospective randomized study. *Acta Obstet Gynecol Scand*, 2007. 86: 1047.
<https://www.ncbi.nlm.nih.gov/pubmed/17712643>
355. Mokhmalji, H., *et al.* Percutaneous nephrostomy versus ureteral stents for diversion of hydronephrosis caused by stones: a prospective, randomized clinical trial. *J Urol*, 2001. 165: 1088.
<https://www.ncbi.nlm.nih.gov/pubmed/11257644>
356. Ngai, H.Y., *et al.* Double-J ureteric stenting in pregnancy: A single-centre experience from Iraq. *Arab J Urol*, 2013. 11: 148.
<https://www.ncbi.nlm.nih.gov/pubmed/26558073>
357. Semins, M.J., *et al.* The safety of ureteroscopy during pregnancy: a systematic review and meta-analysis. *J Urol*, 2009. 181: 139.
<https://www.ncbi.nlm.nih.gov/pubmed/19012926>
358. Ishii, H., *et al.* Current status of ureteroscopy for stone disease in pregnancy. *Urolithiasis*, 2014. 42: 1.
<https://www.ncbi.nlm.nih.gov/pubmed/24374899>
359. Teleb, M., *et al.* Definitive ureteroscopy and intracorporeal lithotripsy in treatment of ureteral calculi during pregnancy. *Arab J Urol*, 2014. 12: 299.
<https://www.ncbi.nlm.nih.gov/pubmed/26019966>
360. Toth, C., *et al.* Percutaneous nephrolithotomy in early pregnancy. *Int Urol Nephrol*, 2005. 37: 1.
<https://www.ncbi.nlm.nih.gov/pubmed/16132747>
361. Kato, H., *et al.* Continent urinary reservoir formation with transverse colon for patients with pelvic irradiation. *Int J Urol*, 2002. 9: 200.
<https://www.ncbi.nlm.nih.gov/pubmed/12010313>
362. Holmes, D.G., *et al.* Long-term complications related to the modified Indiana pouch. *Urology*, 2002. 60: 603.
<https://www.ncbi.nlm.nih.gov/pubmed/12385916>
363. Yang, W.J., *et al.* Long-term effects of ileal conduit urinary diversion on upper urinary tract in bladder cancer. *Urology*, 2006. 68: 324.
<https://www.ncbi.nlm.nih.gov/pubmed/16904445>
364. Assimos, D.G. Nephrolithiasis in patients with urinary diversion. *J Urol*, 1996. 155: 69.
<https://www.ncbi.nlm.nih.gov/pubmed/7490901>
365. Cohen, T.D., *et al.* Long-term incidence and risks for recurrent stones following contemporary management of upper tract calculi in patients with a urinary diversion. *J Urol*, 1996. 155: 62.
<https://www.ncbi.nlm.nih.gov/pubmed/7490899>
366. Deliveliotis, C., *et al.* Shockwave lithotripsy for urinary stones in patients with urinary diversion after radical cystectomy. *J Endourol*, 2002. 16: 717.
<https://www.ncbi.nlm.nih.gov/pubmed/12542873>
367. Stein, J.P., *et al.* Complications of the afferent antireflux valve mechanism in the Kock ileal reservoir. *J Urol*, 1996. 155: 1579.
<https://www.ncbi.nlm.nih.gov/pubmed/8627827>
368. Matlaga, B.R., *et al.* Computerized tomography guided access for percutaneous nephrostolithotomy. *J Urol*, 2003. 170: 45.
<https://www.ncbi.nlm.nih.gov/pubmed/12796641>
369. Hensle, T.W., *et al.* Preventing reservoir calculi after augmentation cystoplasty and continent urinary diversion: the influence of an irrigation protocol. *BJU Int*, 2004. 93: 585.
<https://www.ncbi.nlm.nih.gov/pubmed/15008735>

370. Raj, G.V., *et al.* The incidence of nephrolithiasis in patients with spinal neural tube defects. *J Urol*, 1999. 162: 1238.
<https://www.ncbi.nlm.nih.gov/pubmed/10458475>
371. Gros, D.A., *et al.* Urolithiasis in spina bifida. *Eur J Pediatr Surg*, 1998. 8 Suppl 1: 68.
<https://www.ncbi.nlm.nih.gov/pubmed/9926338>
372. Kondo, A., *et al.* [Urolithiasis in those patients with myelodysplasia]. *Nihon Hinyokika Gakkai Zasshi*, 2003. 94: 15.
<https://www.ncbi.nlm.nih.gov/pubmed/12638200>
373. Rendeli, C., *et al.* Latex sensitisation and allergy in children with myelomeningocele. *Childs Nerv Syst*, 2006. 22: 28.
<https://www.ncbi.nlm.nih.gov/pubmed/15703967>
374. Christman, M.S., *et al.* Morbidity and efficacy of ureteroscopic stone treatment in patients with neurogenic bladder. *J Urol*, 2013. 190: 1479.
<https://www.ncbi.nlm.nih.gov/pubmed/23454151>
375. Harper, J.M., *et al.* Risk factors for calculus formation in patients with renal transplants. *Br J Urol*, 1994. 74: 147.
<https://www.ncbi.nlm.nih.gov/pubmed/7921929>
376. Cheungpasitporn, W., *et al.* Incidence of kidney stones in kidney transplant recipients: A systematic review and meta-analysis. *World J Transplant*, 2016. 6: 790.
<https://www.ncbi.nlm.nih.gov/pubmed/28058231>
377. Trivedi, A., *et al.* Management of calculi in a donor kidney. *Transplant Proc*, 2007. 39: 761.
<https://www.ncbi.nlm.nih.gov/pubmed/17445593>
378. Yigit, B., *et al.* Stone disease in kidney transplantation. *Transplant Proc*, 2004. 36: 187.
<https://www.ncbi.nlm.nih.gov/pubmed/15013342>
379. Gupta, M., *et al.* Treatment of stones associated with complex or anomalous renal anatomy. *Urol Clin North Am*, 2007. 34: 431.
<https://www.ncbi.nlm.nih.gov/pubmed/17678992>
380. Challacombe, B., *et al.* Multimodal management of urolithiasis in renal transplantation. *BJU Int*, 2005. 96: 385.
<https://www.ncbi.nlm.nih.gov/pubmed/16042735>
381. Rifaioglu, M.M., *et al.* Percutaneous management of stones in transplanted kidneys. *Urology*, 2008. 72: 508.
<https://www.ncbi.nlm.nih.gov/pubmed/18653217>
382. Minon Cifuentes, J., *et al.* Percutaneous nephrolithotomy in transplanted kidney. *Urology*, 1991. 38: 232.
<https://www.ncbi.nlm.nih.gov/pubmed/1887537>
383. Wyatt, J., *et al.* Treatment outcomes for percutaneous nephrolithotomy in renal allografts. *J Endourol*, 2009. 23: 1821.
<https://www.ncbi.nlm.nih.gov/pubmed/19814697>
384. Del Pizzo, J.J., *et al.* Ureteroscopic evaluation in renal transplant recipients. *J Endourol*, 1998. 12: 135.
<https://www.ncbi.nlm.nih.gov/pubmed/9607439>
385. Basiri, A., *et al.* Ureteroscopic management of urological complications after renal transplantation. *Scand J Urol Nephrol*, 2006. 40: 53.
<https://www.ncbi.nlm.nih.gov/pubmed/16452057>
386. Lu, H.F., *et al.* Donor-gifted allograft urolithiasis: early percutaneous management. *Urology*, 2002. 59: 25.
<https://www.ncbi.nlm.nih.gov/pubmed/11796274>
387. Rhoderick, T.M., *et al.* Extracorporeal shock wave lithotripsy in the renal transplant patient: a case report and review of literature. *Clin Transplant*, 1992. 6: 375.
<https://www.ncbi.nlm.nih.gov/pubmed/10147926>
388. Atala, A., *et al.* Extracorporeal shock-wave lithotripsy in transplanted kidney. *Urology*, 1993. 41: 60.
<https://www.ncbi.nlm.nih.gov/pubmed/8420082>
389. Klingler, H.C., *et al.* Urolithiasis in allograft kidneys. *Urology*, 2002. 59: 344.
<https://www.ncbi.nlm.nih.gov/pubmed/11880067>
390. Parkhomenko, E., *et al.* Percutaneous Management of Stone Containing Calyceal Diverticula: Associated Factors and Outcomes. *J Urol*, 2017. 198: 864.
<https://www.ncbi.nlm.nih.gov/pubmed/28483573>

391. Bas, O., *et al.* Management of calyceal diverticular calculi: a comparison of percutaneous nephrolithotomy and flexible ureterorenoscopy. *Urolithiasis*, 2015. 43: 155.
<https://www.ncbi.nlm.nih.gov/pubmed/25249328>
392. Raboy, A., *et al.* Laparoscopic ureterolithotomy. *Urology*, 1992. 39: 223.
<https://www.ncbi.nlm.nih.gov/pubmed/1532102>
393. Gaur, D.D. Retroperitoneal endoscopic ureterolithotomy: our experience in 12 patients. *J Endourol*, 1993. 7: 501.
<https://www.ncbi.nlm.nih.gov/pubmed/8124346>
394. Gaur, D.D. Retroperitoneal laparoscopic ureterolithotomy. *World J Urol*, 1993. 11: 175.
<https://www.ncbi.nlm.nih.gov/pubmed/8401638>
395. Gaur, D.D., *et al.* Retroperitoneal laparoscopic pyelolithotomy. *J Urol*, 1994. 151: 927.
<https://www.ncbi.nlm.nih.gov/pubmed/8126827>
396. Escovar Diaz, P., *et al.* [Laparoscopic ureterolithotomy]. *Arch Esp Urol*, 1993. 46: 633.
<https://www.ncbi.nlm.nih.gov/pubmed/8239742>
397. Locke, D.R., *et al.* Extracorporeal shock-wave lithotripsy in horseshoe kidneys. *Urology*, 1990. 35: 407.
<https://www.ncbi.nlm.nih.gov/pubmed/2336770>
398. Gelet, A., *et al.* Endopyelotomy with the Acucise cutting balloon device. Early clinical experience. *Eur Urol*, 1997. 31: 389.
<https://www.ncbi.nlm.nih.gov/pubmed/9187895>
399. Faerber, G.J., *et al.* Retrograde treatment of ureteropelvic junction obstruction using the ureteral cutting balloon catheter. *J Urol*, 1997. 157: 454.
<https://www.ncbi.nlm.nih.gov/pubmed/8996330>
400. Berkman, D.S., *et al.* Treatment outcomes after endopyelotomy performed with or without simultaneous nephrolithotomy: 10-year experience. *J Endourol*, 2009. 23: 1409.
<https://www.ncbi.nlm.nih.gov/pubmed/19694529>
401. Nakada, S.Y., *et al.* Retrospective analysis of the effect of crossing vessels on successful retrograde endopyelotomy outcomes using spiral computerized tomography angiography. *J Urol*, 1998. 159: 62.
<https://www.ncbi.nlm.nih.gov/pubmed/9400437>
402. Skolarikos, A., *et al.* Ureteropelvic obstruction and renal stones: etiology and treatment. *Urolithiasis*, 2015. 43: 5.
<https://www.ncbi.nlm.nih.gov/pubmed/25362543>
403. Age of first stone episode., In: *Urolithiasis*, H.B. Rodgers AL, Hess B, Khan SR, Preminger GM, Editors. 2000, University of Cape Town, Cape Town.
404. Robertson WG, W.H., Unwin RJ, *et al.*, Possible causes of the changing pattern of the age of onset of urinary stone disease in the UK., in *Urolithiasis*, H.B. Rodgers AL, Hess B, Khan SR, Preminger GM, Editor. 2000, University of Cape Town, Cape Town.
405. Djelloul, Z., *et al.* [Urinary stones in Western Algeria: study of the composition of 1,354 urinary stones in relation to their anatomical site and the age and gender of the patients]. *Prog Urol*, 2006. 16: 328.
<https://www.ncbi.nlm.nih.gov/pubmed/16821346>
406. Sarica, K. Pediatric urolithiasis: etiology, specific pathogenesis and medical treatment. *Urol Res*, 2006. 34: 96.
<https://www.ncbi.nlm.nih.gov/pubmed/16432692>
407. Sarica, K. Medical aspect and minimal invasive treatment of urinary stones in children. *Arch Ital Urol Androl*, 2008. 80: 43.
<https://www.ncbi.nlm.nih.gov/pubmed/18683808>
408. Sayasone, S., *et al.* Bladder stones in childhood: a descriptive study in a rural setting in Saravan Province, Lao PDR. *Southeast Asian J Trop Med Public Health*, 2004. 35 Suppl 2: 50.
<https://www.ncbi.nlm.nih.gov/pubmed/15906634>
409. Aldaqadossi, H.A., *et al.* Efficacy and safety of tamsulosin as a medical expulsive therapy for stones in children. *Arab J Urol*, 2015. 13: 107.
<https://www.ncbi.nlm.nih.gov/pubmed/26413330>
410. Aydogdu, O., *et al.* Effectiveness of doxazosin in treatment of distal ureteral stones in children. *J Urol*, 2009. 182: 2880.
<https://www.ncbi.nlm.nih.gov/pubmed/19846149>
411. Mokhless, I., *et al.* Tamsulosin for the management of distal ureteral stones in children: a prospective randomized study. *J Pediatr Urol*, 2012. 8: 544.
<https://www.ncbi.nlm.nih.gov/pubmed/22099477>

412. Glina, F.P., *et al.* The use of alpha-1 adrenergic blockers in children with distal ureterolithiasis: a systematic review and meta-analysis. *Int Braz J Urol*, 2015. 41: 1049.
<https://www.ncbi.nlm.nih.gov/pubmed/26717117>
413. Tian, D., *et al.* The efficacy and safety of adrenergic alpha-antagonists in treatment of distal ureteral stones in pediatric patients: A systematic review and meta-analysis. *J Pediatr Surg*, 2017. 52: 360.
<https://www.ncbi.nlm.nih.gov/pubmed/27837990>
414. Landau, E.H., *et al.* Extracorporeal shock wave lithotripsy in prepubertal children: 22-year experience at a single institution with a single lithotripter. *J Urol*, 2009. 182: 1835.
<https://www.ncbi.nlm.nih.gov/pubmed/19692011>
415. Frick, J., *et al.* Long-term follow-up after extracorporeal shock wave lithotripsy in children. *Eur Urol*, 1991. 19: 225.
<https://www.ncbi.nlm.nih.gov/pubmed/1855529>
416. D'Addessi, A., *et al.* Is extracorporeal shock wave lithotripsy in pediatrics a safe procedure? *J Pediatr Surg*, 2008. 43: 591.
<https://www.ncbi.nlm.nih.gov/pubmed/18405701>
417. Lu, P., *et al.* The clinical efficacy of extracorporeal shock wave lithotripsy in pediatric urolithiasis: a systematic review and meta-analysis. *Urolithiasis*, 2015. 43: 199.
<https://www.ncbi.nlm.nih.gov/pubmed/25721456>
418. Salem, H.K., *et al.* Slow vs rapid delivery rate shock wave lithotripsy for pediatric renal urolithiasis: a prospective randomized study. *J Urol*, 2014. 191: 1370.
<https://www.ncbi.nlm.nih.gov/pubmed/24262496>
419. Aldridge, R.D., *et al.* Anesthesia for pediatric lithotripsy. *Paediatr Anaesth*, 2006. 16: 236.
<https://www.ncbi.nlm.nih.gov/pubmed/16490086>
420. Sarica, K., *et al.* Long-term follow-up of renal morphology and function in children after lithotripsy. *Urol Int*, 1995. 54: 95.
<https://www.ncbi.nlm.nih.gov/pubmed/7747366>
421. Griffin, S.J., *et al.* Safety of shock wave lithotripsy for treatment of pediatric urolithiasis: 20-year experience. *J Urol*, 2010. 183: 2332.
<https://www.ncbi.nlm.nih.gov/pubmed/20400129>
422. Reisiger, K., *et al.* Pediatric nephrolithiasis: does treatment affect renal growth? *Urology*, 2007. 69: 1190.
<https://www.ncbi.nlm.nih.gov/pubmed/17572213>
423. Kurien, A., *et al.* Extracorporeal shock wave lithotripsy in children: equivalent clearance rates to adults is achieved with fewer and lower energy shock waves. *BJU Int*, 2009. 103: 81.
<https://www.ncbi.nlm.nih.gov/pubmed/18727616>
424. Lahme, S. Shockwave lithotripsy and endourological stone treatment in children. *Urol Res*, 2006. 34: 112.
<https://www.ncbi.nlm.nih.gov/pubmed/16446980>
425. Smaldone, M.C., *et al.* Contemporary surgical management of pediatric urolithiasis. *Urol Clin North Am*, 2010. 37: 253.
<https://www.ncbi.nlm.nih.gov/pubmed/20569803>
426. Desai, M. Endoscopic management of stones in children. *Curr Opin Urol*, 2005. 15: 107.
<https://www.ncbi.nlm.nih.gov/pubmed/15725934>
427. Straub, M., *et al.* Pediatric urolithiasis: the current surgical management. *Pediatr Nephrol*, 2010. 25: 1239.
<https://www.ncbi.nlm.nih.gov/pubmed/20130924>
428. Smaldone, M.C., *et al.* Endourological management of pediatric stone disease: present status. *J Urol*, 2009. 181: 17.
<https://www.ncbi.nlm.nih.gov/pubmed/19012920>
429. Kapoor, R., *et al.* Safety and efficacy of percutaneous nephrolithotomy in the pediatric population. *J Endourol*, 2008. 22: 637.
<https://www.ncbi.nlm.nih.gov/pubmed/18338958>
430. Hosseini, S.R., *et al.* One shot tract dilation for percutaneous nephrolithotomy: is it safe and effective in preschool children? *Urol Int*, 2014. 92: 440.
<https://www.ncbi.nlm.nih.gov/pubmed/24603110>
431. Song, G., *et al.* Advantages of tubeless mini-percutaneous nephrolithotomy in the treatment of preschool children under 3 years old. *J Pediatr Surg*, 2015. 50: 655.
<https://www.ncbi.nlm.nih.gov/pubmed/25840082>

432. Samad, L., *et al.* Tubed vs tubeless PCNL in children. J Pak Med Assoc, 2012. 62: 892.
<https://www.ncbi.nlm.nih.gov/pubmed/23139970>
433. Cannon, G.M., *et al.* Ureteroscopic management of lower-pole stones in a pediatric population. J Endourol, 2007. 21: 1179.
<https://www.ncbi.nlm.nih.gov/pubmed/17949321>
434. Erturhan, S., *et al.* Ureteroscopic management of ureteral calculi in children. J Endourol, 2007. 21: 397.
<https://www.ncbi.nlm.nih.gov/pubmed/17451329>
435. Basiri, A., *et al.* A multicenter, randomized, controlled trial of transureteral and shock wave lithotripsy--which is the best minimally invasive modality to treat distal ureteral calculi in children? J Urol, 2010. 184: 1106.
<https://www.ncbi.nlm.nih.gov/pubmed/20650490>
436. Basiri, A., *et al.* Ureteral calculi in children: what is best as a minimally invasive modality? Urol J, 2008. 5: 67.
<https://www.ncbi.nlm.nih.gov/pubmed/18592456>
437. Ishii, H., *et al.* Ureteroscopy for stone disease in the paediatric population: a systematic review. BJU Int, 2015. 115: 867.
<https://www.ncbi.nlm.nih.gov/pubmed/25203925>
438. Safwat, A.S., *et al.* Experience with ureteroscopic holmium laser lithotripsy in children. Pediatr Surg Int, 2008. 24: 579.
<https://www.ncbi.nlm.nih.gov/pubmed/18365216>
439. Kim, S.S., *et al.* Pediatric flexible ureteroscopic lithotripsy: the children's hospital of Philadelphia experience. J Urol, 2008. 180: 2616.
<https://www.ncbi.nlm.nih.gov/pubmed/18950810>
440. Ishii, H., *et al.* Flexible ureteroscopy and lasertripsy (FURSL) for paediatric renal calculi: results from a systematic review. J Pediatr Urol, 2014. 10: 1020.
<https://www.ncbi.nlm.nih.gov/pubmed/25241397>
441. Mokhless, I.A., *et al.* Retrograde intrarenal surgery monotherapy versus shock wave lithotripsy for stones 10 to 20 mm in preschool children: a prospective, randomized study. J Urol, 2014. 191: 1496.
<https://www.ncbi.nlm.nih.gov/pubmed/24679882>
442. Gokce, M.I., *et al.* Effect of Prestiting on Success and Complication Rates of Ureterorenoscopy in Pediatric Population. J Endourol, 2016. 30: 850.
<https://www.ncbi.nlm.nih.gov/pubmed/27189236>
443. Saad, K.S., *et al.* Percutaneous Nephrolithotomy vs Retrograde Intrarenal Surgery for Large Renal Stones in Pediatric Patients: A Randomized Controlled Trial. J Urol, 2015. 194: 1716.
<https://www.ncbi.nlm.nih.gov/pubmed/26165587>
444. Lu, P., *et al.* Clinical efficacy of percutaneous nephrolithotomy versus retrograde intrarenal surgery for pediatric kidney urolithiasis: A PRISMA-compliant article. Medicine (Baltimore), 2017. 96: e8346.
<https://www.ncbi.nlm.nih.gov/pubmed/29069011>
445. Muslumanoglu, A.Y., *et al.* Extracorporeal shock wave lithotripsy as first line treatment alternative for urinary tract stones in children: a large scale retrospective analysis. J Urol, 2003. 170: 2405.
<https://www.ncbi.nlm.nih.gov/pubmed/14634438>
446. Casale, P., *et al.* Transperitoneal laparoscopic pyelolithotomy after failed percutaneous access in the pediatric patient. J Urol, 2004. 172: 680.
<https://www.ncbi.nlm.nih.gov/pubmed/15247760>
447. Fragoso, A.C., *et al.* Minimal access surgery in the management of pediatric urolithiasis. J Pediatr Urol, 2009. 5: 42.
<https://www.ncbi.nlm.nih.gov/pubmed/18805739>
448. Elderwy, A.A., *et al.* Dissolution therapy versus shock wave lithotripsy for radiolucent renal stones in children: a prospective study. J Urol, 2014. 191: 1491.
<https://www.ncbi.nlm.nih.gov/pubmed/24679880>
449. Sarica, K., *et al.* Effect of potassium citrate therapy on stone recurrence and regrowth after extracorporeal shockwave lithotripsy in children. J Endourol, 2006. 20: 875.
<https://www.ncbi.nlm.nih.gov/pubmed/17144854>
450. Parks, J.H., *et al.* A single 24-hour urine collection is inadequate for the medical evaluation of nephrolithiasis. J Urol, 2002. 167: 1607.
<https://www.ncbi.nlm.nih.gov/pubmed/11912373>

451. Nayan, M., *et al.* Variations between two 24-hour urine collections in patients presenting to a tertiary stone clinic. *Can Urol Assoc J*, 2012. 6: 30.
<https://www.ncbi.nlm.nih.gov/pubmed/22396364>
452. Ferraz, R.R., *et al.* Preservation of urine samples for metabolic evaluation of stone-forming patients. *Urol Res*, 2006. 34: 329.
<https://www.ncbi.nlm.nih.gov/pubmed/16896690>
453. Yilmaz, G., *et al.* Are preservatives necessary in 24-hour urine measurements? *Clin Biochem*, 2008. 41: 899.
<https://www.ncbi.nlm.nih.gov/pubmed/18371307>
454. Coe, F.L., *et al.* Kidney stone disease. *J Clin Invest*, 2005. 115: 2598.
<https://www.ncbi.nlm.nih.gov/pubmed/16200192>
455. Norman, R.W., *et al.* When should patients with symptomatic urinary stone disease be evaluated metabolically? *J Urol*, 1984. 132: 1137.
<https://www.ncbi.nlm.nih.gov/pubmed/6502804>
456. Urine evaluation (in: Evaluation of the stone former), in 2ND International Consultation on Stone Disease, H.M. Assimos D. Chew B, Hautmann R, Holmes R, Williams J, Wolf JS, Editor. 2007, Health Publications.
457. Hesse A, *et al.* Urinary Stones: Diagnosis, Treatment and Prevention of Recurrence., In: Uric acid stones. 2002, S Karger AG, Basel.
458. Tiselius, H.G. Standardized estimate of the ion activity product of calcium oxalate in urine from renal stone formers. *Eur Urol*, 1989. 16: 48.
<https://www.ncbi.nlm.nih.gov/pubmed/2714318>
459. Ackermann, D., *et al.* Use of the computer program EQUIL to estimate pH in model solutions and human urine. *Urol Res*, 1989. 17: 157.
<https://www.ncbi.nlm.nih.gov/pubmed/2749945>
460. Kavanagh, J.P., *et al.* Why does the Bonn Risk Index discriminate between calcium oxalate stone formers and healthy controls? *J Urol*, 2006. 175: 766.
<https://www.ncbi.nlm.nih.gov/pubmed/16407047>
461. Rodgers AL, *et al.* What can it teach us?, In: Proceedings of Renal Stone Disease 1st Annual International Urolithiasis Research Symposium, 2-3 November 2006., Evan A.P., Lingeman J.E. Eds. 2007, American Institute of Physics: Melville, New York
462. Hoppe, B., *et al.* Diagnostic examination of the child with urolithiasis or nephrocalcinosis. *Pediatr Nephrol*, 2010. 25: 403.
<https://www.ncbi.nlm.nih.gov/pubmed/19104842>
463. Borghi, L., *et al.* Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5-year randomized prospective study. *J Urol*, 1996. 155: 839.
<https://www.ncbi.nlm.nih.gov/pubmed/8583588>
464. Sarica, K., *et al.* The effect of calcium channel blockers on stone regrowth and recurrence after shock wave lithotripsy. *Urol Res*, 2006. 34: 184.
<https://www.ncbi.nlm.nih.gov/pubmed/16463053>
465. Fink, H.A., *et al.* Medical management to prevent recurrent nephrolithiasis in adults: a systematic review for an American College of Physicians Clinical Guideline. *Ann Intern Med*, 2013. 158: 535.
<https://www.ncbi.nlm.nih.gov/pubmed/23546565>
466. Siener, R., *et al.* Dietary risk factors for hyperoxaluria in calcium oxalate stone formers. *Kidney Int*, 2003. 63: 1037.
<https://www.ncbi.nlm.nih.gov/pubmed/12631085>
467. Wabner, C.L., *et al.* Effect of orange juice consumption on urinary stone risk factors. *J Urol*, 1993. 149: 1405.
<https://www.ncbi.nlm.nih.gov/pubmed/8501777>
468. Gettman, M.T., *et al.* Effect of cranberry juice consumption on urinary stone risk factors. *J Urol*, 2005. 174: 590.
<https://www.ncbi.nlm.nih.gov/pubmed/16006907>
469. Shuster, J., *et al.* Soft drink consumption and urinary stone recurrence: a randomized prevention trial. *J Clin Epidemiol*, 1992. 45: 911.
<https://www.ncbi.nlm.nih.gov/pubmed/1624973>
470. Kocvara, R., *et al.* A prospective study of nonmedical prophylaxis after a first kidney stone. *BJU Int*, 1999. 84: 393.
<https://www.ncbi.nlm.nih.gov/pubmed/10468751>

471. Hess, B., *et al.* Effects of a 'common sense diet' on urinary composition and supersaturation in patients with idiopathic calcium urolithiasis. *Eur Urol*, 1999. 36: 136.
<https://www.ncbi.nlm.nih.gov/pubmed/10420035>
472. Ebisuno, S., *et al.* Results of long-term rice bran treatment on stone recurrence in hypercalciuric patients. *Br J Urol*, 1991. 67: 237.
<https://www.ncbi.nlm.nih.gov/pubmed/1902388>
473. Hiatt, R.A., *et al.* Randomized controlled trial of a low animal protein, high fiber diet in the prevention of recurrent calcium oxalate kidney stones. *Am J Epidemiol*, 1996. 144: 25.
<https://www.ncbi.nlm.nih.gov/pubmed/8659482>
474. Dussol, B., *et al.* A randomized trial of low-animal-protein or high-fiber diets for secondary prevention of calcium nephrolithiasis. *Nephron Clin Pract*, 2008. 110: c185.
<https://www.ncbi.nlm.nih.gov/pubmed/18957869>
475. Turney, B.W., *et al.* Diet and risk of kidney stones in the Oxford cohort of the European Prospective Investigation into Cancer and Nutrition (EPIC). *Eur J Epidemiol*, 2014. 29: 363.
<https://www.ncbi.nlm.nih.gov/pubmed/24752465>
476. Auer, B.L., *et al.* The effect of ascorbic acid ingestion on the biochemical and physicochemical risk factors associated with calcium oxalate kidney stone formation. *Clin Chem Lab Med*, 1998. 36: 143.
<https://www.ncbi.nlm.nih.gov/pubmed/9589801>
477. Borghi, L., *et al.* Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. *N Engl J Med*, 2002. 346: 77.
<https://www.ncbi.nlm.nih.gov/pubmed/11784873>
478. Fink, H.A., *et al.* Diet, fluid, or supplements for secondary prevention of nephrolithiasis: a systematic review and meta-analysis of randomized trials. *Eur Urol*, 2009. 56: 72.
<https://www.ncbi.nlm.nih.gov/pubmed/19321253>
479. Curhan, G.C., *et al.* Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. *Ann Intern Med*, 1997. 126: 497.
<https://www.ncbi.nlm.nih.gov/pubmed/9092314>
480. von Unruh, G.E., *et al.* Dependence of oxalate absorption on the daily calcium intake. *J Am Soc Nephrol*, 2004. 15: 1567.
<https://www.ncbi.nlm.nih.gov/pubmed/15153567>
481. Harris, S.S., *et al.* Effects of Hydration and Calcium Supplementation on Urine Calcium Concentration in Healthy Postmenopausal Women. *J Am Coll Nutr*, 2015. 34: 340.
<https://www.ncbi.nlm.nih.gov/pubmed/25856469>
482. Curhan, G.C., *et al.* A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. *N Engl J Med*, 1993. 328: 833.
<https://www.ncbi.nlm.nih.gov/pubmed/8441427>
483. Coe, F.L. Hyperuricosuric calcium oxalate nephrolithiasis. *Adv Exp Med Biol*, 1980. 128: 439.
<https://www.ncbi.nlm.nih.gov/pubmed/7424690>
484. Hyperuricosuric calcium stone disease, In: *Kidney Stones: Medical and Surgical Management*, Coe FL, Pak CYC, Parks JH, Preminger GM, Eds. 1996, Lippincott-Raven: Philadelphia.
485. Siener, R., *et al.* The role of overweight and obesity in calcium oxalate stone formation. *Obes Res*, 2004. 12: 106.
<https://www.ncbi.nlm.nih.gov/pubmed/14742848>
486. Madore, F., *et al.* Nephrolithiasis and risk of hypertension. *Am J Hypertens*, 1998. 11: 46.
<https://www.ncbi.nlm.nih.gov/pubmed/9504449>
487. Madore, F., *et al.* Nephrolithiasis and risk of hypertension in women. *Am J Kidney Dis*, 1998. 32: 802.
<https://www.ncbi.nlm.nih.gov/pubmed/9820450>
488. Tiselius, H.G., *et al.* Effects of citrate on the different phases of calcium oxalate crystallization. *Scanning Microsc*, 1993. 7: 381.
<https://www.ncbi.nlm.nih.gov/pubmed/8316807>
489. Barcelo, P., *et al.* Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. *J Urol*, 1993. 150: 1761.
<https://www.ncbi.nlm.nih.gov/pubmed/8230497>
490. Hofbauer, J., *et al.* Alkali citrate prophylaxis in idiopathic recurrent calcium oxalate urolithiasis--a prospective randomized study. *Br J Urol*, 1994. 73: 362.
<https://www.ncbi.nlm.nih.gov/pubmed/8199822>
491. Ettinger, B., *et al.* Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. *J Urol*, 1997. 158: 2069.
<https://www.ncbi.nlm.nih.gov/pubmed/9366314>

492. Soygur, T., *et al.* Effect of potassium citrate therapy on stone recurrence and residual fragments after shockwave lithotripsy in lower caliceal calcium oxalate urolithiasis: a randomized controlled trial. *J Endourol*, 2002. 16: 149.
<https://www.ncbi.nlm.nih.gov/pubmed/12028622>
493. Premgamone, A., *et al.* A long-term study on the efficacy of a herbal plant, *Orthosiphon grandiflorus*, and sodium potassium citrate in renal calculi treatment. *Southeast Asian J Trop Med Public Health*, 2001. 32: 654.
<https://www.ncbi.nlm.nih.gov/pubmed/11944733>
494. Lojanapiwat, B., *et al.* Alkaline citrate reduces stone recurrence and regrowth after shockwave lithotripsy and percutaneous nephrolithotomy. *Int Braz J Urol*, 2011. 37: 611.
<https://www.ncbi.nlm.nih.gov/pubmed/22099273>
495. Phillips, R., *et al.* Citrate salts for preventing and treating calcium containing kidney stones in adults. *Cochrane Database Syst Rev*, 2015: CD010057.
<https://www.ncbi.nlm.nih.gov/pubmed/26439475>
496. Favus, M.J., *et al.* The effects of allopurinol treatment on stone formation on hyperuricosuric calcium oxalate stone-formers. *Scand J Urol Nephrol Suppl*, 1980. 53: 265.
<https://www.ncbi.nlm.nih.gov/pubmed/6938003>
497. Miano L, *et al.* A placebo controlled double-blind study of allopurinol in severe recurrent idiopathic renal lithiasis, In: *Urolithiasis and Related Clinical Research*, Schwille PO, Robertson WG, Vahlensieck W., Eds. 1985, Plenum Press: New York.
498. Ettinger, B., *et al.* Randomized trial of allopurinol in the prevention of calcium oxalate calculi. *N Engl J Med*, 1986. 315: 1386.
<https://www.ncbi.nlm.nih.gov/pubmed/3534570>
499. Robertson, W.G., *et al.*, A Multicentre Trial to Evaluate Three Treatments for Recurrent Idiopathic Calcium Stone Disease — A Preliminary Report, In: *Urolithiasis and Related Clinical Research*, Schwille P, Smith L, Robertson W. & Vahlensieck W., Editors. 1985, Springer US.
<https://www.ncbi.nlm.nih.gov/pubmed/>
500. Smith, M.J. Placebo versus allopurinol for renal calculi. *J Urol*, 1977. 117: 690.
<https://www.ncbi.nlm.nih.gov/pubmed/875139>
501. Cohen, T.D., *et al.* Clinical effect of captopril on the formation and growth of cystine calculi. *J Urol*, 1995. 154: 164.
<https://www.ncbi.nlm.nih.gov/pubmed/7776415>
502. Coulthard, M.G., *et al.* The treatment of cystinuria with captopril. *Am J Kidney Dis*, 1995. 25: 661.
<https://www.ncbi.nlm.nih.gov/pubmed/7702068>
503. Goldfarb, D.S., *et al.* Randomized controlled trial of febuxostat versus allopurinol or placebo in individuals with higher urinary uric acid excretion and calcium stones. *Clin J Am Soc Nephrol*, 2013. 8: 1960.
<https://www.ncbi.nlm.nih.gov/pubmed/23929928>
504. Nouvenne, A., *et al.* New pharmacologic approach to patients with idiopathic calcium nephrolithiasis and high uricosuria: Febuxostat vs allopurinol. A pilot study. *Eur J Int Med* . 24: e64.
[http://www.ejinme.com/article/S0953-6205\(13\)00364-6/abstract](http://www.ejinme.com/article/S0953-6205(13)00364-6/abstract)
505. Jarrar, K., *et al.* Struvite stones: long term follow up under metaphylaxis. *Ann Urol (Paris)*, 1996. 30: 112.
<https://www.ncbi.nlm.nih.gov/pubmed/8766146>
506. Hesse, A., *et al.* Causes of phosphate stone formation and the importance of metaphylaxis by urinary acidification: a review. *World J Urol*, 1999. 17: 308.
<https://www.ncbi.nlm.nih.gov/pubmed/10552150>
507. Ettinger, B., *et al.* Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. *J Urol*, 1988. 139: 679.
<https://www.ncbi.nlm.nih.gov/pubmed/3280829>
508. Prien, E.L., Sr., *et al.* Magnesium oxide-pyridoxine therapy for recurrent calcium oxalate calculi. *J Urol*, 1974. 112: 509.
<https://www.ncbi.nlm.nih.gov/pubmed/4414543>
509. Pinheiro, V.B., *et al.* The effect of sodium bicarbonate upon urinary citrate excretion in calcium stone formers. *Urology*, 2013. 82: 33.
<https://www.ncbi.nlm.nih.gov/pubmed/23602798>
510. Hoppe, B., *et al.* The primary hyperoxalurias. *Kidney Int*, 2009. 75: 1264.
<https://www.ncbi.nlm.nih.gov/pubmed/19225556>

511. Borghi, L., *et al.* Randomized prospective study of a nonthiazide diuretic, indapamide, in preventing calcium stone recurrences. *J Cardiovasc Pharmacol*, 1993. 22 Suppl 6: S78.
<https://www.ncbi.nlm.nih.gov/pubmed/7508066>
512. Brocks, P., *et al.* Do thiazides prevent recurrent idiopathic renal calcium stones? *Lancet*, 1981. 2: 124.
<https://www.ncbi.nlm.nih.gov/pubmed/6361755>
513. Mortensen, J.T., *et al.* Thiazides in the prophylactic treatment of recurrent idiopathic kidney stones. *Int Urol Nephrol*, 1986. 18: 265.
<https://www.ncbi.nlm.nih.gov/pubmed/3533825>
514. Laerum, E., *et al.* Thiazide prophylaxis of urolithiasis. A double-blind study in general practice. *Acta Med Scand*, 1984. 215: 383.
<https://www.ncbi.nlm.nih.gov/pubmed/6375276>
515. Ohkawa, M., *et al.* Thiazide treatment for calcium urolithiasis in patients with idiopathic hypercalciuria. *Br J Urol*, 1992. 69: 571.
<https://www.ncbi.nlm.nih.gov/pubmed/1638340>
516. Scholz, D., *et al.* Double-blind study with thiazide in recurrent calcium lithiasis. *J Urol*, 1982. 128: 903.
<https://www.ncbi.nlm.nih.gov/pubmed/7176047>
517. Nicar, M.J., *et al.* Use of potassium citrate as potassium supplement during thiazide therapy of calcium nephrolithiasis. *J Urol*, 1984. 131: 430.
<https://www.ncbi.nlm.nih.gov/pubmed/6699979>
518. Fernandez-Rodriguez, A., *et al.* [The role of thiazides in the prophylaxis of recurrent calcium lithiasis]. *Actas Urol Esp*, 2006. 30: 305.
<https://www.ncbi.nlm.nih.gov/pubmed/16749588>
519. Ahlstrand, C., *et al.* Prophylactic treatment of calcium-stone-formers with hydrochlorothiazide and magnesium., In: *Renal Stones—Aspects on Their Formation, Removal and Prevention*, H.G. Tiselius, Editor. 1996, Akademityrck AB: Edsbruk, Sweden.
520. Dolin, D.J., *et al.* Effect of cystine-binding thiol drugs on urinary cystine capacity in patients with cystinuria. *J Endourol*, 2005. 19: 429.
<https://www.ncbi.nlm.nih.gov/pubmed/15865542>
521. Chow, G.K., *et al.* Medical treatment of cystinuria: results of contemporary clinical practice. *J Urol*, 1996. 156: 1576.
<https://www.ncbi.nlm.nih.gov/pubmed/8863541>
522. Pak, C.Y., *et al.* Management of cystine nephrolithiasis with alpha-mercaptopyronylglycine. *J Urol*, 1986. 136: 1003.
<https://www.ncbi.nlm.nih.gov/pubmed/3534301>
523. Tekin, A., *et al.* Cystine calculi in children: the results of a metabolic evaluation and response to medical therapy. *J Urol*, 2001. 165: 2328.
<https://www.ncbi.nlm.nih.gov/pubmed/11371943>
524. Worcester, E.M., *et al.* New insights into the pathogenesis of idiopathic hypercalciuria. *Semin Nephrol*, 2008. 28: 120.
<https://www.ncbi.nlm.nih.gov/pubmed/18359393>
525. Wolf, H., *et al.* Do thiazides prevent recurrent idiopathic renal calcium oxalate stones? *Proc Eur Dial Transplant Assoc*, 1983. 20: 477.
<https://www.ncbi.nlm.nih.gov/pubmed/6361755>
526. Johansson, G., *et al.* Effects of magnesium hydroxide in renal stone disease. *J Am Coll Nutr*, 1982. 1: 179.
<https://www.ncbi.nlm.nih.gov/pubmed/6764473>
527. Khan, S.R., *et al.* Magnesium oxide administration and prevention of calcium oxalate nephrolithiasis. *J Urol*, 1993. 149: 412.
<https://www.ncbi.nlm.nih.gov/pubmed/8426432>
528. Pearle, M.S., *et al.* Meta-analysis of randomized trials for medical prevention of calcium oxalate nephrolithiasis. *J Endourol*, 1999. 13: 679.
<https://www.ncbi.nlm.nih.gov/pubmed/10608521>
529. Silverberg, S.J., *et al.* A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. *N Engl J Med*, 1999. 341: 1249.
<https://www.ncbi.nlm.nih.gov/pubmed/10528034>
530. Mollerup, C.L., *et al.* Risk of renal stone events in primary hyperparathyroidism before and after parathyroid surgery: controlled retrospective follow up study. *Bmj*, 2002. 325: 807.
<https://www.ncbi.nlm.nih.gov/pubmed/12376441>

531. Evan, A.E., *et al.* Histopathology and surgical anatomy of patients with primary hyperparathyroidism and calcium phosphate stones. *Kidney Int*, 2008. 74: 223.
<https://www.ncbi.nlm.nih.gov/pubmed/18449170>
532. Rizzato, G., *et al.* Nephrolithiasis as a presenting feature of chronic sarcoidosis: a prospective study. *Sarcoidosis Vasc Diffuse Lung Dis*, 1996. 13: 167.
<https://www.ncbi.nlm.nih.gov/pubmed/8893387>
533. Takei, K., *et al.* Oral calcium supplement decreases urinary oxalate excretion in patients with enteric hyperoxaluria. *Urol Int*, 1998. 61: 192.
<https://www.ncbi.nlm.nih.gov/pubmed/9933846>
534. Domrongkitchaiporn, S., *et al.* Dosage of potassium citrate in the correction of urinary abnormalities in pediatric distal renal tubular acidosis patients. *Am J Kidney Dis*, 2002. 39: 383.
<https://www.ncbi.nlm.nih.gov/pubmed/11840381>
535. Maxwell P.A. Genetic renal abnormalities. *Medicine*, 2007. 35: 386.
[http://www.medicinejournal.co.uk/article/S1357-3039\(07\)00109-0/abstract](http://www.medicinejournal.co.uk/article/S1357-3039(07)00109-0/abstract)
536. Mandel, N.S., *et al.* Urinary tract stone disease in the United States veteran population. II. Geographical analysis of variations in composition. *J Urol*, 1989. 142: 1516.
<https://www.ncbi.nlm.nih.gov/pubmed/2585627>
537. Cameron, M.A., *et al.* Uric acid nephrolithiasis. *Urol Clin North Am*, 2007. 34: 335.
<https://www.ncbi.nlm.nih.gov/pubmed/17678984>
538. Millman, S., *et al.* Pathogenesis and clinical course of mixed calcium oxalate and uric acid nephrolithiasis. *Kidney Int*, 1982. 22: 366.
<https://www.ncbi.nlm.nih.gov/pubmed/7176335>
539. Pak, C.Y., *et al.* Biochemical distinction between hyperuricosuric calcium urolithiasis and gouty diathesis. *Urology*, 2002. 60: 789.
<https://www.ncbi.nlm.nih.gov/pubmed/12429297>
540. Chou, Y.H., *et al.* Clinical study of ammonium acid urate urolithiasis. *Kaohsiung J Med Sci*, 2012. 28: 259.
<https://www.ncbi.nlm.nih.gov/pubmed/22531304>
541. Wagner, C.A., *et al.* Urinary pH and stone formation. *J Nephrol*, 2010. 23 Suppl 16: S165.
<https://www.ncbi.nlm.nih.gov/pubmed/21170875>
542. Miano, R., *et al.* Stones and urinary tract infections. *Urol Int*, 2007. 79 Suppl 1: 32.
<https://www.ncbi.nlm.nih.gov/pubmed/17726350>
543. Rodman JS, *et al.* Diagnosis and treatment of uric acid calculi., In: *Kidney Stones. Medical and Surgical Management*, Coe FL, Pak CYC, Parks JH, Preminger GM., Eds. 1996, Lippincott-Raven: Philadelphia.
544. Low, R.K., *et al.* Uric acid-related nephrolithiasis. *Urol Clin North Am*, 1997. 24: 135.
<https://www.ncbi.nlm.nih.gov/pubmed/9048857>
545. Shekarriz, B., *et al.* Uric acid nephrolithiasis: current concepts and controversies. *J Urol*, 2002. 168: 1307.
<https://www.ncbi.nlm.nih.gov/pubmed/12352383>
546. Pak, C.Y., *et al.* Mechanism for calcium urolithiasis among patients with hyperuricosuria: supersaturation of urine with respect to monosodium urate. *J Clin Invest*, 1977. 59: 426.
<https://www.ncbi.nlm.nih.gov/pubmed/14173>
547. Wilcox, W.R., *et al.* Solubility of uric acid and monosodium urate. *Med Biol Eng*, 1972. 10: 522.
<https://www.ncbi.nlm.nih.gov/pubmed/5074854>
548. Mattle, D., *et al.* Preventive treatment of nephrolithiasis with alkali citrate--a critical review. *Urol Res*, 2005. 33: 73.
<https://www.ncbi.nlm.nih.gov/pubmed/15875173>
549. Marchini, G.S., *et al.* Gout, stone composition and urinary stone risk: a matched case comparative study. *J Urol*, 2013. 189: 1334.
<https://www.ncbi.nlm.nih.gov/pubmed/23022002>
550. Kramer, G., *et al.* Role of bacteria in the development of kidney stones. *Curr Opin Urol*, 2000. 10: 35.
<https://www.ncbi.nlm.nih.gov/pubmed/10650513>
551. Gettman, M.T., *et al.* Struvite stones: diagnosis and current treatment concepts. *J Endourol*, 1999. 13: 653.
<https://www.ncbi.nlm.nih.gov/pubmed/10608517>
552. Bichler, K.H., *et al.* Urinary infection stones. *Int J Antimicrob Agents*, 2002. 19: 488.
<https://www.ncbi.nlm.nih.gov/pubmed/12135839>

553. Carpentier, X., *et al.* Relationships between carbonation rate of carbapatite and morphologic characteristics of calcium phosphate stones and etiology. *Urology*, 2009. 73: 968.
<https://www.ncbi.nlm.nih.gov/pubmed/19394492>
554. Thompson, R.B., *et al.* Bacteriology of infected stones. *Urology*, 1973. 2: 627.
<https://www.ncbi.nlm.nih.gov/pubmed/4587909>
555. McLean, R.J., *et al.* The ecology and pathogenicity of urease-producing bacteria in the urinary tract. *Crit Rev Microbiol*, 1988. 16: 37.
<https://www.ncbi.nlm.nih.gov/pubmed/3053050>
556. Wong HY, *et al.* Medical management and prevention of struvite stones, in *Kidney Stones: Medical and Surgical Management*, Coe & F.M. FL, Pak CYC, Parks JH, Preminger GM., Editors. 1996, Lippincott-Raven: Philadelphia.
557. Wall, I., *et al.* Long-term acidification of urine in patients treated for infected renal stones. *Urol Int*, 1990. 45: 336.
<https://www.ncbi.nlm.nih.gov/pubmed/2288050>
558. Griffith, D.P., *et al.* Randomized, double-blind trial of Lithostat (acetohydroxamic acid) in the palliative treatment of infection-induced urinary calculi. *Eur Urol*, 1991. 20: 243.
<https://www.ncbi.nlm.nih.gov/pubmed/1726639>
559. Williams, J.J., *et al.* A randomized double-blind study of acetohydroxamic acid in struvite nephrolithiasis. *N Engl J Med*, 1984. 311: 760.
<https://www.ncbi.nlm.nih.gov/pubmed/6472365>
560. Milliner, D.S., *et al.* Urolithiasis in pediatric patients. *Mayo Clin Proc*, 1993. 68: 241.
<https://www.ncbi.nlm.nih.gov/pubmed/8474265>
561. Rogers, A., *et al.* Management of cystinuria. *Urol Clin North Am*, 2007. 34: 347.
<https://www.ncbi.nlm.nih.gov/pubmed/17678985>
562. Dello Strologo, L., *et al.* Comparison between SLC3A1 and SLC7A9 cystinuria patients and carriers: a need for a new classification. *J Am Soc Nephrol*, 2002. 13: 2547.
<https://www.ncbi.nlm.nih.gov/pubmed/12239244>
563. Lee, W.S., *et al.* Cloning and chromosomal localization of a human kidney cDNA involved in cystine, dibasic, and neutral amino acid transport. *J Clin Invest*, 1993. 91: 1959.
<https://www.ncbi.nlm.nih.gov/pubmed/8486766>
564. Knoll, T., *et al.* Cystinuria in childhood and adolescence: recommendations for diagnosis, treatment, and follow-up. *Pediatr Nephrol*, 2005. 20: 19.
<https://www.ncbi.nlm.nih.gov/pubmed/15602663>
565. Finocchiaro, R., *et al.* Usefulness of cyanide-nitroprusside test in detecting incomplete recessive heterozygotes for cystinuria: a standardized dilution procedure. *Urol Res*, 1998. 26: 401.
<https://www.ncbi.nlm.nih.gov/pubmed/9879820>
566. Nakagawa, Y., *et al.* Clinical use of cystine supersaturation measurements. *J Urol*, 2000. 164: 1481.
<https://www.ncbi.nlm.nih.gov/pubmed/11025687>
567. Fjellstedt, E., *et al.* Cystine analyses of separate day and night urine as a basis for the management of patients with homozygous cystinuria. *Urol Res*, 2001. 29: 303.
<https://www.ncbi.nlm.nih.gov/pubmed/11762791>
568. Ng, C.S., *et al.* Contemporary management of cystinuria. *J Endourol*, 1999. 13: 647.
<https://www.ncbi.nlm.nih.gov/pubmed/10608516>
569. Biyani, C.S., *et al.* Cystinuria—diagnosis and management. *EAU-EBU Update Series* 2006. 4: 175.
[http://www.eusupplements.europanurology.com/article/S1871-2592\(06\)00038-4/abstract](http://www.eusupplements.europanurology.com/article/S1871-2592(06)00038-4/abstract)
570. Matlaga, B.R., *et al.* Drug-induced urinary calculi. *Rev Urol*, 2003. 5: 227.
<https://www.ncbi.nlm.nih.gov/pubmed/16985842>
571. Beltrami, P., *et al.* The endourological treatment of renal matrix stones. *Urol Int*, 2014. 93: 394.
<https://www.ncbi.nlm.nih.gov/pubmed/24969358>
572. Nakagawa, Y., *et al.* A modified cyanide-nitroprusside method for quantifying urinary cystine concentration that corrects for creatinine interference. *Clin Chim Acta*, 1999. 289: 57.
<https://www.ncbi.nlm.nih.gov/pubmed/10556653>

6. CONFLICT OF INTEREST

All members of the Urolithiasis Guidelines Panel have provided disclosure statements of all relationships that they have that might be perceived as a potential source of a conflict of interest. This information is publicly accessible through the European Association of Urology website: <http://www.uroweb.org/guidelines/onlineguidelines/>. This guidelines document was developed with the financial support of the European Association of Urology. No external sources of funding and support have been involved. The EAU is a non-profit organisation and funding is limited to administrative assistance and travel and meeting expenses. No honoraria or other reimbursements have been provided.

7. CITATION INFORMATION

The format in which to cite the EAU Guidelines will vary depending on the style guide of the journal in which the citation appears. Accordingly, the number of authors or whether, for instance, to include the publisher, location, or an ISBN number may vary.

The compilation of the complete Guidelines should be referenced as:

EAU Guidelines. Edn. presented at the EAU Annual Congress London 2018. ISBN 978-94-92671-01-1.

If a publisher and/or location is required, include:

EAU Guidelines Office, Arnhem, The Netherlands. <http://uroweb.org/guidelines/compilations-of-all-guidelines/>

References to individual guidelines should be structured in the following way:

Contributors' names. Title of resource. Publication type. ISBN. Publisher and publisher location, year.